curriculum vitae: daniel j. wallace, m.d., …6. wallace dj, peter jb, bowman rl, wormsley sb,...
TRANSCRIPT
Page 1 of 54
CURRICULUM VITAE: DANIEL J. WALLACE, M.D., F.A.C.P., M.A.C.R. Up to date as of July 1, 2018
Personal:Address: 8750 Wilshire Blvd, Suite 350 Beverly Hills, CA 90211Phone: (310) 652-0010FAX: (310) 360-6219E mail: [email protected] Education:University of Southern California, 2/67-6/70, BA Medicine, 1971.University of Southern California, 9/70-6/74, M.D, 1974.
Postgraduate Training: 7/74-6/75 Medical Intern, Rhode Island (Brown University) Hospital, Providence, RI. 7/75-6/77 Medical Resident, Cedars-Sinai Medical Center, Los Angeles, CA. 7/77-6/79 Rheumatology Fellow, UCLA School of Medicine, Los Angeles, CA.
Medical Boards and Licensure: Diplomate, National Board of Medical Examiners, 1975. BoardCertified,AmericanBoardofInternalMedicine,1978. BoardCertified,Rheumatologysubspecialty,1982.CaliforniaLicense:#G-30533. Present Appointments: Medical Director, Wallace Rheumatic Study Center AttuneHealthAffiliate,BeverlyHills,CA90211 Attending Physician, Cedars-Sinai Medical Center, Los Angeles, 1979- ClinicalProfessorofMedicine,DavidGeffenSchoolofMedicineatUCLA,1995- ProfessorofMedicine,Cedars-SinaiMedicalCenter,2012- Expert Reviewer, Medical Board of California, 2007- AssociateDirector,RheumatologyFellowshipProgram,Cedars-SinaiMedicalCenter,2010- BoardofGovernors,Cedars-SinaiMedicalCenter,2016- Member,MedicalPolicyCommittee,UnitedRheumatology,2017-Honorary Appointments: Fellow, American College of Physicians (FACP) Fellow, American College of Rheumatology (FACR) 1979-2015 Master,AmericanCollegeofRheumatology,2015- Member,RoyalCollegeofPhysicians(London) OrganizingCommittee:Lupus2014,Quebec,Quebec,Canada Hospital Appointments:Cedars Sinai: ClinicalChiefofRheumatology,1991-1996 Chairman,MedicalPeerReview1985-1987,Member1982-1989 Intern Selection Committee, 1979-1993 Medical Advisory Committee, 1985-1988, 1991-1996 Performance Improvement Committee, 1991-1996 Hospital Peer Review Committee, 1986-1989, 1992-1994 Division of Rheumatology Reappointment/Peer Review, 1988-present Pharmacygammaglobulincommittee,2002-present Chairman of Department of Medicine Search Committee 2011-2012 Clinical Academic Promotions and Appointments Council 2011-2014 Division of Rheumatology Executive Committee 2011-
Chief Rheumatology Consultant, City of Hope Medical Center, Duarte, CA 1980-1988
Page 2 of 54
Attending Physician, UCLA Center for the Health Sciences, 1981-Prior Academic Appointments: Associate Clinical Professor, UCLA School of Medicine 1988-1995 Assistant Clinical Professor, UCLA School of Medicine, 1981-1988 Assistant Clinical Professor, USC School of Medicine 1979-1981
Books1. Wallace,DJandDuboisEL,eds.,Dubois’Lupus Erythematosus, 3rd Edition, LeaandFebiger,Philadelphia,PA,
1987, 775 pp2. Wallace,DJandHahn,BH,eds,Dubois’Lupus Erythematosus, 4th Edition, LeaandFebiger,Philadelphia,PA,1993,
953 pp3. Wallace DJ, The Lupus Book, Oxford University Press, NY/London, 1995, 258 pp4. WallaceDJ,HahnBH,Eds.,Dubois’Lupus Erythematosus, 5th Edition, Williams and Wilkins, Baltimore, MD, 1997,
1289 pp5. Wallace DJ, Wallace JB, Making sense of fibromyalgia, Oxford University Press, NY/London, 1999, 242pp6. Wallace DJ, The Lupus Book, New and Revised, Oxford University Press, NY/ London, 2000, 271 pp7. Lane NE, Wallace DJ, All About Osteoarthritis, Oxford University Press, NY/London, 2001, 258 pp.8. WallaceDJ,HahnBH,Eds,Dubois’Lupus Erythematosus, 6th Edition, Lippincott Williams & Wilkins, Philadelphia,
PA, 2002, 1348 pp9. Wallace DJ, Wallace JB, All About Fibromyalgia, Oxford University Press, NY/London, 2002, 258 pp10. Wallace DJ, Wallace JB, Fibromyalgia: An essential guide for patients and their families, Oxford University Press,
NY/London, 2003, 196 pp.11. Wallace DJ, Editor, The New Sjogren’s Syndrome Handbook, Oxford University Press, NY/London, Revised and
Expanded 3rd Edition, 2005, 265 pp.12. Wallace DJ, Clauw DJ, Fibromyalgia and other central pain syndromes, Lippincott Williams & Wilkins, Philadelphia,
PA, 421 pages, 2005. 10.13. Wallace DJ, The Lupus Book: A Guide for Patients and their Families, Oxford U Press, NY/London, 2005, 291 pp.14.WallaceDJ,HahnBHEds,Dubois’Lupus Erythematosus, 7th Edition, Lippincott Williams & Wilkins, 2007,
Philadelphia, PA, 1441 pp.15. Wallace DJ, Lupus: The Essential Clinician’s Guide, OxfordAmericanRheumatologyLibrary,OxfordUniversityPress,
New York, 2008.16. Clauw DJ, Wallace DJ, Fibromyalgia: The Essential Clinician’s Guide, OxfordAmericanRheumatologyLibrary,
Oxford University Press, New York, 2009.17. Wallace DJ, Editor, The Sjogren’s Book: Sjogren Syndrome Foundation, Fourth Edition, Oxford University Press,
New York 2012, 395 pages.18. Rheumatoid Arthritis,MichaelWeisman,OxfordAmericanRheumatologyLibrary,DanielJWallace,SeriesEditor,90
pages, 2011.19. Wallace DJ, Hahn BH, Dubois’ Lupus Erythematosus and Related Syndromes, 8th edition, Elsevier Saunders,
Philadelphia, PA, 694 pages, 201320. Wallace DJ, The Lupus Book: A Guide for patients and their families, Oxford U Press, NY/Oxford, 2013.21. Wallace DJ, Lupus: The Essential Clinician’s Guide, OxfordAmericanRheumatologyLibrary,OxfordUPress,
Oxford/New York, 2014. 115 pp.22. Wallace DJ, Wallace JB, Making Sense of Fibromyalgia, Oxford U Press, NY/Oxford, 2nd Edition, 2014, 257 pp.23. Wallace DJ, Hahn BH, Dubois’ Lupus Erythematosus and Related Syundromes, 9th edition, Elsevier, Philadelphia, PA
2018 (in press)
Book Chapters/Supplements1. Plasma-lymphocytapheresisforthetreatmentofrheumatoidarthritis,D.Goldfinger,D.Wallace,J.Klinenberg,in
Plasma Exchange Therapy, Ed.byH.Borberg,RReuther,pp.215-219,GeorgThiemeVerlag,Stuttgart,1981.2. Thecurrentstatusoftherapeuticapheresisinthemanagementofrheumatoidarthritis,DJWallace,D.Goldfinger,J.
Klinenberg,inTherapeutic Apheresis and Plasma Perfusion, Ed.byJTyndall,ARLiss,NewYork,pp.27-32,1982.(AlsopublishedasProg.Clin.Biol.Res.106:27-321982).
3. A controlled study on the use of plasmapheresis in steroid/immunosuppressive resistant systemic lupus erythematosuswithnephroticsyndrome,DJWallace,DGoldfinger,S.Nichols,DGoodman,MFichman,MStewart,JRKlinenberg,inProceedings of the First International Congress of the World Apheresis Association, Ed.byTUda,Y Shlokawa, N Inoue, ISAO Press, pp. 91-102, 1987.
4. Newandexperimentaltherapeuticmodalities,JRKlinenbergandDJWallace,inDiagnosis and Management of Rheumatic Diseases, W. Katz,ed,Lippincott,Philadelphia,pp855-858,1988.
Page 3 of 54
5. WallaceD,TheTreatmentofMildLupus,inProceedings of the 2nd Intl Conference on S.L.E., Professional Postgraduate Services, Singapore, 1989, pp. 126-129.
6. WallaceDJ,PeterJB,BowmanRL,WormsleySB,SilvermanS,Fibromyalgia,cytokines,fatiguesyndromes,andimmune regulation, in Advances in Pain Research and Therapy: Myofascial Pain and Fibromyalgia, Volume 17, JR Fricton and EA Awad, Eds, Raven Press, NY, 1990, pp. 277-287.
7. WallaceD,MetzgerAL,Theantiphospholipidsyndrome,inA Decade of Lupus, H Aladjem editor, Lupus Foundation of America, 1991, Rockville, MD, pp. 126-127.
8. Wallace DJ, Does stress or trauma cause aggravate rheumatic disease?, in Bailliere’s Clinical Rheumaology, Exercise and Rheumatic Disease, 8:149-159,1994.RichardPanushandNancyLaneeditors,BaillierereTindall,London.
9. Wallace DJ, Antimalarial agents and lupus. Rheumatic Disease Clinics, in Systemic Lupus Erythematosus, WJ McCune editor, 20: 243-263, 1994, WB Saunders, Philadelphia, PA.
10. Wallace DJ, Metzger AL, Ashman RF, Rheumatic diseases, in Manual of Allergy and Immunology, 3rd edition, GLawlor,TFischer,DAdelman,eds,Little,Brown&Company,1995,pp303-352.
11.SilvermanS,GluckO,SilverD,TesserJ,WallaceD,NeumannK,MetzgerA,MorrisR,Theprevalenceofautoantibodiesinsymptomaticandasymptomaticpatientswithbreastimplantsandpatientswithfibromyalgia,inImmunology of Silicones, MPotterandNRRose,Eds,Springer-VerlagBerlin,Heidelberg,Germany,pp317-322,1996.(AlsopublishedasCurr Top Microbiol Immunol 1996; 210:317-322.)
12.WallaceD,MetzgerAL,SystemiclupusErythematosus:Clinicalaspectsandtreatment,inKoopmanWJ,editor,Arthritis and Allied Conditions: A Textbook of Rheumatology, 13th Edition, Williams and Wilkins, Baltimore, MD, 1997, pp 1319-1345.
13.WallaceD,AutoimmuneConnectiveTissueDisorders,RakelRE,Conn’s Current Therapy 2000, WB Saunders, Philadelphia, PA, pp 774-778.
14. Wallace DJ, Severe lupus, in Rheumatology (3rd Ed), MCHochberg,AJSilman,JSSmolen,MEWeinblatt,MHWeisman,Mosby,Edinburgh,2003,pp.1419-1426.
15,ShinadaS,WallaceDJ,Laboratoryfeaturesofcutaneouslupus,Cutaneous lupus erythematosus, Springer, Berlin, 2004, p.p. 311-322.
16.WallaceDJ,Fibromyalgiaandtheneurobiologyofsleep,inSleep and Psychosomatic Medicine, SR Pandi-Perumal, RRRuoti,MKramer,Eds,2007;InformaHealthcare,Abington,UnitedKingdom,pp.249-259.
17. Wallace DJ, Systemic lupus erythematosus, Encyclopedia of Stress, 2ndedition,GFink,editor,Elsevier,2007,OxfordUK,v3pp708-712.
18.HalleguaDS,WallaceDJ,Sleepandfibromyalgiaintheelderly,inPrinciplesandPracticeofGeriatricSleepMedicine,SRPandi-Perumal,JMMontiandAAMonjan,Eds,CambridgeUniversityPress2009,pp160-166.
19.WallaceDJ,Managementofnonrenalsystemiclupuserythematosus2,inTargetedTreatmentoftheRheumaticDiseases, M Weisman et al Eds, Saunders Elsevier, Philadelphia, PA, 2009, pp 91-107.
20.GoldenbergDM,WallaceDJ,EpratuzumabinSLE,In:ImmunotherapeuticagentsforSLE.ShoenfeldY,MeroniPL,CerveraR(Eds).FutureMedicineLtd,London,UK,56–68(2012).
21.EditorofUptoDatesectionssince2011for:a)Antimalarialdrugsinthetreatmentofrheumaticdiseases,b) Diagnosis and differential diagnosis of systemic lupus erythematosus in adults, c) Musculoskeletal manifestations of systemic lupus erythematosus, d) Overview of therapy of the therapy and prognosis of systemic lupus erythematosus in adults, e) Patient education: Systemic lupus erythematosus (Beyond the Basics), Lippincott 22. Wallace DJ, Management of nonrenal and non-central nervous system lupus, in Rheumatology (5th edition), MC Hochberg,AJSilman,JSSmolen,MEWeinblatt,MHWeismanEds,SaundersElsevier,Philadelphia,PA2014, Chapter 134 pp 1099-1106. 23.WallaceDJ,Fibromyalgiaandtheneurobiologyofsleep,inSleep and Psychosomatic Medicine, SR Pandi- Perumal,Narasimhan,KramerM,Eds.2016,pp127-136,2nd edition, CRC Press, Boca Raton, FL 24.WallaceDJ,Editor,SpecialIssue:BiologicTherapies,Lupus2016;volume25,number10 25. Wallace DJ, Weisman MH, Clinical features of systemic lupus erythematosus, in Rheumatology (6th edition), MC Hochberg,EGravallese,ASilman,JSmolen,MEWeinblatt,MHWeisman,Eds,Elsevier,Philadelphia,PA,2018, Chapter 135, pages 35.1-35.12. 26. Wallace DJ, Systemic and Biologic Agents for Lupus Erythematosus, Springer, Cham Switzerland, 2018, in Biologic and Systemic Agents in Dermatology, Paul Yamauchi Ed, 2018, pp 377-390
Organizations and Positions Held:
Lupus Foundation of America Co-chairman,1999-2000 Member,BoardofDirectors1991-1998,VicePresident1999-2000 National Medical Advisory Board, 1988- Los Angeles Chapter Medical Advisory Board, Co-Chair 1989-1999
Page 4 of 54
Member,LosAngelesCountyMedicalAssociationMember,CaliforniaMedicalAssociationMember,AmericanMedicalAssociationMember,SouthernCaliforniaRheumatismSocietyMember,ArthritisFoundationPacificRegion LA. Metro Committee Chairman, 1989-1994 Community Services Committee, 1989-1994 MedicalandScientificCommittee,1989-1994 InstitutionalGrantsCommittee,1989-1994 FibromyalgiaSubcommittee,1988-;Chairman1990-1995 Representative, National House of Delegates, 1987, 1990 Board of Directors, Southern California, 1994-2006Member,AmericanCollegeofRheumatology Committee on Rheumatologic Practice, 1982-1985 Lupus Council, 1986-; Chairman 1990-1991 Nominations Committee 1991-1994 Research&EducationFoundationBoardofDirectors,1993-1999;Chairman1995-1999 Nominating Committee, 2005-2007 LupusAbstractSelectionCommittee2010-2015 Research and Education Foundation, National Advisory Council Meeting, 2011-TheAmericanLupusSociety(mergedwithLupusFoundationofAmerica,1996) National Medical Advisory Board, 1988-1996 Los Angeles Chapter Medical Advisory Board, 1980-1996 LosAngelesChapterChiefMedicalAdvisor,SanFernandoValleyMedicalAdvisoryBoardMember,AmericanSocietyforApheresis Medical Executive Committee, 1987-1989 Editor, ASFA Newsletter, 1987-1989United Scleroderma Foundation Board of Directors, 1990-1997Scleroderma Foundation, Southern California, Board of Directors, 2001-2004AmericanFibromyalgiaSyndromeAssociation,MedicalAdvisoryBoard,1994-BoardofDirectors,LupusResearchInstitute,2000-2015 Founder, Lupus LA 2000- Co-Chairman, Industrial Relations Council 2012-Sjogren’sSyndromeFoundationMedicalAdvisoryBoard,1997-Medical Advisory Board, Maryland Lupus Foundation, 2001-2004Examination writer, American Board of Internal Medicine, for Internal Medicine Boards, 1994, 1995Member,SLICC(SystemicLupusInternationalCoordinatingCommittee),2003-NIH Lupus Biomarkers Committee, 2004-2010Member,LupusClinicalTrialsConsortium(LCTC),2005-2010ScientificAdvisoryBoardforlupus,23andme,2015-NYU Judith and Stewart Colton Center for Autoimmunity, NYU Langone Medical Center, External Advisory Committee, 2014-Lupus Research Alliance, Co-chairman, Lupus Industry Council 2016- Executive Board, Lupus Clinical Investigative Network, 2016-
Laboratory Experience:Therapeuticapheresisproject,Cedars-SinaiMedicalCenter,1977-1997Cedars-SinaiLupusResearchLaboratory1990-Summer research fellow, Cedars-Sinai Medical Center, 1968-1970, under Dr. Leon Morgenstern, Chairman,DepartmentofSurgery,dealingwithwoundhealingofintestinalanastamosesandsynthesizingtrypsininhibitor.USCCancerVirologyLaboratory,Dr.MurrayGardnerandJ.EarleOfficer,PhD,1972-1974,retrovirusesandaging. PublicationReviewExperience:Editorial Board, Journal of Clinical Apheresis, 1982 -2004 Editorial Board, Lupus, 1997-Editorial Board, Bulletin on the Rheumatic Diseases, 1998-2004Editorial Board, Arthritis & Rheumatism, 1998- 2003 Editorial Board, Journal of Musculoskeletal Pain, 1999-Editorial Board, Journal of Rheumatology, 1999-Editorial Board, Journal of Clinical Rheumatology, 2003-
Page 5 of 54
Editorial Board, Future Rheumatology, 2006-2016Editor, Current Opinion in Rheumatology, Lupus issues, 1994-2000Editor-in-Chief, Current Rheumatology Reviews, 2005-2008Reviewer for over 50 medical journals
Honors GlobusAward,BestMedicalPaper,1984-5,Mt. Sinai J Medicine Humanitarian Award, Lupus Foundation of America, 1989 and 1991 BestDoctorsintheUnitedStates,TownandCountryMagazine,October,1989 TheAmericanLupusSociety,LupusHallofFame,1989 “TheBestDoctorsinAmerica,”Woodward/White,Aiken,SC,1994 Best Doctors in Los Angeles, Los Angeles Magazine, 1996 Jane Wyman Humanitarian Award, Arthritis Foundation, 1996 Expert Consultant, Medical Board of California, 1995- Lupus Foundation of America, Outstanding Service Award, 1997 “SpiritofHope”Award,SouthernCaliforniaSclerodermaFoundation,2001 Achievement Award, SLE Foundation, 2002 JamesRKlinenbergAchievementAward,ArthritisFoundationSouthernCaliforniaChapter,2004 Founder’sAward,LupusLA,SLEFoundation,2008 TopDoctor,USNewsandWorldReport,2011- Medical Achievement Award, SLE Foundation 2011 Sjogren’sSyndromeFoundation,HealthcareProfessionalLeadershipAward,2012 LupusFoundationofNorthernCalifornia,OutstandingCoitimenttoTreatmentandResearch,2016 Los Angeles County Medical Association, Innovation Award for Community Service, 2017 Jane Wyman Humanitarian Award, Arthritis Foundation, 2018 ResearchGrants:BSRGCedars-SinaiResearchGrant,$10,000,1978-1979, Apheresis in rheumatoid arthritisHaemoneticsResearchInstituteGrant,$25,000,1980-1981, Double-blindcontrolledtrialofapheresisinrheumatoidarthritisKrocFoundationGrant,$59,000,1981-1982, Apheresis in systemic lupus erythematosusHaemoneticsResearchInstituteGrant,$25,000,1982, TheimmunologyofapheresisParkerFoundationGrant,$76,250,1983-1985, Selective immunoadsorption in rheumatoid arthritisWinthropPharmaceuticalsGrant,$5,000,1989-199, TheroleofhydroxychloroquineonlipidsTheAmericanLupusSocietyGrant,$28,000,1990-1992, An index of lupus literatureWinthropPharmaceuticalsGrant$7,500,1991-1993, CytokinesandtheirinfluenceonhydroxychloroquineCo-InvestigatorwithDr.MarianaLinker-Israeli,3yearNIHgrantfor$350,000 “Interleukin-6geneticpolymorphisms”,1994-1996Co-InvestigatorwithDr.MarianaLinker-Israeli,NIHgrantfor$442,670, “AbnormalIL-6ProductioninSLE,”AgencyAward#2RolAR4252-04,1997-1999AmericanFibromyalgiaSyndromeAssociation,$24,600,1998-1999, TheroleoftheTh-1/Th-2axisinfibromyalgiaFoodandDrugAdministration,RF412-3324A,$24,000,2000-2002 ComparisonofIVcyclophosphamidetomycophenolatemofetilforinductiontherapyofactiveClassIII-IV
nephritis in systemic lupus erythematosus. Co-investigator with M Weisman for Cedars effortCo-investigatorwithDr.MichellePetri,NIHGrant,BrainConections:CognitivefunctioninSLE,NationalInstituteof
Arthritis,MusculoskeletalandSkindisorders,2003-,Grantnumber:R01AR4912501,2004-2008AROSE:RevisingACRdiagnostic/classificationcriteriaforlupus,LupusFoundationofAmerica,NIH-NIAMS
ARO051871-013, 2004-2009Theroleofmycophenolatemofetilinpatientswithextra-renallupus,Aspreva,$62,500,2006-Astudytoinvestigatepro-inflammatoryHDLcholesterolasanindicationofriskforatherosclerosisinsubjectswith
Page 6 of 54
systemiclupuserythematosus,AllianceforLupusResearach,$72,500,2006-2008Co-investigator, Rituxan in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis
(NIHGrant#N01-AR-4-2273),2007-2010Co-investigator,Theuseofabataceptinlupusnephritis(NIHGrant#N01A115416),2008-2014HHSN268200700036C Langford(PI) 09/13/10–08/14/12
ConcurrentPilotStudiesinGiantCellArteritisandTakayasuArteritistoExaminetheSafety,Efficacy, andImmunologicEffectsofAbatacept(CTLA4-IG)inlargeVesselVasculitits Thepurposeofthisstudyistodeterminetheeffectivenessandsafetyofthemedicationabatacept ingiantcellarteritisorTakayasu’sarteritis. Role: Co-Investigator
CanadianArthritisSociety Clarke/Bernatsky(PI)05/05/09–12/31/11 LymphomaRiskinSLE:AConsequenceofImmuneSuppressionorStimulation? ThepurposeofthisresearchistohelpidentifySLEpatientsathighestriskforlymphomaandprovideguidance regardingtheappropriateuseofISDsinbothinducingandmaintainingremissioninSLE.
Role: Co-InvestigatorWallace (PI) Improving the Recognition, Diagnosis, and Referral Patterns of Patients with Systemic Lupus Erythematosus ThroughEnhancedCareCoordinationandPracticeEfficiencies–AQI/PICMEDemonstrationProjectfortheCedars-SinaiMedicalGroup,FranceFoundation,2012-,$150,000BASJ02-Arandomized,double-blind,placebocontrolledtrialofBaminercept,aomphotoxin-Breceptorfusion,protein,forthetreatmenetofprimarySjogren’ssyndrome,2012-2016,AutoimmuneCenersofExcellence
Subject:IntroductionandContactInformationfortheProtocol,“APhaseIbStudyofMilatuzumabAdministeredSubcutaneouslyinPatientswithActiveSystemicLupusErythematosus(SLE),”SubmittedbyDanielWallaceMD,Cedars-Sinai Medical Center, Los Angeles, California in Support of Proposal, “CD74 Immunotherapy of Systemic Lupus Erythematosus,”WilliamWegenerMD,Immunomedics,Incorporated,MorrisPlains,NewJersey,ProposalLogNumberPR121764,AwardNumberW81XWH-13-1-0392,HRPOLogNumberA-17786,2014-NIHR34A114453;Planninggrantfor‘MesenchymalStemCellTherapyforActiveSystemicLupusErythematosus’(7/15/14-6/30-15), Co investigator
5P50AR060804-03;OklahomaSjogren’sSyndromeCenterofResearchTranslation(7/1/13-6/30/15),Co-Investigator
U34 AR067392 Olsen&Karp(MPIs) 02/01/15-01/31/17NIH/NIAMSHydroxychloroquineTreatmentforPreventionofSystemicLupusErythematosusPlanninggrant for amulticenter, placebo-controlled trial of hydroxychloroquine inincomplete lupus patients to determine whether this can ameliorate, delay or prevent progression to SLE.Role: Co-investigator
LR170141 (DepartmentofDefense);Subject:“InflammationandMetabolicReprogrammingofLupusMonocytes–MechanismofthePathobiologyofLupusCardiovascularDisease”PI: Caroline Jefferies (2018 -Role: Co-Investigator
PastDrugStudyCollaborativeProtocols:
Eli Lilly, Benoxaprofen, 1977-1979 in RA
Syntex, Naproxen, 1980-1982 in RA
CIBA-Geigy,Diclofenac,1985-1987inRA
Winthrop,Hydroxychloroquine-methotrexate,1988-1992inRA
Rorer,CalcitonininFibromyalgia,1989
Sandoz,SandostatininFibromyalgia,1990-1991
Smith-Kline,NamebutoneforOsteoarthritis,1991-1992
Page 7 of 54
Genelabs,Dehydroepiandrosterone(DHEA)forLupus,1994-1997,anopenlabelanddoubleblindtrial
LaJollaPharmaceuticals,LJP394forLupusNephritis,1996-1999,Double-blindtrial
Immunex,Double-blindtrialofTNF-alpha(Enbrel)forRheumatoidArthritis,1997-1999
Boehringer-Ingelheim, Meloxicam for Rheumatoid Arthritis, 1998-1999Boehringer-Ingleheim, Meloxicam for Osteoarthritis, 1998-1999
Merck,MK-0966forRheumatoidArthritis,1998
Immunex,Open-labeltrialofTNA-alpha(Enbrel)forRheumatoidArthritis,1997-
Biogen, Anti-CD40L therapy for lupus nephritis, 1998-1999
SmithKline,SB217969/ClenolixibforRheumatoidArthritis,1998-1999
LaJollaPharmaceuticals/Abbott,LJP394forLupusnephritis,openlabel#90-11,1998-2000
Merck,MK-0966forosteoarthritis,1998-1999
SmithKline,SB217969/Clenolixib(OpenLabel),forrheumatoidarthritis1998-1999
Roche,Randomized,double-blindtrialofRo32-3555(Trocade)forrheumatoidarthritis,1998-2000
Amgen,Arandomized,placebocontrolleddouble-blind,multicenter,dose-findingstudytoevaluatethesafetyandefficacyofweeklyadministrationofPEGlycatedrecombinantmethionylhumansolubletumornecrosisfactorreceptorTypeI(PEGsTNF-RI)inpattientswithrheumatoidarthritis,1999-2000
Merck,Anactivecomparitorandplacebocontrolled,parallelgroup,double-blind52weekstudytoassesssafetyandefficacyofMK-0966inrheumatoidarthritispatients,1999-2000
Merck,Randomized,double-blindmulticenterstudytoevaluatetolerabilityandeffectivenessofrofecoxib(MK-0966)25mg/dvsnaproxen500mgbidinpatientswithosteoarthritis,1999-2000
Zeneca,Randomized,doubleblindplacebocontrolled,parallelgroupmulticentertrialtoassesstheanalgesicefficacyandtolerabilityoftreatmentwithmultipledosesof1600mgZD6416bidcomparedwithtreatmentwithplaceboinpatients with osteoarthritis of the hip or knee, 1999-1999
BiogenC99-1021,Anopenlabel,multipledosestudytoevaluatetheefficacy,safetyandpharmokineticsofBG9588(antiCD40antibody)insubjectswithproliferativelupusglomerulonephritis,1999-2001
Anergen,AphaseIdoubleblind,randomizedplacebocontrolled,doseescalationstudytoevaluatethesafety,tolerabilityandbiologicalactivityofa2weekinductioncourseand1maintenancecycleofAG4263insubjectswithrheumatoid arthritis, 1999-1999
IDEC,PhaseIIrandomized,doubleblind,placebo-controlled,multiplecenter,mutipledose,dosefindingsafety,toleranceandefficacystudyofIDEC-131inpatientswithactiveSLE,1999-2000
Centocor,Anopen-labeltrialofanti-TNFchimericmonoclonalantibodyInfliximabinpatientswithactiverheumatoidarthritis, 1999-2000
Merck,Arandomized,placebo-controlled,parallelgroup,double-blindstudytoevaluatethesafetyandefficacyofrofecoxib25mgandceleboxib200mginpatientswithosteoarthritisofthekneeorhip,2000
Cypress,Apostapproval,marketpreference,unblindedgeneralexperiencestudytogatheradditionalinformationabouttheProsorbacolumningeneralrheumatologypracticesettings,1999-2000
Searle,Clinicalprotocoltoevaluatethelongtermsafetyofvaldecoxibintreatingthesignsandsymptomsofrheumatoid arthritis, 1999-2001
Page 8 of 54
Searle,Clinicalprotocolofamulticenter,double-blind,placebo-controlledrandomized,comparisonstudyoftheefficacyandsafetyof3valdecoxibdosesandnaproxenintreatingthesymptomsandsignsofrheumatoidarthritis,1999-2001
Knoll,Amulticenterrandomizedplacebo-controlledPhaseIIstudyofthehumananti-TNFD2E7administeredassubcutaneousinjectionsinrheumatoidarthritispatientstreatedwithmethotrexate,1999-2001Knoll,AmulticenterPhaseIIstudyofthehumananti-TNFantibodyD2E7administeredassubcutaneousinjectionsinrheumatoid arthritis patients treated with methotrexate, 2000-2001
Amgen,Adouble-blindextensionstudytoprovidetreatmentwithPEGylatedrecombinanthumanmethionylsolubletumornecrosisfactorTypeI(PEGsTNF-R1)tosubjectscompletingtrialsTNF980246andTNF990136,2000Fujisawa,Anopen-label,long-termstudytoevaluatethesafetyofPrograf(tacrilimus)forthetreatmentofrheumatoidarthritis, 2000-2002
Fujisawa,arandomizeddouble-blindplacebocontrolledstudytoassesstheefficacyandsafetyofprograf(tacrilimus)inthe treatment of rheumatoid arthritis in patients who have failed one or more disease modifying antirheumatic drugs, 2000-2002
KnollDE031:Amulticenterrandomizeddouble-blindplacebo-controlledstudyofthesafetyofhumananti-TNFmonoclonalantidobyD2E7inpatientswithactiverheumatoidarthritis,2000-2008
Knoll,StudyofNewOnsetRheumatoidArthritis(SONORA),2000-2006
KnollDE013,Aprospectivemulticenterrandomizeddouble-blindactivecomparator-controlledparallel-groupsstudycomparingthefullyhumanmonoclonalantibodyTNFalphaantibodyD2E7everysecondweekwithmethotrexategivenweeklyandthecombinationofD2E7andmethotrexateadministeredover2yearsinpatientswithearlyrheumatoidarthritis, 2000-2008
LaJollaPharmaceuticals,LJP394-90-09,Arandomized,double-blind,placebo-controlled,multicentersafetyandefficacytrialofLJP394insystemiclupuserythematosus(SLE)patientswithahistoryofrenaldisease,2000-2002
Centocor,MEDIIIPso-A-1,Amulticenterplacebo,controlled,doubleblind,randomizedstudyofanti-TNFchimericmonoclonalantibody(cA2,infliximab)inpatientswithactivepsoriaticarthritis,2000-2002
Bristol-MyersSquibb,IM101-101,Amulticenter,randomized,double-blind,placebocontrolledstudytoevaluatethesafetyandefficacyofintravenousinfusionsofBMS-188667givenmonthlyincombinationwithsub-cutaneousinjectionsofetanerceptgiventwiceweeklytosubjectswithactiverheumatoidarthritis,2001-2008
Amgen,2000223,Amulticenterdouble-blindstudytoevaluatethesafetyandefficacyofanakinra(r0metHulIL-ra)andentanerceptinsubjectswithrheumatoidarthritisusingmethotrexate,2001-
Allergan,192371-011-01,Amulticenter,doublemasked,randomized,vehiclecontrolledparallelgroupstudyofthesafetyandefficacyofcyclosporinopthalmicemulationusedtwicedailyfor6monthsinpatientswithmoderatetoseverekeratoconjunctivitis, 2001-2002
Vertex,VX00-745-102,A12week,randomized,double-blind,placebo-controlled,dose-rangingstudyofVX-745inpatients with rheumatoid arthritis, 2001-2002
Hoffman-LaRoche,WA15541c,Adouble-blind,randomized,placebocontrolledstudytoevaluatethesafetyandefficacyofRo32-3555(Trocade)asadjuncttobackgroundantirheumatoidtherapy,inpreventingstructuraldamageinrheumatoid arthritis, 2000-2002
Knoll,DE020,Amulticenter2yearcontinuationstudyofthehumananti-TNFantibodyD2E7administeredasasubcutaneousinjectioninpatientswithrheumatoidarthritis,2001-
ProctorandGamble,Theeffectoftestosteronepatchonactivityofsystemiclupuserythematosus,2001-
Pharmacia,872-IFL-0513-004,Clinicalprotocolforadouble-blind,placebo-controlled,randomizedsixweekcomparisonstudyfortheefficacyofvaldecoxib20mgqdandrofecoxib25mgqdinrelievingthesignsandsymptomsofosteoarthritis of the knee, 2001-2002
Page 9 of 54
OptimeTherapeutics,LEDA.C.001,AphaseIIstudyofthesafetyandefficacyoftopicalliposome-encapsulateddiclofenac analgesic (LEDA) in patients with osteoarthritis of the knee, 2001-2002
Centocor,STARTProtocolCO1168T41,Arandomized,double-blindtrialofthesafetyofTNF-alphachimericmonoclonalantibody(Infliximab)incombinationwithmethotrexatecomparedtomethotrexatealoneinpatientswithrheumatoidarthritisonstandarddiseasemodifyinganti-rheumaticbackgroundtherapy,2001-2003.
XOMA,HURA501.02,APhaseII,Double-blind,Placebo-controlledStudytoDeterminetheSafety,Efficacy,PharmacokineticsandPharmacodynamicsofEfalizumabinSubjectswithModeratetoSevereRheumatoicArthritisonaStableDoseofMethotrexate,2002-2004
CypressBioscience,Inc.,FMS-021,APhaseII,Multicenter,Double-Blind,Randomized,Placebo-ControlledStudyofMilnacipranforTreatmentofFibromyalgia,2002-2003.
Immunex Corporation, 016.0034, Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 1), 2001-2003.ImmunexCorporation,016.0036,Phase3Randomized,Double-Blind,Placebo-controlledStudyof50mgEtanercept(Enbrel®) Administered SC Once Weekly in Patients with Active Rheumatoid Arthritis, 2002-2003
ImmunexCorporation,016.0037,Multicenter,Double-blind,Pacebo-Controlled,RandomizedPhase3StudyofEtanerceptintheTreatmentofpatientswithAnkylosingSpondylitis,2002-2003
Amgen,Inc.,20020103KONTROL,PsychometricAssessmentoftheCedars-SinaiHealthRelatedQualityofLife(CSHQ-RA)InstrumentinRheumatoidArthritisSubjectsReceivingKineretÔ(Anakinra)Therapy,2002-2003.
IsisPharmaceuticals,Inc.,ISIS104838-CS7,ADouble-blind,placebo-controlled,randomizedtrialofthesafety,efficacy,andpharmacokineticprofileofISIS104838(TNF-Ôantisenseoligonucleotide)subcutaneousinjectionsinactiverheumatoid arthritis patients, 2002-2004
Scios,Inc.,782.344,APhaseII,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Dose-EscalatingStudyofSCIO-469 in Patients with Active Rheumatoid Arthritis Receiving Methotrexate, 2002-2004.
Janssen Parmaceutica Products, L.P., CIS-USA-154, Limited access protocol for the use of oral cisapride in the treatment ofrefractorygastroesophagealrefluxdiseaseandothergastrointestinalmotilitydisorders,2002-2005Abbott,Amulticenterstudyofthesafetyofhumananti-TNFmonoclonalantibodyD2E7insubjectswithactiverheumatoid arthritis, 2002-Amgen, Rheumatoid arthritis DMARD intervention and utilization study (RADIUS 2), 2002-2005Genelabs,TheuseofGL701inthepreventionofosteoporosisinpatientsoncorticosteroidswithlupuserythematosus,2003-2005CipherCanada,Adouble-blind,randomized,placebo-controlled,multi-dose,PhaseIII,parallergroupstudyofTramadolER in the relief of signs and symptoms of osteoartahritis of the hip and knee, 2003-2005
Centocor,Amulticenter,double-blindtrialofantiTNFalphachimericmonoclonalantibody(Infliximab)forthetreatmentofsubjectswithpsoriaticarthritis,2003-2005
CentocorOPPOSITE,Openlabel,PilotProtocolofPatientswithRheumatoidArthritiswhoswitchtoInfliximabafterincomplete response to etanercept, 2003-2005
AmgenMRI,TheuseofMRItoDescribeandIdentifytheEarlyFindingsLeadingtoFootErosionsinHighRiskSubjectswith Rheumatoid Arthritis, 2003-
GlaxoSmithKline,CXA20006,AMulticenter,Randomized,Double-Blind,PlaceboandActive-Controlled,Phase2,ParallelGroup,dose-rangingFindingstudyToassesstheSafetyandefficacyofGW406381AdministeredFor42daystoSubjectswithRheumatoidArthritis,2003-2005
IDEC,102-20/WAI17042,ARandomized,Placebo-Controlled,Double-Blind,MulticenterStudytoEvaluatetheSafetyandEfficacyofRituximabinCombinationwithMTXinSubjectswithActiveRheumatoidArthritisWhohavehadaninadequateResponsetoMTXandAnti-TNFalphaTherapies2003-.
Novartis,CCOX189A2335,A13-Week,multicenter,international,randomized,double-blind,placebo-controlled,
Page 10 of 54
parallel-groupstudyofCOX189200mginpatientswithrheumatoidarthritisusingnaproxen500mgb.i.d.ascomparator, 2003-2004
Prometheus,03-MTX-02,MeasurementofMethotrexateandFolatePolyglutamateLevelsandMTHFRPolymorphismsinaCross-SectionofRheumatoidArthritisPatientstoAssessCorrelationsofToxicityandEfficacy,2003-2006
HumanGenomeScience,LBRA01,APhase2,Multicenter,Double-Blind,Placebo-Controlled,Dose-RangingStudytoevaluatethesafety,tolerabilityandEfficacyofLymphoStat-B™(LSB)insubjectswithRA,2004-2005
Abbott,M02-537,AMulticentercontinuationtrialforPatientsCompletingStudyM02-518andM02-570oftheHumanAnti-TNFMonoclonalAntibodyAdalimumab(D2E7)inPatientswithModeratetoSeverelyActivePsoriaticArthritis,2003-2006
Biorad, Collection of Prospective Samples for Investigational Studies of Bio-Rad BioPlex 2200 ANA Screen on the BioPlex 2200, 2004-
SLICC (Systemic lupus erythematosus International Coordinating Committee) Registry for Atherosclerosis, 2003-, Registry for central nervous system lupus, 2003-PrometheusImuranSLE:AnOpenLabelSafetyandEfficacyTrialofImuranforPatientswithSystemicLupusErythematosus, 2004-2006
WyethResearch:Protocol3140A1-200-WW:ADouble-Blind,Placebo-Controlled,Parallel,RandomizedStudytoEvaluatetheEfficacyandSafetyof3OralDoseLevelsofTMI-005inSubjectswithActiveRheumatoidArthritisonaBackground of Methotrexate, 2004-2005.
LJP:Protocol394-90-14:ARandomized,Double-Blind,Placebo-Controlled,Four-ArmParallel-Group,Multicenter,MultinationalSafetyandEfficacyTrialof100mgand300mgofLJP394inSystemicLupusErythematosus(SLE)Patientswith a History of Renal Disease, 2004-2007.
Scios:ProtocolB007:A24-Week,Randomized,Double-Blind,Placebo-Controlled,Parallel-GroupStudyoftheEfficacyofOralSCIO-469inSubjectswithActiveRheumatoidArthritisWhoarenotReceivingDMARDSOtherthanHydroxychloroquine,2004-2006
OrphanMedical,Inc.:ProtocolOMC-SXB-26:Randomized,Double-Blind,Placebo-Controlled,Parallel-Group,Multi-CenterTrialComparingtheEffectsofOrallyAdministeredXyrem(sodiumoxybate)withPlacebofortheTreatmentofFibromyalgia,2004-2005
AmgenBcell:AnexploratorystudytocharacterizethevariabilityincirculatingBcellpopulationsinsubjectswithsystemic lupus erythematosus (SLE), 2004-2006
APhaseIIBMultiCenter,Randomized,Double-Blind,Placebo-ControlledStudytoEvaluatetheEfficacyandSafetyofAbataceptinCombinationTherapywithGlucocorticosteroidsvs.PlaceboplusGlucocorticosteroidsintheTreatmentofActiveSLEandthePreventionofSubsequentLupusFlares,BMS,2005-2007
ARandomized,Double-Blind,Placebo-ControlledMulticenterPhaseII/IIIStudytoEvaluatetheEfficacyandSafetyofRituximabinSubjectswithModeratetoSevereSLE,Genentech,2005-
AMultinational,Multicenter,randomized,doubleblind,placebocontrolled,multipledose,fourarmstudytoassesstheefficacy,tolerabilityandsafety,ofthreedifferentdosesofEdratide(TV-4710)SubcutaneousinjectionsinSLEpatients,TEVA2005-2007
AphaseIII,Randomized,Doubleblind,Placebocontrolled,multicenterstudyofEpratuzumabinpatientswithacutesevere SLE Flares Excluding the Renal or Neurologic Systems, Immunomedics, 2005-2006
APhase2,Multi-Center,Double-Blind,Placebo-Controlled,Dose-RangingStudytoEvaluatetheSafety,Tolerability,andEfficacyofLymphoStat-B™Antibody(MonoclonalAnti-BLySAntibody)inSubjectswithSystemicLupusErythematosus(SLE),HumanGenomeSciences,2005-2007
APhaseIb,multi-centre,double-blind,placebo-controlled,dose-escalating,singledosestudytoassessthesafety,pharmacokineticsandpharmacodynamcsofTACI-Fc5whenadministeredsubcutaneouslytopatientswithSLE,Serono,
Page 11 of 54
2005-2006
Arandomized,double-blind,placebo-controlledstudytoevaluatethesafety,tolerability,pharmacokineticsandpharmacodynamicsofAMG623followingmultidoseadministrationinsubjectswithSLE,Amgen,2005-2006
APhase2studytoevaluatethesafety,tolerabilityandactivityoffontolizumab(HuZaf)inpatientswithactiverheumatoidarthritis,ProtocolZAF-711,sponsoredbyProteinDesignLabs,Inc(PDL),2006-2007
Phase1SingleAscendingDoseStudyoftheSafety,Pharmacokinetics,andPharmacodynamicsofTRU-015AdministeredIntravenouslyinSubjectswithRheumatoidArthritis.Protocol15001,Trubion2004-
Adouble-blind,randomised,placebocontrolled,doseescalating,multi-centerphaseI/IItrialofHuMax-CD20,afullyhumanmonoclonalanti-CD20antibody,inpatientswithactiverheumatoidarthritiswhohavepreviouslyfailedoneormore disease modifying anti-rheumatic drugs. Protocol Hx-CD20-403Genmab,2005-2007
Arandomized,double-blind,parallelgroup,internationalstudytoevaluatethesafetyandefficacyofOcrelizumabcomparedtoplaceboinpatientswithactiveRheumatoidArthritiscontinuingMethotrexatetreatment.ProtocolWA20494/ACT3985g,Genetech,2005-2007
APhaseIII,Multicenter,Open-Label,ContinuationTrialofLymphoStat-BAntibody(MonoclonalAnti-BLysAntibody)inSubjectswithRheumatoidArthritis(RA)whoCompletedthePhaseIILBRA01.ProtocolLBRA99,HumanGenomeSciences, 2006-2009
AnExploratorystudytocharacterizebiomarkerassaysinhealthysubjectsandinsubjectswithRheumatoidArthritis.Protocol 92005637, Amgen 2006-2007
APhaseI,Randomized,Double-Blind,Placebo-Controlled,Dose-EscalationStudytoEvaluateSafetyandTolerabilityofaSingleIVDoseofMEDI-545,aFullyHumanMonoclonalAntibodyDirectedAgainstInterferonAlphaSubtypes,in Patients Who Have Mild System Lupus Erythematosus (SLE) With Cutaneous Involvement. Protocol MI-CP126, MedImmune, 2006-2008
“APhaseIII,Randomized,Double-Blind,PlaceboControlled,MulticenterstudytoevaluatetheEfficacyandSafetyofRituximabinSubjectswithISN/RPSClassIIIorIVLupusNephritis”ProtocolLunar,Genentech,2006-2008
APhaseIII,Randomized,Double-Blind,PlaceboControlled,Multi-CenterstudyofEpratuzumabinPatientswithActiveSystemic Lupus Erythematosus. Protocol Immu-103-03Immunomedics, 2005-2006
AMultiCenter,openlabel,continuationtrialoflymphostatbantibody(monoclonalanti-blysantibody)insubjectwithSystemicLupusErythematosus(SLE)whocompletedthephase2protocollbsl02.ProtocolLBSL9,HumanGenomeSciences, 2006-
GenentechIFN3958g,APhaseI,Randomized,Double-blind,Placebo-controlled,escalatingsingleandmultipledosestudyofthesafety,tolerability,andPharmacokineticsofrhuMAbIFNalphaInadultswithmildlyactiveSLE,2007-2009.
UCBSL0006,AnOpen-LabelRe-treatmentTrialforPatientsPreviouslyRandomizedintotheSL0003andSL0004,Randomized,Double-Blind,Placebo-Controlled,Multi-CenterStudiesofEpratuzumabinpatientswithSLE,2007-.
UCBSL0007,APhaseIib,Randomized,DoubleBlind,Placebocontrolled,doseanddoseregimen-rangingstudyoftheSafetyandEfficacyofEpratuzumabinSerologically-positiveSystemicLupuserythematosuspatientswithActiveDisease.2008-2009
MedimmuneMPI-CP152,APhaseIB,Multicenter,Randomized,Double-blind,Placebo-controlled,doseescalationstudywithanopenlabelextensiontoevaluatethesafetyandtolerabilityofmultipleintravenousdosesofMEDI-545,afullyhumanAnti-Interferon-AlphaMonoclonalAntibody,inpatientswithSystemicLupusErythematosus2007-2010.
HumanGenomeSciencesC1056,APhase3,Multi-Center,Randomized,Double-Blind,placebo-controlled,76-WeekStudytoEvaluatetheEfficacyandSafetyofBelimumab(HGS1006,LymphoStat-B™),aFullyHumanMonoclonalAnti-BlysAntibody,inSubjectswithSLE,2007-2010.
Page 12 of 54
HumanGenomeSciencesC1066,AMulti-Center,ContinuationTrialofBelimumab(HGS1006,LymphoStat-B_), a Fully HumanMonoclonalAnti-BLySAntibody,inSubjectswithSystemicLupusErythematosus(SLE)whoCompletedthePhase3ProtocolHGS1006-C1056intheUnitedStates.2008-
BMSLupusNephritisIM101-075,AsequentialadaptivephaseII/IIImulti-center,randomized,double-blind,placebocontrolledstudytoevaluatetheefficacyandsafetyof AbateceptversusPlaceboonabackgroundofMycophenolateMofetilandGlucocorticoidsinsubjectswithactiveProliferativeGlomerulonephritisduetoSystemicLupusErythematosus (SLE), 2007-
Thesystemiclupuserythematosus(SLE)activitygeneexpression(SAGE)sudy,XDxprotocolSL105,2007-2009BMSIM101-167,APhaseIIIb,Multicenter,Randomized,WithdrawalstudytoevaluatetheImmunogenicityandsafetyofSubcutaneouslyAdministeredAbataceptinAdultswithActiveRheumatoidArthritis,2008-.
NovoNordiskNN8360-3559,Arandomized,double-blind,placebo-controlled,singledose-escalationandmultipledoseextensiontrialofNNC0152-0000-0001administeredi.v.ors.c.insubjectswithSystemicLupusErythematosus.2009
GenentechIFN4575g,AphaseII,Randomized,Double-blind,placebo-controlledstudytoevaluatetheefficacyandsafetyofRontalizumab(rhuMAbIFNalpha)inpaitentswithmoderatelytoseverelyactiveSystemicLupusErythematosus.2009-
Amgen(AMG827)20070264,ARandomized,Double-blind,Placebo-controlled,AscendingMultiple-doseStudytoEvaluatetheSafety,Tolerability,Pharmacokinetics,PharmacodynamicsandEfficacyofAMG827inSubjectswithRheumatoid Arthritis. 2009- 2010
Crescendo Bioscience, Inc. CR10, Index for Rheumatoid Arthritis Measurement (InFoRM) Study. 2009-
ImmuneToleranceNetwork:ProtocolITN034AI,Arandomized,double-blind,controlled,phaseIIMulticentertrialofCTLA4Ig(Abatacept)PlusCyclophosphamidevsCyclophosphamideAloneintheTreatmentofLupusNephritis.2009-2010
ArrayBioPharmaInc.797-201,APhase2,Randomized,Double-Blind,Multicenter,Placebo-Controlled,Parallel-GroupStudyToInvestigateTheSafety,Efficacy,PharmacokineticsandPharmacodynamicsOf12WeeksOfTreatmentWithARRY-371797InPatientsWithActiveAnkylosingSpondylitisAndInadequateResponseToConventionalTherapy.2009-2009
UCBC87094,APhaseIIIB,multi-centrestudywitha12weekdouble-blind,placebo-controlled,randomizedperiod,followedbyanopen-labelextensionphasetoevaluatethesafetyandefficacyofcertolizumabpegoladministeredtopatients with active rheumatoid arthritis. 2008-2010
RocheLaboratoriesInc.ML22533/A,Anopen-label,randomizedstudytoevaluatethesafety,tolerabilityandefficacyoftocilizumab(TCZ)monotherapyorTCZincombinationwithnon-biologicdiseasemodifyingantirheumaticdrugs(DMARDs)inpatientswithactiverheumatoidarthritiswhohaveaninadequateresponsetocurrentnon-biologicorbiologicDMARDs.2009–
SLICC,LymphomaRiskinSLE:AConsequenceofImmuneSuppressionorStimulation?2009-
LupusClinicalTrialsConsortium,Inc.,LCTCLupusDataRegistry.2009-
CedarsSinaiMedicalCenter,CrossCulturalSpanishValidationofLupusPro:APatientReportedOutcomeMeasureforLupus. 2009-
TEVAPharma-APhaseIIa,Multicenter,Randomized,Double-Blind,Placebo-ControlledStudytoEvaluatetheSafety,TolerabilityandClinicalEffectofLaquinimodinSystemicLupusErythematosusPatientswithActiveLupusArthritis.PROTOCOLLA-LAQ-202.2010-,NCT01085084
Cephalon,Inc.-ARandomized,Double-Blind,Parallel-Group,Placebo-ControlledStudytoEvaluatetheEfficacyandSafety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus. 2010-
SanofiAventisUSInc.-Arandomizeddoubleblind-placebocontrolleddoserangingstudytoevaluatetheefficacyand
Page 13 of 54
safetyofSAR153191inpatientswithAnkylosingSpondylitis(AS).ProtocolNumber:DRI11073–ALIGN.2010–2011
UCB-Aphase3,multicenter,randomized,double-blind,placebo-controlledstudytoevaluateefficacyandsafetyofcertolizumabpegolinsubjectswithactiveaxialspondyloarthritis(AS001).2010–2011
UCB.-Phase3,multicenter,randomized,double-blind,parallel-group,placebo-controlledstudytoevaluatetheefficacyandsafetyofcertolizumabpegolinsubjectswithadult-onsetactiveandprogressivepsoriaticarthritis(PsA).2010–2011
StudyofEpratuzumabinsystemiclupuserythematosus,NCT00383513,2010
Duke Autoimmunity Pregnancy Registrsy (DAP Regristry), 2010-2012
StudiesofBcellabnormalitiesinSystemicLupusErythematosusviaMiRNA.2010–2011
ConcurrrentpilotstudiesinGiantcellarteritisandTakayasu’sarteritistoexaminethesafety,efficacy,andimmunologiceffectsofabatacept(CTLA4-Ig)inlargevesselvasculitis.2010–
Hp-MMP 9 levels in humans: a pilot study. 2010
GlaxoSmithKline-LupusImpactTracker:ALongitudinalValidationStudyProtocolGHO-09-16212011-2012
EliLillyandCompany–APhase3,MultiCenter,Randomized,Double-Blind,PlaceboControlledstudytoevaluatetheefficacyandsafetyofSubcutaneousLY2127399inpatientswithSystemicLupusErythematosus(SLE),ProtocolH9B-MC-BCDS 2011-2012
TevaPharmaceuticalIndustries,LLC-APhaseIIa,Multicenter,Randomized,Double-Blind,Placebo-Controlled,StudytoEvaluatetheSafety,TolerabilityandClinicalEffectofLaquinimodinActiveLupusNephritisPatients,inCombinationwith Standard of Care (Mycophenolate Mofetil and Steroids)ProtocolLN-LAQ-2012011–2012
UCB,Inc.-APhase3,Randomized,Doubleblind,placebocontrolled,multicenterstudyoftheEfficacyandSafetyofFour12-WeekTreatmentCycles(48WeeksTotal)ofEpratuzumabinSystemicLupusErythematosusSubjectswithModeratetoSevereDisease(Embody1).Protocol SL0009 2011- 2012
UCB,Inc.–APhase3,Multicenter,openlabel,extensionstudytoassessthesafetyandtolerabilityofEpratuzumabtreatmentinSystemicLupusErythematosusSubjects(Embody4)Protocol SL0012 2011 -
Roche-Arandomized,double-blind,parallelgroupstudyofthesafetyandeffectonclinicaloutcomeoftocilizumabSCversustocilizumabIV,incombinationwithtraditionaldiseasemodifyinganti-rheumatoidarthritisdrugs(DMARDs),inpatients with moderate to severe active rheumatoid arthritis.ProtocolSummactaWA227622011–2014
StudyofLymphomainSystemicLupusErythematosus,SLICC(SystemicLupusInternationalCollaborativeClinics),2009-2011
IRBIS (Internal Registry for Biologics in SLE) Phase I, Retrospective data collection, SLICC (Systemic Lupus International CollaborativeClinics),2010-2012,PhaseIIandIII,2012-
ACR/EULARDiagnosticandClassificationCriteriaforVasculitis,ACR,EULAR,VasculitisFoundation,OxfordUniversitym,2011-2012
Astudytolearnaboutthesafety,effectivenessandeffectsonthebodyofabataceptinlargevesselvasculitis.ConcurrentpilotstudiesinGiantcellarteritisandTakayasu’sarteritis,VasculitisClinicalResearchConsortium,2011-2012
VasculitisClinicalResearchConsortium(VCRC)GeneticRepositoryDNAProtocol,2011-2016,
Page 14 of 54
APhase3/4,Multi-Center,Randomized,Double-Blind,PlaceboControlled,52weekstudytoevaluatetheefficacyandsafetyofBelimumab(HGS1066)inAdultssubjectsofBlackRacewithSystemicLupusErythematosus(SLE),HumanGenomeSciences,2012-
ARandomized,Double-Blind,Placebo-controlled,multipledose,parallel,Multipledose-levelstudytoevaluatethesafety,tolerabilityandefficacyofAMG557in(SLE)subjectswithactiveLupusArthritis,Amgen,2012-2014
ADoubleBlind,Randomized,Placebo-controlled,Multicenter,doserangingstudytoevaluatetheefficacyandsafetyofPF-04236921insubjectswithSystemicLupusErythematosus,Pfizer,2012-2013.
OMRFSjogren’sStudies:GeneExpressionProfilinginPrimarySjogren’sSyndromeAdoseescalation,multi-centerstudytoevaluatethesafety,tolerabilityandproofofmechanismofDV1179inSubjectswith Systemic Lupus Erythematosus, Dynaxax, 2012
APhase3,multicenter,randomized,double-blind,placebo-controlledstudytoevaluatethesafetyandefficacyofsubcutaneousLY2127399inpatientswithsystemiclupuserythematosus(SLE),2012-2014,Lilly,2012-2015 AlongitudinalobservationalstudyofCXCR5,CXCL13andotherbiomarkersinpatientswithlupusandhealthycontrolsubjects,Sanofi,2012-2015
ProtocolWA27893:Prospective,observationalsafetystudyofpatientswithGranulomatosiswithpolyangiitis(Wegener’s)ormicroscopicpolyangiitistreatedwithrituximab,Genentech2012-2014
AStudytoEvaluatetheEfficacyandSafetyofR3336%OintmentAdministeredTopicallytoDLEandSLEPatientswithActive Cutaneous Discoid Lesions , Rigel, 2012-2013
AMulticenter,Randomized,Double-Blind,Placebo-ControlledStudytoEvaluatetheEfficacy,Safety,andTolerabilityofBIIB023inSubjectsWithLupusNephritis, Biogen, 2012- 2013
Aphase111,Multicenter,Randomized,Double-blindPlacebo-controlledStudytoAssessTheefficacyandSafetyofTocilizumabinSubjectsWithGiantCellArteritis,Roche,2013-2015
Nodality–CharacterizationofImmuneAlterationsinSystemicLupusErythematosus(SLE)usingSingleCellNetworkProfiling(SCNP)Protocol2012087SLELandscaping,2013-2014
Ignyta–MolecularAnalysisinBiologicalSpecimensfromSubjectswithRheumatoidArthritis(RA)Protocol–IGN-RA104Ignyta–MolecularAnalysisinBiologicalSpecimensfromSubjectswithSystemicLupusErythematosus(SLE)andNon-LupusControlProtocol–IGN-SLE104,2013-2014
APhaseIIb,Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Multidose,24-WeekStudytoEvaluatetheEfficacyandSafetyofAtaciceptinSubjectsWithSystemicLupusErythematosus(SLE),2013-
ProtocolIMMU-115-04:APhaseIbStudyofMilatuzumabAdministeredSubcutaneouslyinPatientswithActiveSystemicLupus Erythematosus (SLE) 2014-
PharmacokineticEvaluationsofTabalumabFollowingSubcutaneousAdministrationbyPrefilledSyringeorAutoInjectorin Patients with Systemic Lupus Erythematosus, 2014-2015
AnInternational,OpenLabel,RandomizedControlledTrialComparingRituximabwithAzathioprineasMaintenanceTherapyinRelapsingANCA-AssociatedVasculitis(RITAZAREM) 2014-
Anopen-label,Non-randomized,52-weekstudytoevaluatetreatmentHolidaysandreboundphenomenonaftertreatmentwithBelimumab10mg/kginSystemicLupusErythematosussubjects,2015-
A52-week,randomized,double-blind,parallel-group,placebo-controlledstudytoevaluatetheefficacyandsafetyofa200mcgdoseofIPP-201101plusstandardofcareinpatientswithSLE,ImmuPharm-Orion-Simbec(Lupuzor),2015-
WA29748GenentechLupusNephritisstudy,Arandomized,double-blind,placebo-controlled,multicenterstudytoevaluatethesafetyandefficacyofobinutuzumabinpatientswithISN/RPS2003ClassIIIorIVnephritis,2016-
Page 15 of 54
EMRSeronoResearch&DevelopmentInstitute,ProtocolEMR200527-002ProtocolTitle:APhaseIbstudytoevaluatethesafety,tolerability,PKandBiologicalEffectofMSC2364447insystemiclupuserytematosus,2015-2017
Janssen,2016-,AMulticenter,Randomized,Double-blind,Placebo-controlled,Proof-of-ConceptStudyofUstekinumabinSubjectsWithActiveSystemicLupusErythematosusAPhaseIII,Randomized,Multicenter,Double-Blind,SafetyStudyofFerumoxytolComparedtoFerricCarboxymaltosefortheTreatmentofIronDeficiencyAnemia(IDA),2016-2017
ProtocolI4V-MC-JAHH,Lilly,2016-,ARandomized,Double-Blind,Placebo-Controlled,Parallel-Group,Phase2StudyofBaricitinibinPatientswithSystemicLupusErythematosus(SLE)
RSLV-132Protocol132-03,Resolve,2016-,APhase2A,Double-Blind,PlaceboControlledStudyofRSLV-132inSubjectswith Systemic Lupus Erythematosus
ProtocolSL0023,UCB,2016-,AMulti-Cantered,Randomized,Double-Blind,Placebo-Controlled,Parallel-Group,Dose-RangingStudyFollowedbyanObservationPeriodtoEvaluatetheEfficacyandSafetyofDapirolizumabPegolinSubjectswithModeratetoSeverelyActiveSystemicLupusErythematosus,Phase2B
AMulti-Center,Randomized,Double-Blind,Placebo-Controlled,ParallelGroupPhase2AStudytoAssesstheEfficacyofRO5459072inPatientswithSjogren’sSyndrome
2017,Protocol:MS200527-0018,2017APhaseII,Randomized,Double-Blind,Placebo-ControlledDose-RangingStudyToEvaluatetheSafetyandEfficacyofM2951inSubjectswithSystemicLupusErythematosus(SLE)
2017,AurinaPharma,ARandomized,ControlledDouble-blindStudyComparingtheEfficacyandSafetyofVoclosporin(23.7mgTwiceDaily)withPlaceboinAchievingRenalResponseinSubjectswithActiveLupusNephritis
2017,GILEADAPhase2,Randomized,Double-blind,Placebo-controlledStudytoAssesstheSafetyandEfficacyofFilgotinibandGS-9876inFemaleSubjectswithModerately-to-SeverelyActiveCutaneousLupusErythematosus(CLE)
2017,AMPEL,ARandomized,Double-Blind,ActiveComparator-Controlled,CrossoverStudytoAssesstheCapacityofDelayed-Release Prednisone (RAYOS®) Compared to Immediate-Release Prednisone to Improve Fatigue and Control MorningSymptomsinSubjectswithGeneralizedSystemicLupusErythematosus
2017,GA30044,APhaseII,Randomized,Double-blind,Placebo-controlledStudyoftheSafetyandEfficacyofGDC-0853 in Patients with Moderate to Severe Active Systemic Lupus Erythematosus
2017,Exagen17-SLE1CAREStudy,ClinicalLaboratoryAssessmentsandRecommendationsforLupus
2017,AstraZenecaSPOCSD3461R00001,ProspectiveObservationalCohortofpatientswithmoderate-to-severeSLE to characterize cross-sectional and longitudinal disease activity, treatment patterns and effectiveness, outcomes andcomorbidities,healthcareresourceutilization,andtheimpactofSLEonqualityoflifebytypeIinterferongeneexpression
DataSafety,PeerReviewGrantsandMonitoringBoards
2006---Celecoxibforrheumatoidarthritis
2012- 2013 Novo Nordisk Anti IL-21 Protocol NN8828-4002
2016,DepartmentofDefense,PeerReviewofAutoimmuneGrantProposals
ArticlesorLetterstotheEditorinPeerReviewedPublications
1. Wallace D, Aging research: Yesterday and today, Gerontologist, 14: 110-113, 1974.2. Wallace D, Biology of aging: 1976, An overview, J Am Geriatr Soc, 25: 104-111, 1977.3. KlinenbergJ,WallaceD,PlasmapheresisandRaynaud’sDisease,Lancet 1: 1609-1610, 1978.4. WallaceD,KlinenbergJ,MorhaimD,BerlansteinB,BirenP,CallisG,Coexistentgoutandrheumatoidarthritis, Arthritis Rheum 22: 81-86, 1979.5. WallaceD,KlinenbergJ,GattiR,GoldfingerD,BluestoneR,Atherapeuticroleforpheresisinthemanagementof rheumatoid arthritis, Haemonetics Research Institute Advanced Component Seminar, Boston, 1979.6. WallaceD,GoldfingerD,GattiR,LoweC,FanP,BluestoneR,KlinenbergJ,Plasmapheresisand lymphoplasmapheresis in the management of rheumatoid arthritis, Arthritis Rheum 22:703-710, 1979.
Page 16 of 54
7. SomerT,WallaceD,FanP,Immunecomplexmediatedrheumaticdiseases,Rounds, the J of Wadsworth Hospital 19:1-13, 1980.8. SomerT,WallaceD,FanP,Immunecomplexmediatedrheumaticdiseases,Ann Clin Res, 12:77-86, 1980.9. WallaceD,GoldfingerD,Thompson-BretonR,MartinV,LoweC,BluestoneR,KlinenbergJ,Advancesintheuseof therapeutic pheresis for the management of rheumatic diseases, Semin Arthritis Rheum 10: 81-91, 1980.10.WallaceD,Thomsonians:Thepeople’sdoctors,Clio Med 14: 169-186, 1980.11. WallaceD,PodellT,WeinerJ,KlinenbergJ,ForouzeshS,DuboisE,SystemicLupusErythematosus—survival patterns: Experience with 609 patients, JAMA 245: 934-938, 1981.12. Wallace D, Survival patterns in systemic lupus erythematosus, JAMA 246: 2223, 1981.13. WallaceD,BrachmanM,KlinenbergJ,Jointscanninginrheumatoidarthritis:Aliteraturereview,Semin Arthritis Rheumatism 11: 172-176, 1981.14. WallaceDJ,GoldfingerD,KlinenbergJ,Currentstatusoftherapeuticapheresisinrheumatoidarthritis,Art Organs 5: 297-298, 1981.15. WallaceDJ,PodellTE,WeinerJ,CoxM,KlinenbergJ,ForouzeshS,DuboisEL,Lupusnephritis:Experiencewith 230 patients in a private practice from 1950-1980, Am J Med 72: 209-220, 1982.16.PodellTE,WallaceDJ,FishbeinMC,BransfordK,KlinenbergJR,LevineS,Severegiantcellvalvulitisinapatient withReiter’ssyndrome,Arthritis Rheum 25:232-234, 1982.17.WallaceDJ,GoldfingerD,LowerC,NicholsS,WeinerJ,BrachmanM,KlinenbergJ,Adouble-blindcontrolled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis, N Eng J Med 306: 1406-1410, 1982.18.WallaceD,GoldfingerD,KlinenbergJ,Lymphoplasmapheresisinrheumatoidarthritis,N Eng J Med 307: 1271, 1982.19.WallaceDJ,BluestoneR,KlinenbergJR,Thebiologyofagingandtheimmunesystem,Bull Rheum Dis 32: 13-19, 1982.20. WallaceDJ,GoldfingerD,BluestoneR,KlinenbergJR,Plasmapheresisinlupusnephritiswithnephroticsyndrome: A long term follow-up, J Clin Apheresis 1:42-45, 1982.21. Wallace DJ, Status of therapeutic apheresis in rheumatoid arthritis and systemic lupus erythematosus, Upjohn Monograph,September1982.22. WallaceDJ,HamburgerMI,GoldfingerD,BennettRS,Klinenberg,JRApheresisperspectiveforrheumatoid arthritis, Plasma Ther 3: 395-400, 1982.23. KrakauerRS,WysenbeekAJ,WallaceDJ,JonesJV,SmithJW,MacheskyP,GreenstreetR,GoldfingerD,Klinenberg JR,MacLeodV,NoseY,Therapeutictrialofcryofiltrationinpatient.withrheumatoidarthritis,Am J Med 74: 951-955, 1983.24.WallaceDJ,KlinenbergJR,GoldfingerD,Plasmapheresisforrheumatoidarthritis,N Eng JMed 309: 986-987, 1983.25. WallaceDJ,BarnettEV,NicholsS,HancockW,VibertG,CurdJ,KlinenbergJR,GoldfingerD,Immunologic dynamics in cryapheresis for rheumatoid arthritis, J Rheumatol 10:894-900, 1983.26 Wallace DJ, What to do when the SLE patient is a child, J Musculoskeletal Med 1:11, 1984.27. WallaceDJ,Fibromyalgia:Unusualhistoricalaspectsandnewpathogenicinsights,Mt. Sinai J Med 51: 124-131, 1984.28.WallaceDJ,KlinenbergJR,Apheresis,Disease-a-Month 30: 1-45, 1984.29.WallaceDJ,MediciMA,NicholsMA,NicholsS,KlinenbergJR,BickM,GattiR,GoldfingerD,Plasmapheresisversus Iymphoplasmapheresis: Immunologic comparisons and literature review, J Clin Apheresis 2 : 184-189, 1984.30.WallaceDJ,MetzgerAL,WhiteKK,Combinationimmunosuppressivetreatmentofsteroidresistantpolymyositis/ dermatomyositis, Arthritis Rheum 28:590-592, 1985.31.WallaceDJ,Immunonuorescenceandfibromyalgia,Arthritis Rheum 28:836, 1985.32. Wallace DJ, Systemic lupus erythematosus, rheumatology and medical literature: Current trends, JRheumatol 12:913-915, 1985.33. Wallace DJ, Plasmapheresis in rheumatic diseases, Biomed Pharm 40:284-286, 1986.34. WallaceDJ,Theroleofstressandtraumainrheumatoidarthritisandsystemiclupuserythematosus,Semin Arthritis Rheum 16: 1253-157, 1987.35. AdelmanDC,WallaceDJ,KlinenbergJR,34yeardelayed-onsetlupusnephritis,Arthritis Rheum 30: 479-480, 1987.36.WallaceDJ,GoldfingerD,KlinenbergJR,Useofautologouspregnancyplasmatotreataflareofjuvenile rheumatoid arthritis. Case report and literature review. J Clin Apheresis 3:216218, 1987.37. WallaceDJ,DoeshydroxychloroquinesulfatepreventclotformationinSLE?,Arthritis Rheum 30: 1435-1436. 1987.38.WiedmannCE,WallaceDJ,PeterJB,KnightPK,BearM,KlinenbergJR,StudiesofIgG,IgM,IgAantiphospholipid antibodyisotypesinsystemiclupuserythematosus,JRheumatol 15:74-79, 1988.39. WallaceDJ,CommentonthearticlebyLahita,etal,Arthritis Rheum 31: 150-151, 1988.40. WallaceDJ,MargolinK,WallerP,Fibromyalgiaandinterleukin-2therapyformalignancy,Ann Internal Med 108:909, 1988.41. WallaceDJ,Dubois’LupusErythematosus,Ann Internal Med 109:436-437, 1988.42. WallaceDJ,GoldfingerD,GoodmanD,FichmanM,KlinenbergJR,Predictivevalueofoutcomevariablesin immunosuppressive resistant lupus nephritis, J Clin Apheresis 4:30-34, 1988.43. WigfallDR,SakaiRS,WallaceDJ,JordanSC,Interleukin-2receptorexpressioninperipheralbloodlymphocytes from systemic lupus erythematosus patients: relationship to clinical activity, Clin Immunol Immunopath 47:354-362, 1988.
Page 17 of 54
44. WallaceDJ,CommentonarticlebyStudenskietal,Arthritis Rheum 31: 1208, 1988.45. WallaceDJ,BrachmanM,FeldmanG,ReichmanR,KlinenbergJR,Quantitativecomputerizedjointscanningin rheumatoidarthritis:Anaccuratereproduciblemethodofquantitatingsynovitis.Apreliminaryreport,Mt. Sinai J Med 56: 46-52, 1989.46. WallaceDJ,Theuseofquinacrine(Atabrine)inrheumaticdiseases:areexamination,Seminars Arthritis Rheum 18:282-297, 1989.47. WallaceDJ,MetzgerAL,KlinenbergJR,NSAIDUsagepatternsbyrheumatologistsinthetreatmentofsystemic lupus erythematosus, J Rheumatology 16:557-560, 1989.48. WallaceW,BowmanR,WormsleyS,PeterJ,Cytokinesandimmuneregulationintheprimaryfibromyalgia(fibrositis) syndrome, Arthritis Rheum 32: 1334-1335, 1989.49. ChongPJ,MatznerWL,WallaceDJ,KlinenbergJR,ToyodaM,JordanSC,1-25dihydroxyvitamin-D3regulation ofimmunoglobulinproductioninperipheralbloodmononuclearcellsinpatientswithsystemiclupuserythematosus, Journal of Autoimmunity, 2:861-867, 1989.50. WallaceDJ,Genitourinarymanifestationsoffibrositis:Anincreasedassociationwiththefemaleurethralsyndrome,J Rheumatol, 17:238-239, 1990.51. Wallace DJ, Managing arthritis in the elderly, American Operating Roorm Nurses (AORN) Journal 51: 1074-1080, 1990.52. WallaceDJ,MetzgerAL,StecherVJ,TumbullBA,KernPA,Cholesterol-loweringeffectofhydroxychloroquinein patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids, Amer J Med 89:322-326, 1990.53. WallaceDJ,Lupus,acquiredimmunodeficiencysyndrome,andantimalarialagents,Arthritis Rheum 34:373-373, 1991.54.ClarkWF,DauPC,EulerHH,GuillevinL,HasfordJ,HeerAH,JonesJV,KashgarianM,KnatterudG,Lockwood CM,PuseyCD,RifleG,RobinsonJA,SchroederJO,TanEM,WallaceDJ,WeinerSR,Plasmapheresisand subsequentpulsecyclophosphamideversuspulsecyclophosphamidealoneinseverelupus:DesignoftheLPSG trial, J Clin Apheresis 6:40-47, 1991.55.Linker-IsraeliM,DeansRJ,WallaceDJ,PrehnJ,Ozeri-ChenT,KlinenbergJR,ElevatedlevelsofendogenousIL-6in systemic lupus erythematosus. A putative role in pathogenesis, J Immunol 147:117-123, 1991.56.PistinerM,WallaceDJ,NessimS,MetzgerAL,KlinenbergJR,Lupuserythematosusinthe1980s:Asurveyof570 patients, Seminars Arthritis Rheum 21:55-64, 1991. 57.WallaceDJ,Activeidiopathicsystemiclupuserythematosusina90-yearoldwomanrequiringcorticosteroid therapy, J Rheumatology 18:1611-1612, 1991. 58. ChongP,MatznerWL,YamiguchiD,WallaceD,KlinenbergJR,JordanSC,InhibitionofproteinkinaseCin
peripheralbloodmononuclearcellsofpatientswithsystemiclupuserythematosus:Effectonspontaneousimmunoglobulinproduction,Autoimmunity 10:227-231, 1991.
59.WallaceDJ,PistinerM,NessimS,MetzgerAL,KlinenbergJR,Cutaneouslupuserythematosuswithoutsystemiclupuserythematosus:Clinicalandlaboratoryfeatures,Seminars Arthritis Rheum 21:221-226, 1992.
60. WallaceDJ,Fibromyalgia:Clinicalcareanddisability(Editorial),Journal of Musculoskeletal Medicine 9:3,23:1992 (April).
61.WallaceDJ,MetzgerAL,PositiveLEPrepsandnegativeANAsinbrotherswithSLE:Istherestillarolefor theLECell prep? A literature review, J Rheumatol 19:497, 1992.
62.WallaceDJ,AcritiqueoftheNIHlupusnephritissurvey,Arthritis Rheum 35:605, 1992.63.SilvermanSS,WallaceDJ,Calcitoninmayhavesomeeffectinfibromyalgia,JMusculoskeletal Medicine 9: 10, 1992.64. Wallace DJ, Plasmapheresis for lupus nephritis, N Eng J Med 327: 1029, 1992.65.WallaceDJ,Linker-IsraeliM,MetzgerA,StecherVJ,Therelevanceofantimalarialtherapywithregardto
thrombosis,hypercholesterolemiaandcytokinesinSLE,Lupus 2:S13-S15, 1993.66. Wallace DJ, Autologous pregnancy plasma transfusion in RA, Annals of the Rheumatic Diseases, 52:316,1993.67.WallaceDJ,Isfibromyalgiaalegitimatediagnosis?,Journal of Musculoskeletal Medicine 10:13-14 (no. 7),July 1993.68. Wallace DJ, Plasmapheresis in Lupus (Editorial), Lupus 2:141-143, 1993.69.BarthelsHR,WallaceDJ,False-positivehumanimmunodeficiencyvirustestinginpatientswithlupuserythematosus,
Seminars in Arthritis and Rheumatism 23: 1-7, 1993.70. Wallace DJ, Persistent eosinophilia in 2 patients with eosinophilia-myalgia syndrome, Arthritis and Rheumatism 36:
1488, 1993.71. WallaceDJ,Linker-IsraeliM,HyunS.KlinenbergJR,StecherV,Theeffectofhydroxychloroquinetherapyonserum
levels of immunoregulatory molecules in patients with systemic lupus erythematosus, Journal of Rheumatology 21: 375-376, 1994.
72.WallaceDJ,Biography:EdmundLawrenceDubois(1923-1985),Rheumatology Review 3: 49-50, 1994.73.Linker-IsraeliM,HyunS,Ozeri-ChenT,WallaceDJ,BanksK,KlinenbergJR,Elevatedinvivoandinvitrosecretionof
CD8-a molecules in patients with systemic lupus erythematosus, J Immunol 152:31588-3167, 1994.74.WallaceDJ,SystemiclupuserythematosusandSjogren’ssyndrome,EditorialOverview,Current Opinion in
Rheumatology 6:459-460, 1994.75. Wallace DJ, Schwartz E, Breast implants, N Eng J Med 331:1231-1232, 1994.76. Wallace DJ, Classifying cutaneous lupus erythematosus, Int J Dermatol 33:524, 1994.
Page 18 of 54
77.WallaceDJ,LinH-C,ShenGQ,PeterJB,Antibodiestohistone(H2A-H2B)-DNAcomplexesintheabsenceofantibodiestodouble-strandedDNAorto(H2A-H2B)complexesaremoresensitiveandspecificforscleroderma-related disorders than for lupus, Arthritis Rheum 37: 1795-1797, 1994.
78.WallaceDJ,MetzgerAL,Cananearthquakecauseflaresofrheumatoidarthritisorlupusnephritis?,Arthritis Rheum 37: 1826-1828, 1994.
79.HarleyJB,SheldonP,NeasB,MurphyS,WallaceDJ,ScofieldRH,ShaverTS,MoserKL,Systemiclupuserythematosus—considerationsforageneticapproach,JInves Der 103:S144-S149, 1994.
80. Wallace DJ, Controversy over sclerotherapy for malignant pleural effusions, Ann Int Med 121: 151,1994.81. Wallace DJ, Successful use of nitrogen mustard for cyclophosphamide resistant diffuse proliferative lupus
glomerulonephritis, J Rheumatol 22:801-802, 1995. 82. WallaceDJ,SilvermanS,GoldsteinJ,HughesD,Useofhyperbaricoxygeninrheumaticdiseases;casereportand
critical analysis, Lupus 4:172-175, 1995. 83. WallaceDJ,Prevalenceoffibromyalgiainsystemiclupuserythematosuspatients:commentonthearticleby
Middleton et al, Arthritis Rheum 38:872, 1995.84.BarthelHR,WallaceDJ,KlinenbergJRLivertransplantationinpatientswithsystemiclupuserythematosus,Lupus
1995; 4:15-17. 85. WallaceDJ,SchwartzE,LinH-C,PeterJB,The‘rule-outlupus’rheumatologyconsultation:Clinicaloutcomesand
perspectives, J Clinical Rheumatol 1995; 1:158-164. 86. Wallace DJ, Clinical applications, J Clinical Apheresis 1995; 10:104-106. 87. Wallace DJ, Lupus erythematosus cell test, Amer J Clinical Pathology 1005; 104: 110-111. 88. Wallace DJ, Book
Review:TheFibromyalgiaSyndrome:Currentresearchandfuturedirectionsinepidemiology,pathogenesisandtreatment, N Eng J Med 1995; 333:603.
89.NeumannK,WallaceDJ,AzenC,NessimS,FichmanM,MetzgerAL,KlinenbergJR,Lupusinthe1980s:III.Influenceofclinicalvariables,biopsyandtreatmentontheoutcomeof150patientswithlupusnephritisseenatasingle center, Seminars Arthritis Rheum 1995: 25:4755.
90. WallaceDJ,SystemiclupuserythematosusandSjogren’ssyndrome:Editorialoverview,Current Opinion in Rheumatology 1995; 7:369-370.
91. WallaceDJ,Editor,Scientia,Arthritis/Rheumatology,Volume1,Issues1-4,1995,MedicalEducationNetwork,NewYork, NY.
92.WallaceDJ,QuismorioFPJr,Theelusivesearchforgeographicclustersofsystemiclupuserythematosus,Arthritis Rheum, 1995, 38: 1564-1567.
93. Wallace DJ, Rheumatology: A wolf at the door, Patient Care, Sep. 15, 1995, pp 148-149.94. Barthels HR, Wallace DJ, Lupus erythematosus and the liver, Resident &Staff Physician 1996; 42:30-3495.WallaceDJ,Thehistoryofantimalarials,Lupus 1996; 5(supp 1):S2-S3.96.WallaceDJ,Theuseofchloroquineandhydroxychloroquinefornon-infectiousconditionsotherthanrheumatoid
arthritis or lupus: a critical review, Lupus 1996; 5(supp 1):S59-S64.97.Linker-IsraeliM,WallaceDJ,PrehnJL,NandR,LiL,KlinenbergJR,Agreatervariabilityofthe3’flankingregionof
the IL-6 gene in patients with systemic lupus erythematosus, J Autoimmunity, 1996; 23:199-209.98.WallaceDJ,BasbugE,SchwartzE,ClementsP,MetzgerAL,FurstDE,KlinenbergJR,Acomparisonofsystemic
lupuserythematosusandsclerodermapatientswithandwithoutsiliconebreastimplants,JClinical Rheumatology 1996; 2:257-261.
99.WallaceDJ,Editorialoverview:SystemiclupuserythematosusandSjogren’ssyndrome,Current Opinion in Rheumatology 1996; 8:393-394.
100.WallaceDJ,QuismorioFPQ,Geographicclustersofsystemiclupuserythematosus:reply,ArthritisRheum 1996; 39:1936-1937.
101.BarthelHR,MeierLG,WallaceDJ,AntimalariamittelbeirheumatischenErkrankenungen,Deutsche Medizinische Wochenschrift 1996; 121:1576-1582.
102.WallaceDJ,RheumatologyCaseandCommentGoingtoextremities,Patient Care 1997; (Jan 15), 31:145.103.TsaoBP,CantorRM,KalunianKC,ChenCJ,BadshaH.SinghR,WallaceDJ,KitridouRC,ChenSL,ShenN.Song
YW,IsenbergDA,YuCL,HahnBH,RotterJI,Evidenceforlinkageofacandidatechromosome-1regiontohumansystemic lupus erythematosus, J Clinical Investigation 1997; 99 725-731.
104.WallaceDJ,Thefibromyalgiasyndrome,Annals of Medicine 1997; 29: 9-21.105.WallaceDJ,Ishydroxychloroquinedestinedforalargerroleinmanagingsystemiclupuserythematosus?,JClin
Rheumatol 1997; 3: 1-2.106.WallaceDJ,DruzinML,LahitaRG,Clinicalrheumatologicapplicationsofreproductiveimmunology.Facts,fiction,
fancy, Arthritis Rheumatol 1997; 40: 209-216.107.TsaoB.WallaceDJ,Geneticsofsystemiclupuserythematosus:Commentary,Current Opinion in Rheumatology,
1997; 9: 377-374.108.CleggDO,DietzF.DuffyJ,WillkensRF,HurdE,GermainBF,WallB.WallaceDJ,BellCL,SleckmanJ,Safetyand
efficacyofhydroxychloroquineasmaintenancetherapyforrheumatoidarthritisaftercombinationtherapywith
Page 19 of 54
methotrexateandhydroxychloroquine,JRhetonatol 1997; 24: 1896-1902.109.WallaceDJ,Chloroquineandcytokines,JRheumntol1997;24:2051.110.WallaceDJ,DruzinM,LahitaRG,“‘Expertopinion’versushardscience:commentonthereviewbyWallaceetal:
Reply,”ArthritisRheum 1997; 40:1910-1911.l l l. Wallace, D., “Rethinking Somatization, Annals Intern Med 127:1132-l 133, 1997112.TsaoBP,CantorRM,KalunianKC,WallaceDJ,HahnBH,RotterJI,Thegeneticbasisofsystemiclupus
erythematosus, Proc Assoc Amer Physicians 1998; 110: 113-117.113. Cozen L, Wallace DJ, Risk factors for avascular necrosis in systemic lupus erythematosus, J Rheumatol 1998; 25: 188.114. Wallace DJ, A reason for the rarity of male lupus, Lupus 1998; 7: 60.115.LahitaRG,PisetskyDS,WallaceDJ,Lupus:High-stakesDx,broadtreatmentoptions,Patient Care,February28,
1998, pp. 105-123.116. Cozen L, Wallace DJ, Avascular necrosis in systemic lupus erythematosus: Clinical associations and a 47-year
perspective, Amer J Orthopedics 1998; 27:352-354.117. Post S, Wallace DJ, A prevalence survey of lupus in Moorpark, California. Is there any evidence for a lupus cluster,
J Clin Rheumatol 1998; 4: 137-140.118.WallaceDJ,Don’tdumbdownlupuspatientliterature!, J Rheumatol 1998: 25:1650.119.WallaceDJ,Editorialoverview:TenimportanttopicsrelatingtosystemiclupuserythematosusandSjogren’s
syndrome, Curr Opinion Rheumatol 1998; 10:397-398.120.WallaceDJ,GoldfingerD,PepkowitzSH,FichmanM,MetzgerAL,SchroederJO,EulerHH,Randomizedcontrolled
trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis, J Clinical Apheresis 1998; 13: 163-166
121.ShaiR,QuismorioFPJr,KwonOJ,MorrisonJ,WallaceDJ,NeuweltCM,BrautbarC,GaudermanWJ,JacobCO,Genome-widescreenforsystemiclupuserythematosussusceptibilitygenesinmultiplexfamilies,Hum Mol Genet 1999; 8: 639-644.
122.WallaceDJ,Whatconstitutesafibromyalgiaexpert?Arthritis Care and Research 1999; 12: 82-84.123.AdHocCommitteeonNeuropsychiatricLupusNomenclature,TheAmericanCollegeofRheumatology
nomenclatureandcasedefinitionsforneuropsychiatriclupussyndromes, Arthritis Rheum 1999: 42: 599-608.124.Linker-IsraeliM,HondaM,NandR,MandyamR,MengeshaE,WallaceDJ,MetzgerA,BeharierB,KlinenbergJR,
ExogenousIL-10andIL-4down-regulateIL-6productionbySLE-derivedPBMC,Clin Immunology 1999; 91: 6-16.125.WallaceDJ,LyonI,PierreCazenaveandthefirstdetailedmoderndescriptionoflupuserythematosus, Seminars
Arthritis Rheum 1999; 28: 305-313.126.TsaoBP,CantorRM,GrossmanJM,ShenN,TheophilovNT,WallaceDJ,ArnettFC,HartungK,GoldsteinR,
KalunianKC,HahnBH,RotterJI,PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus, J Clin Invest 1999; 103: 1135-1140.
127. Wallace DJ, Apheresis for lupus erythematosus, Lupus 1999; 8: 174-180.128. Wallace DJ, Systemic lupus erythematosus, Science & Medicine 1999; 6: 18-27.129.WallaceDJ,Linker-IsraeliM,It’snotthesameoldlupusorSjogren’sanymore:onehundrednewinsights,
approaches and options since 1990, Current Opinion Rheumatol 1999; 11: 321-329.130.WallaceDJ,ShapiroS,PanushRS,Updateoffibromyalgiasyndrome,Bulletin Rheum Dis 1999; 48: (no.5)131. Wallace DJ, Advances in the management of systemic lupus erythematosus (Editorial), Saudi Med J 1999; 20: 489-490.132. Wallace DJ, Current care for systemic lupus erythematosus, J Musculoskeletal Medicine 1999; 16: 531-539.133.GladmanDD,UrowitzMB,EsdaileJM,HahnBH,KlippelJH,LahitaR,LiangMH,SchurP,PetriM,WallaceD,
Guidelinesforreferralandmanagementofsystemiclupuserythematosusinadults,ArthritisRheum1999;42:1785-1786.134. Wallace DJ, Lupus for the Non-Rheumatologist, Bulletin on the Rheumatic Diseases 1999; 48: 1-4 (n o 9)135.WallaceDJ,Whatconstitutesamortalitystudy?CommentonthearticlebyUramotoetal,ArthritisRheum1999;
42: 2021-2022.136.WallaceDJ,Leukocytapheresisandrheumatoidarthritis:CommentonthearticlebyHidakaetal,ArthritisRheum
42: 2255-2256, 1999.137.PachinianN,WallaceDJ,KlinenbergJR,Mycophenolatemofetilforsystemiclupuserythematosus,J Clin
Rheumatol 1999; 4: 374-376.138.WallaceDJ,WeismanM,Shouldawarcriminalberewardedwitheponymousdistinction?ThedoublelifeofHans
Reiter (1881-1969), J Clin Rheumatol 2000; 6: 49-54.139.WallaceDJ,Istherearoleforquinacrine(Atabrine)inthenewmillennium?(Editorial),Lupus 2000; 9: 81-82.140. Hallegua DS, Wallace DJ, How accelerated atherosclerosis in SLE has changed our management of the disorder,
Lupus 2000; 9: 228-231.141.HalleguaD,WallaceDJ,MetzgerAL,RinaldiRZ,KlinenbergJR,Cyclosporineforlupusmembranousnephritis:
experience with ten patients and review of the literature, Lupus 2000; 9: 241-251.142.WallaceDJ,SalonenE-M,Avaniss-AghajaniE,MorrisR,MetzgerAL,PashinianN,Anti-telomereantibodiesin
systemic lupus erythematosus: a new ELISA test for anti-DNA with potential pathogenetic implications, Lupus 2000;
Page 20 of 54
9:328-332.143.WallaceDJ,MetzgerAL,NeumannK,Osteoporosis--Lessthanexpectedinpatientswithscleroderma, J Rheumatol
2000; 7:1822-1823.144.HalleguaDS,WallaceDJ,Gastrointestinalmanifestationsofsystemiclupuserythematosus, Current Opinion in
Rheumatology 2000; 12:379-385.145.Linker-IsraeliM,WallaceDJ,PrehnJ,MichaelD,HondaM,TaylorDK,PaullabrM,FischelgN,FraserPA,Klinenberg
JR, Assocaition of IL-6 gene alleles with systemic lupus erythematosus and elevated IL-6 expression, Genes Immun 1999; 1: 45-52.
146.TsaoBP,CantorRM,GrossmanJM,ShenN,TeophilovNI,WallaceDJ,ArnettFC,HartungK,GoldsteinR,KalunianKC,HahnBH,RotterJI,PARPalleleswithinthelinkedchromosomalregionareassociatedwithsystemiclupuserythematosus (Reply to letters), J Clin Invest 2000; 105: 1501-1506.
147. PanushRS,MihailescuGD,GornisiewiczMT,SutariaSH,WallaceDJ,Sexandarthrtis,Bulletin of the Rheumatic Diseases 2000; 49: 1-4 (no. 7).
148. Wallace DJ, Clinical and pharmacological experience with LJP-394, Exp Opin Invst drugs 2001; 10: 111-117.149. Wallace DJ, Apheresis for lupus erythematosus--state of the art, Lupus 2001; 10: 193-196.150.AlbanoSA,WallaceDJ,ManagingfatigueinpatientswithSLE,J Musculoskel Medicine 2001; 18: 149-152.151. WallaceDJ,WeismanMH,CommentsregardingHansReiter’sroleinNaziGermany,J Clin Rheumatol 2001; 7:
127-130.152.Linker-IsareliM,ElstnerE,KlinenbergJR,WallaceDJ,KoefflerHP,VitaminD3anditssyntheticanalogsinhibitthe
spontaneousinvitroimmunoglobulinproductionbySLE-derivedPBMC,Clinical Immunology, 99: 82-93, 2001.153. Wallace DJ, SLE--A prospect for the 21st century: Lessons from the past, The Ryumachi 2001; 41:174.154.HondaM,MengeshaE,AlbanoS,NicholsWS,WallaceDJ,MetzgerA,KlinenbergJR,Linker-IsraeliM,Telomere
shorteninganddecreasedreplicativepotential,contrastedbycontinuedproliferationoftelomerasepositiveCD8+CD28-T-cellsinpatientswithsystemiclupuserythematosus, Clin Immunology 20001; 99: 211-221.
155.WallaceDJ,HalleguaDS,Quality-of-life,legal-financial,anddisabilityissuesinfibromyalgia,Current Pain and Headache Reports 2001; 5: 313-319.
156.WallaceDJ,Antimalarials--the‘real’advanceinlupus,Lupus, 2001; 10: 385-387.157. Wallce DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH, Cytokines play an aetiopathogenetic
roleinfibromyalgia:ahypothesisandpilotstudy,Rheumatology (Oxford), 2001; 40: 74-743.158.RemerCF,WeismanMH,WallaceDJ,Benefitsofleflunomideinsystemiclupuserythematosus:apilotobservational
study, Lupus 2001; 10: 480-483.159.PimentelM,ChowEJ,HalleguaD,WallaceD,LinHC,Smallintestinalbacterialovergrowth:Apossibleassociation
withfibromyalgia,JMusculoskeletalPain2001;9:107-113.160.HalleguaDS,WallaceDJ,SilvermanS,BonertV,MathurJR,Prevalenceoffibromyalgiaingrowthhormone
deficientadults,JMusculoskeletalPain2001:35-42.161.DequetCR,WallaceDJ,Noveltherapiesinthetreatmentofsystemiclupuserythematosus,CurrOpinionInvest
Drugs 2001; 2: 1045-1053.162. Wallace DJ, Clinical correlates of avascular necrosis in systemic lupus erythematosus, J Rheumatol 2001; 28: 2365.163. Wallace DJ, Systemic lupus erythematosus, Drugs of Today 2002; 38: 256-263.164. Wallace DJ, Management of lupus erythematosus: recent insights, Curr Opinion Rheumatol 2002: 14: 212-219.165. Solsky MA, Wallace DJ, New therapies in systemic lupus erythematosus, Best Prac Res Clin Immunol 2002; 16:
293-312.166.LanderSA,WallaceDJ,WeismanMH,Celecoxibforsystemiclupuserythematosus:caseseriesandliteraturereview
of the use of NSAIDs in SLE, Lupus 2002; 11: 340-347.167.SilverDS,WallaceDJ,Themanagementoffibromyalgia-associatedsyndromes,Rhem Dis Clin N Am 2002; 28: 405-417.168.WallaceDJ,Siliconebreastimplantsdonotcauserheumaticdiseases,butcantheyinfluencethem?,Arthritis
Rheum 2002; 46: 2545.169.TsaoBP,GrossmanJM,RiemekastenG,StrongN,KalsiJ,WallaceDJ,ChenC-J,LauCS,GinzlerEM,Goldstein
R,KalunianKC,HarleyJB,ArnettFC,HahnBH,CantorRM,Familialityandco-occurrenceofclinicalfeaturesofsystemic lupus erythematosus, Arthritis Rheum 2002; 46: 2678-2685.
170.WallaceDJ,WeismanMH,Theroleofenvironmentalfactorsinrheumaticdiseases,Bulletin on the Rheumatic Diseases,2002;51:number10.
171.TsaoBP,CantorRM,GrossmanJM,KimSK,StrongN,LauCS,ChenJ-J,ShenN,GinzlerEM,GoldsteinR,KalunianKC,ArnettFC,WallaceDJ,HahnBH,Linkageandinteractionoflocion1q23and16q12maycontributetosusceptibilitytosystemiclupuserythematosus,Arthritis Rheum 2002; 46: 2928-2936.
172.WallaceDJ,Pyridostigmineforfibromyalgia:commentonthearticlebyPaivaandahistoricalvignette,Arthritis Rheum 2003; 48: 277-278.
173.WallaceDJ,WeismanMH,ThephysicianHansReiterasprisonerofwarinNuremberg:Acontextualreviewofhisinterrogations (1945-1947), Semin Arthritis Rheum 2003; 32: 208-230.
Page 21 of 54
174.BoumpasDR,FurieR,ManziS,IleiGG,WallaceDJ,BalowJE,VaishnawA,AshortcourseofBG9588(anti-CD40ligandantibody)imprivesserologicactivityanddecreaseshematuriainpatientswithproliferativelupusglomerulonephritis, Arthritis Rheum 2003; 48: 719-727.
175.WallaceDJ,HistoricalVignette:Whenthoughtleadersmislead:“DiscoidlupusisnotrelatedtoSLE”,J Clin Rheumatol 2003; 9:98.
176.WallaceDJ,HistoricalVignette:Raynaud’sphenomenonasperceivedbymusculoskeletalspecialists(1862-1957),J Clin Rheumatol 2003; 9:87.
177.WallaceDJ,GuestEditorial:Apheresisforrheumticandotherautoimmuneconditions:Wheredowestand?, Therapeutic Apheresis and Dialysis 2003; 7: 143-144.
178.ChenLX,EberhardR,EnzenauerRJ,HorwitzHH,LukAJ,MenicoffI,PepmuellarPH,QueenKT,RamanujamT,StrakaPC,SvaraC,TraversR,WallaceD,WatanabeW,WeissT,SchumacherHR,AlookatrheumatologyinChina,J Clin Rheumatol 2003; 9: 228-238.
179.WallaceDJ,WeismanMH,Theuseofetanerceptandothertumornecrosis-alphablockersininfertility:Itstimetoget serious, J Rheumatol 2003; 30: 1897-1899.
180.StrandV,AranowC,CardielMH,Alarcon-SegoviaA,FurieR,SherrerY,TumlinJ,WallaceDJ,Improvementinhealth-relatedqualityoflifeinsystemiclupuserythematosuspatientsenrolledinarandomizedclinicaltrialcomparingLJP394treatmentwithplacebo,Lupus 2003; 12: 677-686.
181. Wallace DJ, Advances in the management of systemic lupus erythematosus, Bulletin on the Rheumatic Diseases, 2004; 51: (no 11) 1-7.
182.PimentelM,WallaceD,HalleguaD,ChowE,KongY,ParkS,LinHC,Alinkbetweenirritablebowelsyndromeandfibromyalgiamayberelatedtofindingsonlactulosebreathtesting,Ann Rheum Dis 2004; 63: 450-452.
183.WallaceDJ,Tofibromyalgianihilists:Stoppontificatingandtestyourhypothesis(Editorial),J Rheumatol 2004; 31: 632.184.WallaceDJ,TumlinJA,LJP394(abetimussodium,Riquent)inthemanagementofsystemiclupuserythematosus,
Lupus 2004; 13: 323-327.185.HorizonA,WallaceD,Risk:benefitratioofnonsteroidalanti-inflammatorydrugsinsystemiclupuserythematosus,
Expert Opinion in Drug Safety 2004; 3: 273-278.186. Wallace DJ, Fever therapy for arthritis, J Clinical Rheumatology 2004; 10:228.187.WallaceDJ,HalleguaDS,Fibromyalgia:Thegastrointestinallink, Curr Pain Headache Rep 2004; 8: 364-368.188.WallaceDJ,Railwayspine,posttraumaticfibromyalgia,andjunkscienceinthecourtroom(ca.1975), J Clinical
Rheumatology 2004; 10: 284.189.NicholMB,ShiS,KnightTK,WallaceDJ,WeismanMH,Eligibility,utilizationandcostsinaCaliforniaMedicaid
lupus population, Arthritis Care Res 2004; 51: 996-1003.190.WallaceDJ,Theendofanera:AcommentaryonthedemiseoftheBulletin on Rheumatic Diseases (1950-2004), J
Clin Rheumatol 2004; 10: 360.191.WallaceDJ,Whiplash.Acaseofregrettingbeingresponsiblefornamingacondition,J Clin Rheumatol 2005; 11: 61.192.WallaceDJ,Rapidpreventionofvertebralfracturesassociatedwithosteoporosis.
Orthopedics. 2005 Mar;28(3):291-8.193.AntoniCE,KavanaughA,KirkhamB,TutuncuZ,BurmesterGR,SchneiderU,FurstDE,MolitorJ,KeystoneE,
GladmanD,MangerB,WassenbergS,WeierR,WallaceDJ,WeismanMH,KaldenJR,SmolenJ,Sustainedbenefitsofinfliximabtherapyfordermatologicandarticularmanifestationsofpsoriaticarthritis:Resultsfromtheinfliximabmultinationalpsoriaticarthritiscontrolledtrial(IMPACT).ArthritisRheum.2005;52:1227-36.
194.HalleguaDS,WallaceDJ,Managingfibromyalgia:Acomprehensiveapproach,JMusculoskeletalMedicine2005;22: 382-390.
195.WuH,CantorRM,GrahamDSC,LingrenCM,FarwellL,deJagerPL,BottiniN,GrossmanJN,WallaceDJ,HahnBH,JulkunenH,HebertLA,RovinBH,BirminghamDJ,RiouxJD,YuCY,KereJ,VyseTJ,TsaoBP,Associationanalysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families.IncreasedTallelefrequencyinsystemiclupuspatientswithautoimmunethyroiddisease,ArthritisRheum2005; 52: 2396-2402.
196.WallaceDJ,ClauwDJ,HalleguaDS,Adressingbehavioralproblemsinfibromyalgia,JMusculoskeletalMedicine2005; 22: 562-579.
197.GinzlerEM,DooleyMA,AranowC,KimMY,BuyonJ,MerrillJT,PetriM,GilkesonGS,WallaceDJ,WeismanMH,AppelGB,Mycophenolatemofetilorintravenouscyclophosphamideforlupusnephritis,N Engl J Med 2005; 353: 2219-2228.
198.ChiouC-F,WeismanM,SherbourneCD,ReyesC,DylanM,OfmanJ,WallaceDJ,MizutaniW,Suarez-AlmazorME, Measuring preference weights for American College of Rheumatology response criteria for patients with rheumatoid arthritis, Arthritis Rheum 2005; 32: 2326-2329.
199.LuC-S,HorizonAA,HwangK-K,FitzGeraldJ,LinW-S,HahnBH,WallaceDJ,MetzgerAL,WeismanMH,ChenPP,Identificationofpolyclonalandmonoclonalantibodiesagainsttissueplasminogenactivatorintheantiphospholipidsyndrome, Arthritis Rheum 2005; 52: 4018-4027.
200.VinaER,FangAJ.WallaceDJ,WeismanMH,Chronicinflammatorydemyelinatingpolyneuropathyinpatientswith
Page 22 of 54
systemic lupus erythematosus: prognosis and outcome, Seminars Arthritis Rheum 2005; 35: 175-184.201.WallaceDJ,Istherearoleforcytokinebasedtherapiesinfibromyalgia?, Current Pharmaceutical Design 2006; 12:
17-22.202.LiangMH,SchurPH,FortinP,StClairEW,BalowJE,CostenbaderK,CroffordL,PabloPD,DooleyMA,Finckh
A,GordonCP,LundbergIE,MeyrierA,NivedO,PonticelliC,SchneiderMK,SinghA,WallaceDJ,TheAmericanCollegeofRheumatologyresponsecriteriaforproliferativeandmembranousrenaldiseaseinsystemiclupuserythematosus clinical trials, Arthritis Rheum 2006; 54: 421-432.
203.WeismanMH,FurstDE,ParkGS,KremerJM,SmithKM,WallaceDJ,CaldwellJR,DervieuxT,Riskgenotypesinfolate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis, Arthritis Rheum 2006; 54: 607-612.
204. Wallace DJ, Is mycophenolate mofetil a safe and effective treatment for patients with systemic lupus erythematosus?, Nature Clinical Practice Rheumatology 2006; 2:2-3.
205.WallaceDJ,UCTDandunfinishedbusiness(Editorial),Current Rheumatology Reviews, 2006; 2: i 206.WallaceDJ,Newmethodsforantinuclearantibodytesting:doesitcutcostsandcornerswithoutjeapordizing
clinicalreliability?,Nature Clinical Practice Rheumatology 2006; 2: 410-411.207.McMahonM,GrossmanJ,FitzGeraldJ,Dahlin-LeeE,WallaceDJ,ThongBY,BadshaH,KalunianK,CharlesC,
NavabM,FogelmanAM,HahnBH,Proinflammatoryhigh-densitylipoproteinasabiomarkerforatherosclerosisinpatients with systemic lupus erythematosus and rheumatoid arthritis, Arthritis Rheum 2006; 54: 2541-2549.
208.WallaceDJ,Sclerodermaassociatedinflammatoryarthritis:Commonandpainful,butignoredbyresearchers,Current Rheumatology Reviews 2006; 2: 309.
209. Wallace DJ, Antimalarial drugs in the treatment of rheumatic diseases, UpToDate, v14.3,September11,2006.210.WallaceDJ,What’snewinthemanagementoflupussince2000?,J Clin Rheumatol 2006; 12: 307-31.211.HanlyJG,UrowitzMB,Sanchez-GuerreroJ,BaeSC,GordonC,WallaceDJ,IsenbergD,AlarconGS,ClarkeA,
BernatskyS,MerrillJT,PetriM,DooleyMA,GladmanD,FortinPR,SteinssonK,BruceI,ManziS,KhamashtaM,ZomaA,AranowC,GinzlerE,VanVollenhovenR,FontJ,SturfeltG,NivedO,Ramsey-GoldmanR,KalunianK,DouglasJ,ThompsonK,FarewellV,Neuropsychiatriceventsatthetimeofdiagnosisofsystemiclupuserythematosus, Arthritis Rheum 2007; 56: 265-273.
212.SpiegelJ,IshimoriML,WallaceDJ,WeismanMH,Thelowestsurvivingbirthweightreportedinasystemiclupuserythematosus patient: a review of the literature, Lupus 2007; 16: 52-55.
213.WallaceDJ,Editorial:Toimmunizeornot?,CurrentRheumatologyReports2007;3:1.214.PanushRS,WallaceDJ,DorffEN,EnglemanEP,Retractionofthesuggestiontousetheterm“Reiter’ssyndrome”
sixty-fiveyearslater:thelegaceofReiter,awarcriminal,shouldnotbeeponymichonorbutrathercondemnation,Arthritis Rheum 2007; 56: 693-700.
215.WuH,BoackleSA,HanvivadhanakuP,UlgiatiD,GrossmanJM,LeeY,ShenN,AbrahamLJ,MercerTR,ParkE,HebertLA,RovinBH,BirminghamDJ,ChangD,ChenCJ,McCurdyD,BadshaHM,ThongBYH,ChngHH,ArnettFC,WallaceDJ,YuCY,HahnBH,CantorRM,TsaoBP.Associationofacommoncomplementreceptor2haplotypewith increased risk of SLE. Proc. Natl. Acad. Sci 2007; 104: 3961-3966.
216.WallaceDJ,Editorial:Atlast..Aviablebiomedicalmodelforfibromyalgia,CurrentRheumatologyReviews,2007;3:93217.ModerKG,WenerMH,WeismanMH,IshimoriML,WallaceDJ,BuckeridgeDL,HombergerHL,Measurementof
antinuclearantibodiesbymultipleximmunoassay:Aprospective,multicenterclinicalevaluation,JRheumatol2007;34: 978-986.
218.FurstDE,GaylisN,BrayV,OlechE,YocumD,RitterJ,WeismanM,WallaceDJ,CruesJ,KhannaD,EckelG,YeildingN,CallegariP,VisvanathanS,RojasJ,HegedusR,GeorgeL,MamunK,GilmerK,TroumO,Open-label,pilotprotocolofpatientswithrheumatoidarthritiswhoswitchtoinfliximabafteranincompleteresponsetoetanercept: the opposite study, Ann Rheum Dis 2007; 66: 893-899.
219. Wallace DJ, Future management of systemic lupus erythematosus, Future Medicine 2007; 2: 229-231. 220.IshimoriM,PressmanBD,WallaceDJ,WeismanMH,Posteriorreversibleencephalopathysyndrome:another
manifestation of CNS SLE?, Lupus 2007; 16: 436-443. 221. Wallace DJ, Why is Current Rheumatology Reviews different than other rheumatology journals? Curr Rheum
Reviews 2007; 3:171. 222. Wallace DJ, Biologic and innovative therapies for systemic lupus erythematosus, Rheumatic Disease Clinics
Updates; 2007; 2: 2-12. 223.FurstDE,GaylisN,BrayV,OlechE,YocumD,RitterJ,WeismanM,WallaceDJ,CruesJ,KhanaD,EckelG,Yeilding
N,CallegariP,VisvanathanS,RojasJ,HegedusR,GeorgeL,MamunK,GilmerK,TroumO,Open-label,pilotprotocolofpatientswithrheumatoidarthritiswhoswitchtoinfliximabafteranincompleteresponsetoetanercept:apilot study, Ann Rheum Dis 2007; 66: 893-899.
224.UrowitzMB,GladmanD,IbanezD,FortinP,SanchezGuerreroJ,BaeS,ClarkeA,BernatskyS,GordonC,HanlyJ,WallaceD,IsenbergD,GinzlerE,MerrillJ,AlarconG,SteinssonK,PetriM,DooleyMA,BruceI,ManziS,KhamashtaM,Ramsey-GoldmanR,ZomaA,SturfeltG,NivedO,MaddisonP,FontJ,vanVollenhovenR,AranowC,KalunianK,StollT,BuyonJ,Clinicalmanifestationsandcoronaryarteryriskfactorsatdiagnosisandsystemiclupus
Page 23 of 54
erythematosus: data from an international conception group, Lupus 2007; 16: 731-735. 225.WallaceDJ,Neuro-Behcet’ssyndrome:Finally,NewInsights,CurrRheumatologyReviews2007;3:242.226. Horizon AA, Wallace DJ, Lupus case studies shed light on key challenges, J Musculoskeletal Medicine 2007; 24;
454-460. 227.Dall’Era,ChakravartyE,WallaceD,GenoveseM,WeismanM,KavanaughA,KalunianK,DharP,VincentE,Pena-
RossiC,WofsyD,ReducedBlymphocyteandimmunoglobulinlevelsafteratacicepttreatmentinpatientswithsystemiclupuserythematosus.Resultsofamulticenter,PhaseIb,double-blind,placebo-controlled,dose-escalatingtrial, Arthritis Rheum 2007; 56: 4142-4150.
228.WallaceDJ,GottoJ,Hypothesis:Bipolarillnesswithcomplaintsofchronicmusculoskeletalpainisaformofpseudofibromyalgia,SeminArthritisRheum2008;37:256-259.
229.WallaceDJ,ImprovingtheprognosisofSLEwithoutprescribinglupusdrugsandtheprimarycareparadox,Lupus2008; 17: 91-92.
230.UrowitzMB,GladmanD,IbanezD,FortinP,Sanchez-GuererroJ,BaeS,ClarkeA,BernatskyS,GordonC,HanlyJ,WallaceD,IsenbergD,GinzlerE,MerrillJ,AlarconGS,SteinssonK,PetriM,DooleyMA,BruceI,ManziS,KhamashtaM,Ramsey-GoldmanR,ZomaA,SturfeltG,NivedO,MaddisonP,FontJ,vanVollenhovenR,AranowC,KalunianK,StollT,Accumulationofcoronaryarterydiseaseriskfactorsover three years: Data from an International Inception Cohort, Arthritis Care Research 2008; 59: 176-180.
231.HanlyJG,UrowitzMB,SiannisF,FarewellV,GordonC,BaeSC,IsenbergD,DooleyMA,ClarkeA,BernatskyS,GladmanD,FortinPR,ManziS,SteinssonK,BruceIN,GinzlerE,AranowC,WallaceDJ,Ramsey-GoldmanR,vanVollenhovenR,SturfeltG,NivedO,Sanchez-GuerreroJ,AlarcónGS,PetriM,KhamashtaM,ZomaA,FontJ,KalunianK,DouglasJ,QiQ,ThompsonK,MerrillJT;SystemicLupusInternationalCollaboratingClinics.Autoantibodiesandneuropsychiatriceventsatthetimeofsystemiclupuserythematosusdiagnosis:Resultsfromaninternationalinceptioncohortstudy.ArthritisRheum.2008Feb29;58:843-853
232.DriverCB,WallaceDJ,LeeJC,ForbessCJ,PourrabbaniS,MinoshimaS,WaxmanAD,WeismanMH.Clinicalvalidation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008Feb29;59:332-337.
233.GordonC,WallaceDJ,ShinadaS,KalunianKC,ForbessL,BraunsteinGD,WeismanMH,Testosteronepatchesin the management of patients with mild/moderate systemic lupus erythematosus.Rheumatology (Oxford). 2008;47:334-8.
234.VenuturupalliRS,WallaceDJ,LupusNephritis—AnUpdate,USRenalDisease2007;TouchBriefings,pp.63-66,2008.
235.HalleguaDS,WallaceDJ,Fightingfibromyalgia:Fivekeyissues,JMusculoskeletalMedicine2008;25:172-184.
236.HanlyJG,UrowitzMB,Sanchez-GuerreroJ,BaeSC,GordonC,WallaceDJ,IsenbergD,AlarconGS,MerrillJT,Clarke A, Bernatsky S, et al, Short term outcome of neuropsychiatric events in systemic lupus upon enrollment into an international inception cohort study, Arthritis Rheum 2008; 59: 721-729.
237.AntoniC,KavanaughA,vanderHeijdeD,BeutlerA,KeenanG,ZhouB,KirkhamB,TutuncuZ,BurmeisterGR,SchneiderU,FurstDE,MolitorJ,KeystoneE,GladmanDD,MangerB,WassenbergS,WeierR,WalalceDJ,WeismanMH,KaldenJR,SmolenJS,Two-yearefficacyandsafetyofinfliximabtreatmentinpatientswithactivepsoriaticarthritis:FindingsoftheInfliximabMultinationalPsoriaticArthritisControlledTrialIMPACT),JRheumatol2008; 35: 869-876.
238.MPetri,NKasitanon,SSLee,KLink,LMagder,SCBae,JGHanly,DAIsenberg,GS,NivedO,Sturfelt,vanVollenhovenR,DJWallace,Alarcon,DAdu,CACasado,SRBernatsky,INBruce,AEClarke,GContreras,DMFine,DDGladman,CGordon,KCKalunian,MPMadaio,BHRovin,JSanchez-Guererro,KSteinsson,CAranow,JEBalow,JPBuyon,EMGinzler,MAKhamashta,MBUrowitz,MADooley,JTMerrill,RRGoldman,JFnt,JTumlin,TStoll,AZoma,SystemicLupusInternationalCollaborativeClinicsRenalActivity/ResponseExercise.DevelopmentofaRenalActivity Score and Renal Response Index, Arthritis Rheum 2008; 58: 1784-1788.
239.MPetri,NKasitanon,SSLee,KLink,LMagder,SCBae,JGHanly,DAIsenberg,GS,NivedO,Sturfelt,vanVollenhovenR,DJWallace,Alarcon,DAdu,CACasado,SRBernatsky,INBruce,AEClarke,GContreras,DMFine,DDGladman,CGordon,KCKalunian,MPMadaio,BHRovin,JSanchez-Guererro,KSteinsson,CAranow,JEBalow,JPBuyon,EMGinzler,MAKhamashta,MBUrowitz,MADooley,JTMerrill,RRGoldman,JFont,JTumlin,TStoll,AZoma,SystemicLupusInternationalCollaborativeClinicsRenalActivity/ResponseExercise.ComparisonofAgreement in Rating Renal Response, Arthritis Rheum 2008; 58: 1789-1795
240. Wallace DJ, Additional components in measuring fatigue in patients with systemic lupus erythematosus: comment onthearticlebytheAdHocCommitteeonSystemicLupusErythematosusResponseCriteriaforFatigue,ArthritisRheum 2008; 59: 1049.
241. Wallace DJ, Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?, Nature Clinical Practice Rheumatology 2008; 4:
Page 24 of 54
242. Wallace DJ, New European recommendations (European League Against Rheumatism 2008) for the management of lupus erythematosus: American perspective, Polskie Archiwum Medycyny Wewnetrznej 2008.
243.CardielMH,TumlinJA,FurieRA,WallaceDJ,JohT,LinnikMD,Abetimussodiumforrenalflareinsystemiclupuserythematosus, Arthritis Rheum 2008; 58: 240-2480.
244.Sanchez-GuerreroJ,Fragoso-LoyoHE,NeuweltM,WallaceDJ,GinzlerEM,SherrerYRS,McIlwainHH,FreemanPG,AranowC,PetriMA,DeodharAA,BlantonE,ManziS,KavanaughA,LisseJR,Ramsay-GoldmanR,McKayJD,KivitzAJ,MeasePJ,WinklerAF,KalLE,LeeAH,FurieRA,StrandCV,LouL,AhmetM,QuarlesB,SchwartzKE,EffectsofPrasteroneonbonemineraldensityinwomenwithactivesystemic lupus erythematosus receiving chronic glucocorticoid therapy, J Rheumatol 2008; 35: 1567-1575.
245. Wallace DJ, New European recommendations (European League Against Rheumatism 2008) for the management of lupus erythematosus: American perspective, Polskie Archiwum Medycyny Wewnetrznej, 2008; 118: 402-403.
246.WallaceDJ,Celebrexforlupus,ArthritisRheum2008;58:2923247. Wallace DJ, Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?, Nature
Clinical Practice Rheumatology 2008; 4: 450-451. 248.PetriM,NaqibuddinZM,CarlsonKC,SampedroM,WallaceDJ,WeismanMH,HollidaySL,PadillaPA,BreyRL,
Cognitive function in a systemic lupus erythematosus inception cohort, J Rheumatology 2008; 35: 1776-1781. 249.PetriM,NaqibuddinM.CarsonKA,WallaceDJ,WeismanMH,HollildaySL,SampedroM,NarayanaS,Fox
PT,FranklinC,PadillaPA,BreyRL,Brainmagneticresonanceimaginginnewlydiagnosedsystemiclupuserythematosus, J Rheumatology 2008; 35: 2348-2354.
250and251.UptoDate(Epublication)chapters:Antimalarialdrugsinthetreatmentofrheumaticdisease,Differential diagnosis of systemic lupus erythematosus (with Peter Schur) for 2007, 2008 and 2009 editions.
252.AskanaseAD,WallaceDJ,WeismanMH,TsengCE,BernsteinL,BelmontM,SeidmanE,IshimoriM,IzmirlyPM,BuyonJP,Useofpharmacogenetics,enzymaticphenotyping,andmetabolitemonitoringtoguidetreatment with azathioprine in patients with systemic lupus erythematosus, J Rheumatol 2009; 36: 89-95.
253.WallaceDJ,Newtherapiesinsystemiclupuserythematosus---trials,troublesandtribulations---workingtowardsasolution: part 2---the politically incorrect version, Lupus 2009; 18: 101-103.
254.HanlyJG,UrowitzMB,BaeSC,GordonC,WallaceDJ,ClarkeA,BernatskyS,IsenbergD,AnisurA,AlarconGS,GladmanDD,FortinPR,Sanchez-GuererroJ,RomeroDiazJ,MerrillJT,GinzlerE,BruceIN,vanVollenhovenR,NivedO,SturfeltG,AranowA,KalunianK,Ramos-CasalsM,ZomaA,DouglasJ,ThompsonK,FarewelV,Prospective analysis of neuropsychiatric events in an international disese inception cohort of SLE patients, Annals Rheum Dis 2009;
255.PosalskiJD,IshimoriM,WallaceDJ,WeismanMH,Doesmycophenolatemofetilpreventextra-renalflaresinsystemiclupuserythematosus?Resultsfromanobservationalstudyofpatientsinasinglepracticetreatedforupto5 years, Lupus 2009; 18:516-521.
256.McMahonM,GrossmanJ,SkaggsB,FitzGeraldJ,SahakianL,RagavendraN,Charles-ShoemanC,WatsonK,WongWK,VolkmanE,chenW,GornA,KarpouzasG,WeismanM,WallaceDJ,HahnBH,Dysfunctionalproinflammatoryhigh-densitylipopoteinsconferincreasedriskofatherosclerosisinwomenwithsystemiclupuserythematosus, Arthritis Rheum 2009; 60: 2428-2437.
257.BelouskiSS,WallaceD,WeismanM,IshimoriM,HendricksL,ZackD,VincentM,RasmussenE,FerbasJ,ChungJ,SamplestabilityandvariabilityofB-cellsubsetsinbloodfromhealthysubjectsandpatientswithsystemiclupuserythematosus,CytometryPartB:ClinicalCytometry;EPubAug10,2009;2009;00B:78B:49-58,2010
258.FurieRA,PetriMA,WallaceDJ,GinzlerEM,MerrillJT,StohlW,ChathamWW,StrandV,WeinsteinA,ChevrierMR,ZhongZJ,FreimuthWW,Novelevidence-basedsystemiclupuserythematosusresponderindex,ArthritisRheum2009; 61: 1143-1151.
259.WallaceDJ,StohlW,FurieRA,LisseJR,McKayJD,MerrillJT,PetriMA,GinzlerEM,ChathamWW,McCuneWJ,FernandezV,ChevrierMR,ZhongZJ,FreimuthWW,APhaseII,randomized,double-blind,placebo-controlled,dose-rangingstudyofbelimumabinpatientswithactivesystemiclupuserythematosus,ArthritisRheum2009;61:1168-1178.
260.LuLJ,WallaceD,IshimoriM,ScofieldR,WeismanM,Malesystemiclupuserythematosus:areviewofsexdisparities in this disease; Lupus 2009; 19: 119-129.
261.MerillJT,NeuweltCM,WallaceDJ,ShanahanJC,LatinisKM,OatesJC,UtsetTO,GordonC,IsenbergDA,HsiehHJ,ZhangD,BrunettaPG,Efficacyandsafetyofrituximabinmoderately-to-severalyactivesystemiclupuserythematosus, Arthritis Rheum 2010; 62: 222-233.
262.VolkmannER,GrossmanJM,SahakianLJ,SkaggsBJ,FitzGeraldJ,RagavendraN,Charles-SchoemanC,ChenW,GornA,KarpouzasG,WeismanM,WallaceDJ,HahnBH,McMahonM,Lowphysicalactivityisassociatedwithproinflammatoryhigh-densitylipoproteinandincreasedsubclinicalatherosclerosisinwomenwithsystemiclupuserythematosus, Arthritis Care Research 2010; 62: 258-265.
Page 25 of 54
263.RobinsonDJr,AguilarD,SchoenwetterM,DuboisR,RussakS,Ramsey-GoldmanR,NavarraS,HusB,RevickiD,CellaD,RapaportMH,RenahanK,RessR,WallaceD,WeismanM,Impactofsystemiclupuserythematosusonhealth,familyandwork:Thepatientperspective,ArthritisRheum2010;62:266-273.
264.LuL-J,WallaceDJ,NavarraSV,WeismanMH,Lupusregistries:Evolutionandchallenges,SeminarsArthritisRheum2010: 39: 224-245.
265.HanlyJG,UrowitzMB,SuL,BaeSC,GordonC,WallaceDJ,ClarkeA,BernaskyS,IsenbergD,RahmanA,AlarconGS,GladmanDD,FortinPR,SanchezGuererroJ,RomeroDiazJ,MerrillJT,GinzlerE,BruceIN,SteinssonK,KhamashtaM,PetriM,ManziS,DooleyMA,Ramsey-GoldmanR,vanVolenhovenR,NivedO,SturfeltG,AranowC,KalunianK,Ramos-CasalsM,ZomaA,DouglasJ,ThompsonK,Varewell,Prosepectiveanalysisofneuropsychiatricevents in an international disease inception cohort of patients with systemic lupus erythematosus, Annals Rheum Dis 2010; 69: 529-535.
266.BelouskiSS,WallaceD,WeismanM,IshimoriM,HendricksL,ZackD,VincentM,RasmussenE,FerbasJ,ChungJ,SamplestabilityandvariabilityofB-cellsubsetsinbloodfromhelthysubjectsandpatientswithsystemiclupuserythematosus, Cytometry Part B (Clinical Cytometry) 2010, 788: 49-58.
267.WallaceDJ,Telomerediseases,NewEnglJMed2010;362:1150.268. Wallace DJ, Furie RA, Freimuth WW, Reply to letter to the editor, Arthritis Care and Research 2010; 62: 582269.UrowitzMB,GladmanD,IbanezD,BaeSC,Sanchez-Guererro,GordonC,ClarkeA,BernatskyS,FortinPR,Hanly
JG,WallaceDJ,IsenbergD,RahmanA,AlarconGS,MerrillJT,GinzlerE,KhamashtaM,NivedO,SturfeltG,BruceIN,SeinssonK,ManziS,RamseyGoldmanR,DooleyMA,ZomaA,KalunianK,RamosM,VanVollenhovenR,AranowC,StollT,PetriM,MaddisonP,Atheroscleroticvasculareventsinamultinationalinceptioncohortofsystemic lupus erythematosus, Arthritis Care Res 2010; 62: 881-887.
270.MerrillJT,Burgos-VaragasR,WesthovensR,ChalmersA,D’CruzD,WallaceDJ,BaeSC,SigalL,BeckerJC,RaphupathiK,PengLT,KinasczukM,NashP,Theefficacyandsafetyofabataceptinpatientswithnon-life-threatening manifestations of SLE: Results of a 12-month exploratory study, Arthritis Rheum 2010; 62: 3077-3087.
271.OsstergaardM,BaslundB,RibbyW,RojkovichB,JorgensonC,DawesPT,WiellC,WallaceDJ,TamerSC,KastbergH,PetersenJ,SierakowskiS,Ofatumumab,ahumanantiCD-20monoclonalantibodyfortreatmentofrheumatoidarthritispatientswithaninadequateresponsetooneormoreDMARDs:resultsofadouble-blind,randomized,placebo-controlled,PhaseI/IIstudy,ArthritisRheum2010;62:2227-2238.
272.PetriM,NaqibuddinM,CarsonKA,WallaceDJ,WeismanMH,HollidaySL,SampedroM,PadillaPA,BreyRL,Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus, J Rheumatol. 2010; 37: 2032-2038.
274.IsenbergDA,AlleneE,FarewellV,d’CruzD,AlarsonGS,AranowA,BruceIN,DooleyMA,FortinPR,GinzlerEM,GladmanDD,HanlyJG,InancM,KalunianK,KhamashtaM,MerrillJT,NivedO,PetriM,Ramsey-GoldmanR,SturfeltG,UrowitzM,WallaceDJ,GordonC,RahmanA,Anassessmentofdiseaseflareinpatientswithsystemiclupuserythematosus:acomparisonofBILAG2004andtheflareversionofSLEDAI,AnnalsRheumDis2010;70:54-59.
275.WallaceDJ,Thrombovasculareventsinsystemiclupuserythematosus:commentonthearticlebyJungetal,Arthritis Rheum 2010; 68: 2823.
276.HalleguaDS,WallaceDJ,Fightingfibromyalgia:Fiveissues,JMusculoskeletalMedicine,2010;27:S3-9.277.WallaceDJ,ClauwDJ,HalleguaDS,Addressingbehavioralabnormalities,JMusculoskeletalMedicine2010;27:
S21-27. 278.CarrFN,NicassioPM,IshimoriML,MoldovanI,KatsarosE,TorralbaK,ShinadaS,CoorayD,WallaceDJ,FinckS,
Jolly M, Wilson AL, Weisman MH, Depression predicts self-reported disease activity in systemic lupus erythematosus (SLE), Lupus 2011; 20: 80-84.
279.OstergaardM,BaslundB,RigbyW,RojkovichB,JorgensenC,DawesPT,WiellC,WallaceDJ,TamerSC,KastbergH,PetersenJ,SierakowskiS,Reducedfrequencyandseverityofinfusion-relatedadverseeventsafterchangeinofatumumabinfusionregimen—ReplytocommentbyAbeles,ArthritisRheum2011;63:305-310.
280.RasmussenA,SevierS,KellyJA,GlennSB,AberleT,CooneyCM,GretherA,JamesE,NingJ,TesiramJ,MorriseyJ,PoweT,DrexelM,DanielW,NamjouB,OjwangJO,NguyenKL,CavettJW,TeJL,JamesJA,ScofieldRH,MoserK,GilkesonGS,KamenDL,CarsonCW,Quintero-Del-RioAI,BallesterosMD,PunaroMG,KarpDR,WallaceDJ,WeismanM,MerrillJT,RiveraR,PetriMA,AlbertDA,EspinozaLR,UtsetTO,ShaverTS,ArthurE,AnayaJM,BrunerGR,HarleyJB,TheLupusFamilyRegistryandRepository,Rheumatology(Oxford).2010;
281. Wallace DJ, Advances in drug therapy for systemic lupus erythematosus, BMC Medicine 2010; 8:77, 1-19.282.Ishimori,M.L,Martin,R.,Berman,D.S.,Goykhman,P.,Shaw,L.J.,Shufelt,C.,Slomka,P.J.,Thomson,L.E.J.,
Schapira,J.,Yang,Y.,Wallace,D.J.,Weisman,M.H.,BaireyMerz,N.Myocardialischemiaintheabsenceofobstructivecoronaryarterydiseaseinsystemiclupuserythematosus.JAmCollCardiolImg2011;4(1):27-33.
283.MundwilerML,MaranianP,BrownDH,SilvermanJM,WallaceD,KhannaD,LouieJ,FurstDE,WeismanMH.,Theutility of MRI in predicting radiographic erosions in the metatarsalphalangeal joints of the joints of the rheumatoid
Page 26 of 54
foot:aprospectivelongitudinalcohortstudy,ArthritisResTher.2009;11(3):R94.Epub2009Jun22.284. Ippolito A, Wallace DJ, GladmanD, Fortin P, Urowitz M, WerthV, Costner M, GordonC, AlarcónG, Ramsey-
GoldmanR, Maddison P, Clarke A, Bernatsky S, Manzi S, Bae SC, Merrill J, GinzlerE, Hanly J, Nived O, SturfeltG, Sanchez-GuerreroJ, Bruce I, Aranow C, IsenbergD, Zoma A, Magder L, Buyon J, KalunianK, Dooley M, Steinsson K, VollenhovenR, StollT, Weisman M, Petri M.,Autoantibodiesinsystemiclupuserythematotosus:Comparisonofhistorical and current assessment of seropositivity, Lupus 2011; 20: 250-255.
285.HanlyJG,UrowitzMB,JacksonD,BaeSC,GordonC,WallaceDJ,ClarkeA,BernatskyS,VasudevanA,IsenbergD,RahmanA,Sanchez-GuerreroJ,Romero-DiazJ,MerrillJT,FortinPR,GladmanDD,BruceIN,SteinssonK,KhamashtaM,AlarcónGS,FesslerB,PetriM,ManziS,NivedO,SturfeltG,Ramsey-GoldmanR,DooleyMA,AranowC,VanVollenhovenR,Ramos-CasalsM,ZomaA,KalunianK,FarewellV,Autoantibodiesasbiomarkersforthe prediction of neuropsychiatric events in systemic lupus erythematosus, Ann Rheum Dis 2011; 70: 1726-1732.
286.FiroozN,AlbertDA,WallaceDJ,IshimoriM,BerelD,WeismanMH,HighsensitivityC-reactiveproteinanderythrocyte sedimentation rate in systemic lupus erythematosus, Lupus 2011;20: 588-597.
287.WallaceDJ,BookReview:UnderstandingHughes’Syndrome.Casestudiesforpatients,JRheum2011;38:787.288.HanlyJG,UrowitzMB,JacksonD,BaeSC,GordonC,WallaceDJ,ClarkeA,BernatskyS,VasudvanA,Isenberg
D,RahmanA,Sanchez-GuerreroJ,Romero-DiazJ,MerrillJT,FortinPR,GladmanDD,BruceIN,SteinssonK,KhamashtaM,AlarconGS,FesslerB,PetriM,ManziS,NivedO,SturfeltG,Ramsey-GoldmanR,DooleyMA,AranowC,vanVollenhovenR,Ramos-CasalsM,ZomaA,KalunianK,FarwellV,SF-36summaryandsubscalescoresarerelaiableoutcomesofneuropsychiatriceventsinsystemiclupuserythematosus,AnnRheumDis2011:70:961-967.
289.McMahonM,SkaggsBJ,SahakianL,GrossmanJ,FitzGeraldJ,RagavendraN,Charles-SchoemanC,ChernishofM,GornA,WitztumJL,WongWK,WeismanM,WallaceDJ,LaCavaA,HahnBH,Highplasmaleptinlevelsconferincreasedriskofatherosclerosisinwomenwithsystemiclupus,andareassociatedwithinflammatoryoxidixedlipids,Ann Rheum Dis doi:10.1136/ard 2010.142737 2011: 70: 1619-1624.
290.VinetE,ClarkeAE,GordonC,UrowitzM,HanlyJG,PineauCA,IsenbergD,RahmanA,WallaceD,AlarconGS,BruceI,PetriM,DooleyMA,KalunianK,MaddisonP,AranowC,vonVollenhovenR,BernatskyS,Decreasedlivebirthsinwomenwithsystemiclupuserythematosus,ArthritisCareResearch2011;63:1068-1072.
291.MerrillJT,WallaceDJ,PetriM,KirouKA,YaoY,WhiteWI,RobbieG,LevinR,BerneySM,ChindaloreV,OlsenN,RichmanL,LeC,JallalB,WhiteB,Safetyprofileandclinicalactivityofsifalumumab,afullyhumananti-interferonalphamonoclonalantibody,insystemiclupuserythematosus:aphaseI,multicentre,double-blindrandomizedstudy,Annals Rhem Dis ; 2011; 70: 1905-1913.
292.BagheriS,WallaceDJ,PrescribingtrendsfortargetedtherapiesinrheumatoidarthritisamongrheumatologistsinSouthern California (2008-2010), Arthritis Rheum 2011; 63: 3641.
293.MoldovanI,KatsarosE,CarrFN,CoorayD,TorralbaK,ShinadaS,IshimoriML,JollyM,WallaceDJ,WeismanMH,NicassioPM,ThepatientreportedoutcomesinLupus(PATROL)study:roleofdepressioninhealth-relatedqualityoflifeinasouthernCalifornialupuscohort,Lupus2011;20:1285-1292.
294.RamageAE,FoxPT,BreyRL,NarayanaS,CykowskiMD,NaqibuddinM,SampedroM,HollidaySL,FranklinC,WallaceDJ,WeismanMH,PetriM,Neuroimagingofwhitematterinflammationinnewlydiagnosedsystemiclupuserythematosus, Arthritis Rheum 2011; 63: 3048-3057.
295.FurieR,PetriM,ZamaniO,CerveraR,WallaceDJ,TegzovaD,Sanchez-guererroJ,SchwartingA,MerrillJT,ChathamWW,StohlW,GinzlerEM,HoughDR,FreimuthW,vanVollenhovenR,APhaseIII,randomized,placebo-controlledstudyofbelimumab,amonoclonalantibodythatinhibitsBlymphocytestimulator,inpatientswithsystemic lupus erythematosus, Arthritis Rheum 2011; 63: 3918-3930.
296.JollyM,PickardAS,SequeiraW,WallaceDJ,SolemCT,MikolaitisRA,FoggL,WeismanMH,BlockJA,CashTF,Abriefassessmenttoolforbodyimageinsystemiclupuserythematosus,BodyImage.2012;9:279-284.
297.DillonSP,KurienBT,LiS,BrunerGR,HarleyJB,GaffneyPM,WallaceDJ,WeismanMH,ScofieldRH,Sexchromosome aneuploidies among men with systemic lupus erythematosus, J Autoimmun 2012; 38L J129-134.
298.UrowitzMB,GladmanDD,IbanezD,FortinPR,BaeSC,GordonC,ClarkeA,BernatskyS,HanlyJG,IsenbergD,RahmanA,Sanchez-Guererro,WallaceDJ,GinzlerE,AlarsonGS,MerrillJT,BruceIN,SturfeltG,NivedD,SteinssonK,KhamashtaM,PetriM,ManziS,Ramsey-GoldmanR,DooleyMA,vanVollenhovenR,RamosM,StollT,ZomaA,KalunianK,AranowC,Evolutionofdiseaseburdenoverfiveyearsinamulticenterinceptionlupuserythematosuscohort, Arthritis Care Res 2012; 64: 132-137.
299. Wallace DJ, A guide to successfully treating patients with SLE, Medscape Rheumatology (SF 75820.1)300.GoykhmanP,MehtaPK,MinissianM,ThompsonLEJ,BermanDS,IshimoriM,WallaceDJ,WeismanMH,Shufelt
CL,BaireyMerzN,Subendocardialischemiaandsystemiclupuserythematosusdetectedbycardiacmagneticresonance imaging, J Rheumatol 2012; 39: 448-450.
301.vanVollenhovenRF,JacobsenS,WallaceD,HanlyJG,PetriM,IsenbergDA,ClarkeAE,PineauCA,BernatskyS,
Page 27 of 54
SimardJF,BaeS-C,Ramos-CasalsM,Diaz-LigaresC,Ruiz-IrastorzaG,Martinez-BerriotxoaA,Garcia-HernandezFJ,Castilo-PalmaMJ,SaezL,CallejasJL,RasconJ,deRamonE,Ayala-GutierrezMM,CampsM,MildM,InancM,Artim-EisenB,Ramsay-GoldmanR,PeschkenCA,SquartritoD,EmmiL,KovacsL,DoriaA,SkekaneczZ,FerraccioliG,GremeseE,SatoEI,BiologicsuseinSLEin23centers—datafromtheinternationalregistryforbiologicsinSLE,Annals Rheum Dis 2012; 71:
302.HanlyJA,UrowitzMB,SuL,GordonC,BaeS-C,Sanchez-GuererroJ,Romero-DiazJ,WallaceDJ,ClarkeAE,GinzlerEM,MerrillJT,IsenbergDA,RahmanA,PetriM,FortinPR,GladmanDD,BruceIN,SteinssonK,DooleyMA,KhamashtaMA,AlarconGS,FesslerBJ,Ramsey-GoldmanR,ManziS,ZomaAA,SturfeltGK,NivedO,AranowC,MackayM,Ramos-CasalsM,vanVollenhovenRF,KalunianKC,Ruiz-IrastorzaG,LimS,KamenDL,PeschkenCA,InancM,TheriaultC,ThompsonK,FarewellV,Seizuredisordersinsystemiclupuserythematosus:Resultsfromaninternational, prospective, inception cohort, Annals Rheum Dis 2012: 71: 1502-1509.
303.JollyM,PickardAS,BlockJA,KumarRB,MikolaitisRA,WilkeCT,RodbyRA,FoggL,SequeiraW,UtsetTO,CashTE,MoldovanJ,KalastarosE,NicassioP,IshimoriML,KosinskyM,MerrillJT,WeismanMH,WallaceDJ,Disease-specificpatientreportedoutcometoolsforsystemiclupuserythematosus,SeminarsArthRheum2012;42:56-65.
304.HahnBH,McMachonMA,WilkinsonA,WallaceWD,DaikhD,FitzgeraldJD,KarpouzasGA,MerrillJA,WallaceDJ,YazdanyY,Ramsay-GoldmanR,SinghK,KhalighiM,ChoiSI,GoogiaM,KafajaS,KamgarM,LauC,MartinWJ,ParikhS,PengJ,RastogiA,ChenW,GrossmanJM,AmericanCollegeofRheumatologyGuidelinesforScreening,TreatmentandManagementofLupusNephritis,ArthritisCareRes2012;64:797-808.
305.PetriM,OrbaiAM,AlarconGS,GordonC,MerrillJT,FortinPR,BruceIN,IsenbergD,WallaceDJ,NivedO,SturfeltG,Ramsay-GoldmanR,BaeSC,HanlyJG,Sanchez-GuerreroJ,ClarkeA,AranowC,ManziS,UrowitzM,GladmanD,KallunianK,CostnerM,WerthVP,ZomaA,BernatskyS,Ruiz-IrastorzaG,KhamashtaMA,JacobsenS,BuyonJP,MaddisonP,DooleyMA,VanvollenhovenRF,GinzlerE,StollT,PeschkenC,JorizzoJL,CallenJP,LimSS,FesslerBJ,InancM,KamenDL,RahmanA,SteinssonK,FranksAGJr,SiglerL,HameedS,FangH,PhamN,BreyR,WeismanMH,McGwinGJr,MagderLS,Derivationandvalidationofsystemiclupusinternationalcollaboratingclinicsclassificationcriteriaforsystemiclupuserythematosus,ArthritisRheum2012;64:2677-2686.
306. Wang FF, Zhu LA, Zou YQ, Zheng H, Wilson A, Yang CD, Shen N, Wallace DJ, Weisman MH, Chen SL, Lu LJ, New insightsintotheroleandmechanismofmacrophagemigrationinhibitioryfactorinsteroid-resistantpatientswithsystemiclupuserythematosus,ArthritisResTher2012;May14:R103.
307.MerrillJT,GinzlerEM,WallaceDJ,McKayJD,LisseJR,AranowC,WellborneFR,BurnetteM,CondemiJ,ZhongZH,PindedaL,Klein,FreimuthWW,Long-termsafetyofbelimumabplusstandardtherapyinpatientswithsystemiclupus erythematosus, Arthritis Rheum 2012
308.ChathamWW,WallaceDJ,StohlW,LatinisKM,ManziS,McCuneWY,TegzovaD,McKayJD,Avila-ArmengolHE,UtsetTO,ZhongZJ,FreimuthWW,MigoneTS,Effectofbelimumabonvaccineantigenantibodiestoinfluenza,pneumococcal and tetanus vaccines in patiens with systemic lupus erythematosus in the BlISS-76 trial, J Rheumatol 2012; 39:1632-1640.
309.WallaceDJ,GudsoorkarVS,WeismanMH,VenuturupalliSR,Newinsightsintomechanismsoftherapeuticeffectsof antimalarial agents in SLE, Nat Rev Rheumatol 2012; 8: 522-533.
310.McBrideJM,JiangJ,AbbasA,MorimotoA,LiJ,MaciucaR,TownsendM,WallaceDJ,KennedyWP,DrappaJ,SafetyandpharmacodynamicsresultsofrontilzumabinaphaseI,placebo-controlled,double-blind,dose-escalationstudy in systemic lupus erythematosus, Arthritis Rheum 2012: 64:3666-3676
311.ParkerB,UrowitzMB,GladmanDD,LuntM,BaeS-C,Sanchez-GuerreroJ,Romero-DiazJ,GordonC,WallaceDJ,ClarkeAE,BernatskyS,GinzlerEM,IsenbergDA,RahmanA,MerrillJT,AlarconGS,FesslerBJ,FortinPR,HanlyJG,PetriM,SteinssonK,DooleyMA,ManziS,KhamashtaMA,Ramsey-GoldmanR,ZomaAA,SturfeltGK,NivedO,AranowC,McKayM,Ramos-CasalsM,vanVollenhovenRF,KalunianKC,Ruiz-IrastorzaF,LimS,KamenDL,PeschkenCA,InancM,BruceIN,Clinicalassociationsofthemetabolicsyndromeinsystemiclupuserythematosus:data from an international inception cohort, Annals Rheum Dis 2012:
312.LuR,RobertsonJM,BrunerBF,GuthridgeJM,NeaseBR,NathSK,KellyJA,MoserSivlisKL,ChakavartyEF,KamenDL,GilkesonGS,WallaceDJ,ScofieldRH,KarleyJB,JamesJA,Multipleautoantibodiesdisplayassociationwithlymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort, Autoimmune diseases, 2012;
313.VenuturupalliS,GudsoorkarV,WallaceD,Reconsideringantimalarialsinsystemiclupuserythematosus:Developments of translational interest, J Rheumatology 2012; 39: 1769-1771
314.MerrillJT,GinzlerEM,WallaceDJ,McKayJD,LisseJR,AranowC,WellborneFR,BurnetteM,CondemiJ,ZhongZJ,PinedaL,KleinJ,FreimuthWW,Longtermsafeyprofileofbelimumabplusstandardtherapyinpatientswithsystemic lupus erythmatosus, Arthritis Rheum 2012; 64: 3364-3373
315. Wu B, Wilson A, Wang FF, Wang SI, Wallace DJ, Weisman MH, Lu LJ, Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China, PLoS One 2012; 7 (10): e47373, doid: 10.1371/journal.pone.0047373
316.WangSL,WangFF,ChenSL,ShenN,XueF,YeP,BaoCD,GuYY,WilsonA,WallaceDJ,WeismanMH,LiLJ,Expression, localization and clinical application of exogenous Smith proteins D1 in gene transfected HEp-2 cells, Int
Page 28 of 54
J Rheum Dis 2012; 1-7. 317.WallaceDJ,NavarraS,PetriMA,GallacherA,ThomasM,FurieR,LevyRA,vanVollenhovenRF,CooperS,Zhong
ZJ,FreimuthW,CerveraR,Safetyprofileofbelimumab:pooleddatafromplacebo-controlledphase2and3studiesin patients with systemic lupus erythematosus, Lupus 2013; 22: 144-154.
318.ParkerB,UrowitzMB,GladmanDD,LuntM,BaeSC,Sanchez-GuerreroJ,Romero-DiazJ,GordonC,WallaceDJ,ClarkeAE,BernatskyS,GinzlerEM,IsenbergDA,RahmanA,MerrillJT,AlarcónGS,FesslerBJ,FortinPR,HanlyJG,PetriM,SteinssonK,DooleyMA,ManziS,KhamashtaMA,Ramsey-GoldmanR,ZomaAA,SturfeltGK,NivedO,AranowC,MackayM,Ramos-CasalsM,vanVollenhovenRF,KalunianKC,Ruiz-IrastorzaG,LimS,KamenDL,PeschkenCA,InancM,BruceIN,Clinicalassociationsofthemetabolicsyndromeinsystemiclupuserythematotus:data from an international inception cohort, Ann Rheum Dis. 2012 Sep 22. 72: 1308-1314
319.WallaceD,NavarraS,PetriM,GallacherA,ThomasM,FurieR,LevyR,vanVollenhovenR,CooperS,ZhongZ,FreimuthW,CerveraR,Safetyprofileofbelimumab:pooleddatafromplacebo-controlledphase2and3studiesinpatientswithsystemiclupuserythematosus,Lupus.2012Dec4.[Epubaheadofprint]
320.WallaceDJ,KalunianK,PetriMA,StrandV,HoussiauFA,PikeM,KalgallenB,BongardtS,BarryA,KelleyL,GordonL,Efficacyandsafetyofepratuzumabinaptientswithmoderate/severeactivesystemiclupuserythematosus:resultsfromEMBLEM,aphaseIIb,randomized,double-blind,placebo-controlledmulticentrestudy,Ann Rheum Dis 2014; 73: 183-190.
322.BernatskyS,Ramsey-GoldmanR,JosephL,BolvenJ-F,CostenbanderK,UrowitzM,GladmanDD,FortinFR,NivedO,PetriMA,JacobsenS,ManziS,GinzlerEM,IsenbergID,RahmanA,GordonC,Ruiz-IrastorzaG,YelinE,BaeSC,WallaceDJ,PeschkenCA,DooleyMA,EdworthySM,AranowC,KamenDL,Romero-DiazJ,AskanaseA,WitteT,BarrSG,CriswellLA,SturfeltGK,BlancoI,FeldmanCH,DreyerL,PatelNM,StPierreY,ClarkeAE,Lymphomariskin systemic lupus: effects of disease activity versus treatment, Ann Rheum Dis 2014; 13: 138-142
323.ClowseMEB,WallaceDJ,WeismanM,JamesA,Criscione-SchreiberLG,PisetskyDS,Predictorsofpretermbirthinpatientswithmildsystemiclupuserythematosus,AnnalsRheumDis2013;72:1536-1539.
324.BernatskyS,Ramsey-GoldmanR,LabrecqueJ,JosephL,BoivinJF,PetriM,ZomaA,ManziS,UrowitzMB,GladmanD,FortinPR,GinzlerE,YelinE,BaeSC,WallaceDJ,EdworthyS,JacobsenS,GordonC,DooleyMA,PeschkenCA,HanlyJG,AlarcónGS,NivedO,Ruiz-IrastorzaG,IsenbergD,RahmanA,WitteT,AranowC,KamenDL,SteinssonK,AskanaseA,BarrS,CriswellLA,SturfeltG,PatelNM,SenécalJL,ZummerM,PopeJE,EnsworthS,El-GabalawyH,McCarthyT,DreyerL,SibleyJ,StPierreY,ClarkeAE,Cancerriskinsystemiclupus:Anupdatedinternational multi-centre cohort study,J Autoimmun. 2013; 42: 130-135.
325.PetriM,WallaceDJ,SpindlerA,ChindaloreV,KalunianK,MyslerE,NeuweltCM,RobbieG,WhiteWI,HiggsBW,YaoY,WangL,EthgenD,GrethW,Sifalimumab,ahumananti-interferon-amonoclonalantibody,insystemiclupuserythematosus:AphaseIrandomizedcontrolled,dose-escalationstudy,ArthritisRheum.201365:1011-1021Feb11. doi: 10.1002/art.37824
326.DJWallace;CGordon;VStrand;KHobbs;MPetri;KKalunian;FHoussiau;PP.Tak;DA.Isenberg;LKelley;BKilgallen;AN.Barry;WA.Wegener;DM.Goldenberg,Efficacyandsafetyofepratuzumabinpatientswithmoderate/severeflaringsystemiclupuserythematosus:resultsfromtworandomized,double-blind,placebo-controlled,multicentrestudies(ALLEVIATE)andfollow-up Rheumatology 2013; doi: 10.1093/rheumatology/ket129. 1313-1322
327.JollyM,TolozaS,BlockJ,MikolaitisR,KosinskiM,WallaceD,Durran-BarraganS,BertoliA,BlavezicI,LillallL,CoorayD,MoldovanI,KastarosE,WeismanM,TorralbaKM,AlcaronG,SpanishLupusPRO:Crossculturalvalidation study in lupus; Lupus 2013: 22: 431-436.
328.WallaceDJ,GoldenbergD,Epratuzumabforsystemiclupuserythematosus,Lupus.2013;22(4):400-5.doi:10.1177/0961203312469692.
329.IshimoriML,AndersonL,WeismanMH,MehtaPK,BaireyMerzCN,WallaceDJ,Microvascularangina:Anunderappreciated cause of SLE chest pain, J Rhumatol 2013; 40: 746-747.
330.WallaceDJ,Qualityguidelinesforsystemiclupuserythematosus:Slowbutsteadyprogress,JRheumatol2013;40:542-543.
331.WallaceDJ,Tendevelopmentsintheuseofbiologicalforsystemiclupuserythematosus,CurrRheumatolRep2013; 15:337
332.RossiEA,GoldenbergDM,MichelR,RossiDL,WallaceDJ,ChangC-H,TrogocytosisofmultipleB-cellsurfacemarkersbyCD-22-targetingwithepratuzumab,Blood2013;122:3020-3029.Blood-2012-publishedaheadofprintJuly2,2013,doi:10.1182/blood-2012-12-473744
334.MoldovanI,CoorayD,FarrF,KatsarosE,TorralbaK,ShinadaS,IshimoriM,JollyM,WilsonA,WallaceD,WeismanM, Nicassio P, Pain and depression predict self-reported fatigue/energy in lupus, Lupus 2013; 22: 684-689.
335.TessierCloutierB,ClarkeAE,Ramsey-GoldmanR,WangY,FoulkesW,GordonC,HansenJE,YelinE,UrowitzMB,GladmanD,FortinPR,WallaceDJ,PetriM,ManziS,GinzlerEM,LabrecqueJ,EdworthyS,DooleyMA,SenécalJL,PeschkenCA,BaeSC,IsenbergD,RahmanA,Ruiz-IrastorzaG,HanlyJG,JacobsenS,NivedO,WitteT,CriswellLA,BarrSG,DreyerL,SturfeltG,BernatskyS,Breastcancerinsystemiclupuserythematosus,Oncology.2013Jul
Page 29 of 54
25;85(2):117-121. 336.GrossmanJM,HahnBH,McMahonMA,FitzGeraldJD,MerrillJT,YazdanyJ,WallaceDJ,Ramsey-GoldmanR,
Managinglupusnephritisinpregnantwomen:commentonthearticlebyHahnetal:Reply,ArthritisCareRes2013;65: 1392.
337.WangSL,WangFF,ChenSL,ShenN,XueF,YeP,BaoCD,GuYY,YuCZ,WilsonA,WallaceDJ,WeismanMH,LuJL, Expression, localization and clinical application of exogenous Smith proteins D1 in gene transfected HEp-2 cells, Int J Rheum Dis 2013; 16: 303-309.
338.McMahonM,SkaggsB,GrossmanJ,SahakianL,FitzgeraldL,WongWK,LaurencoE,RagavendraN,Charles-SchoemanC,GornA,KarpouzasG,TaylorM,WatsonK,WeismanM,WallaceDJ,HahnBH,Apanelofbiomarkersis associated with increased risk for the presence and progression of atherosclerosis in women with systemic lupus erythematosus,ArthritisRheum2013;Sept24doi:10.1992/art38204(Epubaheadofprint)2014;66:130—139.
339.LuM,BernatskyS,Ramsy-GoldmanR,PetriM,ManziS,UrowitzMB,GladmanMB,FortinFR,GinzlerEM,YelinE,BaeSC,WallaceDJ,JacobsenS,DooleyMA,PeschkenCA,AlarconGS,NivedO,GottesmanL,CriswellLA,SturfeltG,DreyerL,LeeJL,ClarkeAE,Non-lymphomahematologicalmalignanciesinsystemiclupuserythematosus,Oncology 2013; 85: 235-240.
340.HanlyJG,UrowitzMB,O’KeefeAG,GorsonC,BaeSC,Sanchez-GuerrerroJ,Romero-DiazJ,ClarkeAE,BernatskyS,WallaceDJ,GinzlerEM,IsenbergDA,RahmanA,MerrillJT,PetriM,FortinPR,gladmanDD,FesslerBJ.AlarconGS,BruceIN,DooleyMA,SteinssonK,KhamashtaMA,Ramsey-GoldmanR,ManziS,SturfeltGK,NivedO,ZomaAA,vanVolenhovenRF,Ramos-CasalsM,AranowC,MackeyM,Ruiz-IrastorzaG,KalunianKC,LimSS,KamenDL,PeschkenCA,JacobsenS,TheriaultC<ThompsonK,FarewellV,Headacheinsystemiclupuserythematosus:resultsfrom a prospective, International inception cohort study, Arthritis Rheum 2013; 65: 2887-2297.
341.GinzlerEM,WallaceDJ,MerrillJT,FurieRA,StohlW,ChathamWW,WeinsteinA,McKayJD,McCuneWJ,ZhongZJ,FreimuthWW,PetriMA,Diseasecontrolandsafetyofbelimumabplusstandardtherapyover7yearsinpatientswithsystemiclupuserythematosus,JRheumatol2013;Nov1(Epubaheadofprint)41:300-307.
342.StrandV,PetriM,KalunianK,GordonC,WallaceDJ,HobbsK,KelleyL,KilgallenB,WegenerWA,GoldenbergDM,EpratuzumabforpatientswithmoderatetosevereflaringSLE:healthrelatedqualityoflifeoutcomesandcorticosteroiduseintherandomizedcontrolledALLEVIATEtrialsandextensionstudySL0006,Rheumatology(Oxford);2013;Nov22(Epubaheadofprint)
343. 25-Hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: Data from a large internationalinceptioncohort,LertratanakulA,WuP,DyerA,UrowitzM,GladmanD,FortinP,BaeSC,GordonC,ClarkeA,BernatskyS,HanlyJG,IsenbergD,RahmanA,MerrillJ,WallaceDJ,GinzlerE,KhamashtaM,BruceI,NivedO,SturfeltG,SteinssonK,ManziS,DooleyMA,KalunianK,PetriM,AranowC,FontJ,vanVollenhovenR,StollT,Ramsey-GoldmanR,ArthritisCareRes2014;Jan27,doi10.1002/acr22291(Epubaheadofprint).
344.Changesinqualityoflifeinthefirst5yearsofdiseaseinamulticentrecohortofpatientswithsystemiclupuserythematosus(SLE),UrowitzM,GladmanDD,IbañezD,Sanchez-GuerreroJ,BaeSC,GordonC,FortinPR,ClarkeA,BernatskyS,HanlyJG,WallaceDJ,IsenbergD,RahmanA,MerrillJ,GinzlerE,AlarcónGS,FesslerB,KhamashtaM,SteinssonK,PetriM,DooleyM,BruceIN,ManziS,SturfeltG,NivedO,Ramsey-GoldmanR,ZomaA,MaddisonP,KalunianK,vanVollenhovenR,AranowC,Romero-DiazJ,StollT.,ArthritisCareRes(Hoboken).2014;66:1374-1379 345. Martin DA, ChurchillM,Flores-SuarezL,CardielMH,WallaceD,MartinR,PhillipsK,KaineJL,DongH,SalingerD,StevensE,RussellCB,ChungJB,AphaseIbmultipleascendingdosestudyevaluatingsafety,pharmacokinetics,andearlyclinicalresponseofbrodalumab,ahumananti-IL-17Rantibody,inmethotrexate-resistantrheumatoidarthritis.ArthritisResTher.2013Oct25;15(5):R164.doi:10.1186/ar4347.
346.MullerS,WallaceDJ.Theimportanceofimplementingproperselectionofexcipientsinlupusclinicaltrials,Lupus2014;23:609-614.25Feb2014doi:10.1177/0961203314525249.347.ParkerB,UrowitzMB,GladmanDD,LuntM,DonnR,BaeS-C,Sanchez-Guererro,Romero-DiazJ,GordonC,WallaceDJ,etal,Impactofearlydiseasefactorsonmetabolicsyndromeinsystemiclupuserythematosus:datafrom an international inception cohort, Ann Rheum Dis 2013-203033 doi10.1136/ ; 2105; 74:1530-1536. 348.UrowitzMB,GladmanDD,IbanezD,Sanchez-GuererroJ,Romero-DizJ,GordonC,BaeSC,ClarkeAE,BernatskyS,FortinPR,HanlyJG,IsenbergD,RahmanA,WallaceDJ,GinzlerE,MetriM,BruceIN,MerrillJT,NivedO,SturfeltG,DooleyMA,AlarconGS,FesslerB,SteinssonK,Ramsey-GoldmanR,ZomaA,KhamashtaM,ManziS,vanVollenhovenR,Ramos-CasalsM,AranowC,StollT,AmericanCollegeofRheumatologyCriteriaatinception,and accrual over 5 years in the SLICC inception cohort, J Rheumatol 2014; Apr 1; 41: 875-880.
349.Bourré-TessierJ,UrowitzMB,ClarkeAE,BernatskyS,KrantzMJ,HuynhT,JosephL,BelisleP,BaeSC,HanlyJG,WallaceDJ,GordonC,IsenbergD,RahmanA,GladmanDD,FortinPR,MerrillJT,Romero-DiazJ,Sanchez-GuerreroJ,FesslerB,AlarcónGS,SteinssonK,BruceIN,GinzlerE,DooleyMA,NivedO,SturfeltG,KalunianK,Ramos-CasalsM,PetriM,ZomaA;SLICCinvestigators,PineauCA,Electrocardiographicfindingsinsystemiclupuserythematosus:Datafromaninceptioncohort,ArthritisCareRes(Hoboken).2015;67:128-135.
Page 30 of 54
350.JollyM,GarrisCP,MIkolaitisRA,JhingranPM,DennisD,WallaceDJ,ClarkeA,DooleyMA,ParkeA,StrandV,AlarconGS,KosinskiM,DevelopmentandvalidationoftheLupusImpactTracker:Apatient-completedtoolforclinical practice to access and monitor the impact of systemic lupus erythematosus; Arthritis Care & Research 2014; 64: 1542-1550.
351.LertratanakulA,WuP,DyerA,UrowitzM,GladmanD,FortinP,BaeS-C,GordonC,ClarkeA,BernatskyS,HanlyJG,IsenbergD,RahmanA,MerrillJ,WallaceDJ,GinzlerE,KhamashtaM,BruceI,NivedO,SturfeltG,SteinssonK,ManziS,DooleyMA,KalunianK,PetriM,AranowC,FontJ,vanVollenhovenR,StollT,Ramsey-GoldmanR,25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: Data from a large large international inception cohort, Arthritis Care Res 2014: 66: 1167-1176.
352.OrbaiAM,TruedssonL,SturfeltG,NivedO,FangH,AlarcónG,GordonC,MerrillJ,FortinP,BruceI,IsenbergD,WallaceD,Ramsey-GoldmanR,BaeSC,HanlyJ,Sanchez-GuerreroJ,ClarkeA,AranowC,ManziS,UrowitzM,GladmanD,KalunianK,CostnerM,WerthV,ZomaA,BernatskyS,Ruiz-IrastorzaG,KhamashtaM,JacobsenS,BuyonJ,MaddisonP,DooleyM,VanVollenhovenR,GinzlerE,StollT,PeschkenC,JorizzoJ,CallenJ,LimS,FesslerB,InancM,KamenD,RahmanA,SteinssonK,FranksAJr,SiglerL,HameedS,PhamN,BreyR,WeismanM,McGwinGJr,MagderL,PetriM,Anti-C1qantibodiesinsystemiclupuserythematosus,Lupus.2015;24:42-49
353.WallaceDJ,GavinIM,KarpenkoO,BarkhordarF,GillisBS,Cytokineandchemokineprofilesinfibromyalgia,rheumatoidarthritisandsystemiclupuserythematosus:apotentiallyusefultoolindifferentialdiagnosis,RheumatolInt;DOI10.1007/s00296-014-3172-2,EpubNov7,2014.354.HanlyJG,SuL,UrowitzMB,Romero-DiazJ,GordonC,BaeSC,BernatskyS,ClarkeAE,WallaceDJ,MerrillJT,IsenbergDA,RahmanA,GinzlerEM,PetriM,BruceIN,DooleyMA,FortinP,GladmanDD,Sanchez-GuerreroJ,SteinssonK,Ramsey-GoldmanR,KhamashtaMA,AranowC,AlarcónGS,FesslerBJ,ManziS,NivedO,SturfeltGK,ZomaAA,vanVollenhovenRF,Ramos-CasalsM,Ruiz-IrastorzaG,SamLimS,KalunianKC,InancM,KamenDL,PeschkenCA,JacobsenS,AskanaseA,TheriaultC,ThompsonK,FarewellV,Mooddisordersinsystemiclupuserythematosus: Results from an international, inception cohort study, Arthritis Rheumatol. 2015; 67:1837-1847.
355.SandhuVK,WallaceDJ,WeismanMH,Monoclonalantibodies,systemiclupuserythematosusandpregnancy:Insightsfromanopen-labelstudy,JRheumatology2015;42:728-730.
356.ModiM,IshimoriML,SandhuVK,WallaceDJ,WeismanMH,Chestpaininlupuspatients:theemergencydepartmentexperience,ClinRheumatol2015;April26(Epubaheadofprint)
357.WallaceDJ,Theevolutionofdrugdiscoveryinsystemiclupuserythematosus,NatRevRheumatol2015:June30doi:10.1038/nrrheum.2015.86(Epubaheadofprint)
358.Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus InternationalCollaboratingClinics(SLICC)InceptionCohort IanNBruce,AidanGO’Keeffe,VernFarewell,JohnGHanly,SusanManzi, LiSu,DafnaDGladman,Sang-CheolBae,JorgeSanchez-Guerrero,Juanita Romero-Diaz,CarolineGordon,DanielJWallace,AnnEClarke,Sasha Bernatsky,EllenMGinzler,DavidAIsenberg,AnisurRahman,JoanT Merrill,GracielaSAlarcón,BarriJFessler,PaulRFortin,Michelle Petri,KristjanSteinsson,MaryAnneDooley,MuntherAKhamashta, RosalindRamsey-Goldman,AsadAZoma,GunnarKSturfelt,OlaNived, Cynthia Aranow, Meggan Mackay, Manuel Ramos-Casals, Ronald F van Vollenhoven,KennethCKalunian,GuillermoRuiz-Irastorza,SamLim,Diane LKamen,ChristineAPeschken,MuratInanc,MurrayBUrowitz AnnRheumDis2015;74:1706-1713PublishedOnlineFirst:16May2014
359.UrowitzMB,IsenbergDA,WallaceDJ,SafetyandefficacyofhCDR1(Edratide)inpatientswithactivesystemiclupus erythematosus; results of phase II study, Lupus Science & Medicine 2-15;2:e000104, doi:10,1136/lupus-2015-000104.
360.StohlW,MerrillJT,LooneyRJ,BuyonJ,WallaceDJ,WeismanMH,GinzlerEM,CookeB,HollowayD,KaliyaperumalA,KuchimanchiKR,CheahTC,RasmussenE,FerbasJ,BelouskiSS,TsumiW,ZackDJ,TreatmentofsystemiclupuserythematosuspatientswiththeBAFFantagonist“peptibody”blisibimod(AMG623/A623):resultsfromrandomized,double-blindphase1aandphase1btrials,ArthritisResearch&Therapy2015;17:215(1-14)
361.IsenbergDA,PetriM,KalunianK,TanakaY,UrowitzMB,HoffmanRW,Morgan-coxM,Iikuni,SilkM,WallaceDJ,Efficacyandsafetyofsubcutaneoustabalumabinpatientswithsystemiclupuserythematosus:resultsfromILLUMINATE-1,a52week,phaseIII,multicenter,randomized,double-blind,placebo-controlledstudy,AnnRheuumDis2015;0:1-9doiL10.1136/annrheumdis-2015-207653.75:323-331361.HanlyJG,O’KeeffeAG,SuL,UrowitzMB,Romero-DiazJ,GordonC,BaeSC,BernatskyS,ClarkeAE,WallaceDJ,MerrillJT,IsenbergDA,RahmanA,GinzlerEM,FortinP,GladmanDD,Sanchez-GuerreroJ,PetriM,BruceIN,DooleyMA,Ramsey-GoldmanR,AranowC,AlarcónGS,FesslerBJ,SteinssonK,NivedO,SturfeltGK,ManziS,KhamashtaMA,vanVollenhovenRF,ZomaAA,Ramos-CasalsM,Ruiz-IrastorzaG,LimSS,StollT,InancM,KalunianKC,KamenDL,MaddisonP,PeschkenCA,JacobsenS,AskanaseA,TheriaultC,ThompsonK,FarewellV,Thefrequencyandoutcomeoflupusnephritis:
Page 31 of 54
resultsfromaninternationalinceptioncohortstudy,Rheumatology(Oxford).2015Sep5.pii:kev311.[Epubaheadofprint]
362.WallaceDJ,HobbsK,ClowseME,PetriM,StrandV,PikeM,MerrillJT,LeszczynskiP,NeuweltCM,JekaS,HoussiauF,KeisermanM,Ordi-RosJ,BongardtS,KilgallenB,GalateanuC,KalunianK,FurieR,GordonC.,Long-termsafetyandefficacyofepratuzumabinthetreatmentofmoderate-to-severesystemiclupuserythematosus:resultsfromanopen-labelextensionsstudy,ArthritisCareRes(Hoboken).2015Aug28.doi:10.1002/acr.22694.[Epubaheadofprint]PMID:26316325
363.Hui-YuenJS,ReddyA,TaylorJ,LiX,EichenfieldAH,BermudezLM,StarrAJ,ImundoLF,BuyonJ,FurieRA,KamenDL,ManziS,PetriM,Ramsey-GoldmanR,vanVollenhovenRF,WallaceDJ,AskanaseA,Safetyandefficacyofbelimumabtotreatsystemiclupuserythematosusinacademicclinicalpractices,JRheumatol.2015Nov1.pii:jrheum.150470.[Epubaheadofprint]
364.LiuK,KurienBT,ZimmermanSL,KaufmanKM,TaftDH,KottyanLC,LazaroS,WeaverCA,IceJA,AdlerAJ,ChodoshJ,RadfarL,RasmussenA,StoneDU,LewisDM,LiS,KoelschKA,IgoeA,TalsaniaM,KumarJ,Maier-MooreJS,HarrisVM,GopalakrishnanR,JonssonR,LessardJA,LuX,GottenbergJE,AnayaJM,Cunninghame-GrahamDS,HuangAJ,BrennanMT,HughesP,IlleiGG,Miceli-RichardC,KeystoneEC,BykerkVP,HirschfieldG,XieG,NgWF,NordmarkG,ErikssonP,OmdalR,RhodusNL,RischmuellerM,RohrerM,SegalBM,VyseTJ,Wahren-HerleniusM,WitteT,Pons-EstelB,Alarcon-RiquelmeME,GuthridgeJM,JamesJA,LessardCJ,KellyJA,ThompsonSD,GaffneyPM,MontgomeryCG,EdbergJC,KimberlyRP,AlarcónGS,LangefeldCL,GilkesonGS,KamenDL,TsaoBP,McCuneWJ,SalmonJE,MerrillJT,WeismanMH,Wallace DJ,UtsetTO,BottingerEP,AmosCI,SiminovitchKA,MarietteX,SivilsKL,HarleyJB,ScofieldRH,XChromosomedoseandsexbiasinautoimmunediseases:Increased47,XXXinsystemiclupuserythematosusandSjogren’ssyndromeArthritisRheumatol.2015Dec29.doi:10.1002/art.39560.[Epubaheadofprint]
365.WallaceDJ,HobbsK,ClowseMEB,PetriM,StrandV,PikeM,MerrillJT,LeszczynskiP,NeuweltCM,JekaS,HoussiauF,KeisermanM,Ordi-RosJ,BongardtS,KilgallenB,GalatenanuC,KalunianK,FurieR,GordonC,Long-termsafetyandefficacyofepratuzumabinthetreatmentofmoderate-to-severesystemiclupuserythematous:Resultsfromanopen-labelextensionstudy,ArthritisCare&Research2016;68:534-543
366.WallaceDJ,SilvermanSL,ConklinJ,BarkenD,DervieuxT,Systemiclupuserythematosusandprimaryfibromyalgiacanbedistinguishedbytestingforcell-boundcomplementactivationproducts,LupusSciMed,2016:3e000127.doi10.1136/lupu-2015-000127 1-7
367.KanH,NagarS,PatelJ,WallaceDJ,MoltaC,ChangDJ,Longitudinaltreatmentpatternsandassociatedoutcomesinpatientswithnewlydiagnosedsystemiclupuserythematosus,ClinicalTherapeutics,doi:10.1016/j.clinthera.2016.01.016
368.vanVollenhovenRF,PetriM,WallaceDJ,RothD,MoltaCT,HammerAE,TangY,ThompsonA,Cumulativecorticosteroids over 52 weeks in patients with systemic lupus erythematotus: Pooled analyses from the phase III belimumabtrials,ArthritisRheumatol2016March18doi:10.1002/art36982,p2184-2192.
369.RasmussenA,RadfarL,LewisD,GrundahlK,StoneDU,KaufkmanCE,RhodusNL,SegalB,WallaceDJ,WeismanMH,VenuturupalliS,KurienBT,LessardCJ,SivilsKL,ScofieldRH,PreviousdiagnosisofSjogren’ssyndromeasrheumatoid arthritis or systemic lupus erythematosus, Rheumatology (Oxford) 2016 Mar 21. pii:kew023
369.UrowitzMB,GladmanDD,AndersonNM,SuJ,Romero-DiazJ,BaeSC,FortinPR,Sanchez-GuerreroJ,ClarkeA,BernatskyS,GordonC,HanlyJG,WallaceDJ,IsenbergD,RahmanA,MerrillJ,GinzlerE,AlarcónGS,FesslerBF,PetriM,BruceIN,KhamashtaM,AranowC,DooleyM,ManziS,Ramsey-GoldmanR,SturfeltG,NivedO,SteinssonK,ZomaA,Ruiz-IrastorzaG,LimS,KalunianKC,ỈnançM,vanVollenhovenR,Ramos-CasalsM,KamenDL,JacobsenS,PeschkenC,AskanaseA,StollT,Cardiovasculareventspriortoorearlyafterdiagnosisofsystemiclupuserythematosusinthesystemiclupusinternationalcollaborativeclinicscohort,LupusSciMed.2016Apr12;3(1):e000143. doi: 10.1136/lupus-2015-000143. eCollection 2016.
370 . HarrisVM1, Sharma R2, Cavett J3, KurienBT4, LiuK5, KoelschKA4, Rasmussen A6, Radfar L7, Lewis D7, Stone DU8, KaufmanCE9, Li S10, Segal B11, Wallace DJ12, Weisman MH12, VenuturupalliS12, KellyJA6, Alarcon-RiquelmeME13, Pons-Estel B14, Jonsson R15, Lu X10, GottenbergJE16, Anaya JM17, Cunninghame-GrahamDS18, Huang AJ19, Brennan MT20, Hughes P19, Alevizos I21, Miceli-Richard C22, KeystoneEC23, BykerkVP24, HirschfieldG25, XieG26, Ng WF27, NordmarkG28, Bucher SM29, Eriksson P30, Omdal R31, Rhodus NL32, Rischmueller M33, Rohrer M19, Wahren-Herlenius M34, WitteT35, Mariette X22, Lessard CJ6, Harley JB36, SivilsKL1, ScofieldRH37,Klinefelter’ssyndrome(47,XXY)isinexcessamongmenwithSjogren’ssyndrome,Clin Immunol. 2016 Apr 21. pii: S1521-6616(16)30061-4. doi: 10.1016/j.clim.2016.04.002.[Epubaheadofprint]
371.HanlyJG,SuL,UrowitzMB,Romero-DiazJ,GordonC,BaeSC,BernatskyS,ClarkeAE,WallaceDJ,MerrillJT,IsenbergDA,RahmanA,GinzlerEM,PetriM,BruceIN,DooleyMA,FortinP,GladmanDD,Sanchez-GuerreroJ,SteinssonK,Ramsey-GoldmanR,KhamashtaMA,AranowC,AlarcónGS,FesslerBJ,ManziS,NivedO,Sturfelt
Page 32 of 54
GK,ZomaAA,vanVollenhovenRF,Ramos-CasalsM,Ruiz-IrastorzaG,SamLimS,KalunianKC,InancM,KamenDL,PeschkenCA,JacobsenS,AskanaseA,TheriaultC,FarewellV,A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate ModelApproach.Arthritis Rheumatol. 2016 Mar 18. doi:10.1002/art.39674.[Epubaheadofprint],pp1932-1944
372. Wallace DJ, Does my daughter have lupus?, Lupus 2016; 25: 957-958 373.YoungKA,MunroeME,GuthridgeJM,KamenDL,NiewoldTB,GilkesonGS,WeismanMH,IshimoriML,Kelly
J,GaffneyPM,SivilsKH,LuR,WallaceDJ,KarpDR,HarleyJB,JamesJA,NorrisJM,CombinedroleofvitaminD status and CYP24A1 in the transition to systemic lupus erythematosus,Ann Rheum Dis. 2016 Jun 9. pii: annrheumdis-2016-209157.doi:10.1136/annrheumdis-2016-209157.[Epubaheadofprint]
374. Wallace DJ, Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience, Lupus 2016; 25: 1141-1149.
375.ClowseMD,WallaceDJ,FurieRA,PetriMA,PikeMC,LeszczynskiP,NeuweltCM,HobbsK,KeisermanM,DucaL,KalunianKC,GalatenauC,BongardtS,StachC,BeaudotC,KilgallenB,GordonC,Efficacyandsafetyofepratuzumabinmoderatelytoseverelyactivesystemiclupuserythematosus:ResultsfromthePhase3,ramdomized,double-blind,placebo-controlledtrials,EMBODY1andEMBODY2,ArthritisRheumatol2016Sep6doi:101002/art39856(Epubaheadofprint),69:362-375,2017.
376.WallaceDJ,StrandV,MerrillJT,PopaS,SpindlerAJ,EimonA,PetriM,SmolenJS,WajdulaJ,ChristensenJ,LiC,DiehlA,VincentMS,BeebeJ,HealeyP,SridharanS.,Efficacyandsafetyofaninterleukin-6monoclonalantibodyfor the treatment of systemic lupus erythematosus: a phase II dose-ranging randomized controlled trial, Ann Rheum Dis.2016Sep26.pii:annrheumdis-2016-209668.doi:10.1136/annrheumdis-2016-209668.[Epubaheadofprint)76:543-542.
377.IsenbergD,SturgessJ,AllenE,AranowC,AskanaseA,Sang-CheolB,BernatskyS,BruceI,BuyonJ,CerveraR,ClarkeA,DooleyMA,FortinP,GinzlerE,GladmanD,HanlyJ,InancM,JacobsenS,KamenD,KhamashtaM,LimS,ManziS,NivedO,PeschkenC,PetriM,KalunianK,RahmanA,Ramsey-GoldmanR,Ruiz-IrastorzaG,Sanchez-GuerreroJ,SteinssonK,SturfeltG,UrowitzM,vanVollenhovenR,Wallace DJ,ZomaA,MerrillJ,GordonC,Astudyofflareassessmentinsystemiclupuserythematosus(SLE)basedonpaperpatients,ArthritisCareRes(Hoboken).2017Apr7.doi:10.1002/acr.23252.[Epubaheadofprint]PMID:28388813
378.StoneDU,FifeD,BrownM,EarleyKE,RadfarL,KaufmanCE,LewisDM,RhodusNL,SegalBM,WallaceDJ,WeismanMH,VenuturupalliS,BrennanMT,LessardCJ,MontgomeryCG,ScofieldRH,SivilsKL,RasmussenA.,Theeffectoftobaccosmokingontheclinical,histopathological,andserologicalmanifestationsofSjogren’ssyndrome,PLOSFeb6,2017,p1-18,
379.Zamora-RacazaG,AzizoddinDW,IshimoriML,OrmsethSR,WallaceDJ,PensergaEG,SumnerL,AyeroffJ,DraperT,NicassioPM,WeismanMH,Roleofpsychosocialreservecapacityinanxietyanddepressioninpatientswithsystemiclupuserythematosus,IntJRheumDis2017;Mar6.Doi:10:1111/1756-185X13033(Epubaheadofprint)
380.ForbessLJ,BreseeC,WallaceDJ,WeismanMH,Failureofasystemiclupuserythematosusresponseindexdeveloped from clinical trial data: lessons examined and earned, Lupus 2017; Jan 1: 961203317692433. Doi:10.1177/0961203317692433(EPubaheadofprint)
381.MunroeME,YoungKA,KamenDL,GuthridgeJM,NiewoldTB,CostenbaderKH,WeismanMH,IshimoriML,WallaceDJ,GilkesonGS,KarpDR,HarleyJB,NorrisJM,JamesJA,Discerningriskofdiseasetransitioninrelativesofsystemiclupuserythematosuspatientsutilizingsolublemediatorsandclinicalfeatures,ArthritisRheumatology2017; 69: 630-642.
382.ChoiMY,ClarkeAE,StPierreY,HanlyJG,UrowitzMB,Romero-DiazJ,GordonC,BaeSC,BernatskyS,Wallace DJ,MerrillJT,IsenbergDA,RahmanA,GinzlerEM,PetriM,BruceIN,DooleyMA,FortinP,GladmanDD,Sanchez-GuerreroJ,SteinssonK,Ramsey-GoldmanR,KhamashtaMA,AranowC,AlarcónGS,ManziS,NivedO,ZomaAA,vanVollenhovenRF,Ramos-CasalsM,Ruiz-IrastorzaG,LimSS,KalunianKC,InancM,KamenDL,PeschkenCA,JacobsenS,AskanaseA,BuyonJ,MahlerM,FritzlerMJ,AntiDFS70autoantibodiesinaninternational inception cohort of systemic lupus erythematosus patients, Lupus. 2017 Jan 1:961203317692437. doi: 10.1177/0961203317692437.[Epubaheadofprint]PMID:28420054,pp1051-1059
383.MillsSD,AzizoddinD,RacazaGZ,Wallace DJ,WeismanMH,NicassioPM,Thepsychometricpropertiesoftheperceived stress scale-10 among patients with systemic lupus erythematosus,Lupus. 2017 Jan 1:961203317701844. doi:10.1177/0961203317701844.[Epubaheadofprint]PMID:28406052
384.IdentificationofaSjogren’ssyndromesusceptibilitylocusatOAS1thatinfluencesisoformswitching,proteinexpression,andresponsivenesstotype1interferons,LiH,RekstenTR,IceJA,KellyJA,AdriantoI,RasmussenA,WangS,HeB,GrundahlKM,GlennSB,Miceli-RichardC,BowmanS,LesterS,ErikssonP,ElorantaML,BrunJG,GøranssonLG,HarboeE,GuthridgeJM,KaufmanKM,KvarnströmM,CunninghameGrahamDS,PatelK,AdlerAJ,FarrisAD,BrennanMT,ChodoshJ,GopalakrishnanR,WeismanMH,VenuturupalliS,Wallace DJ, Hefner KS,HoustonGD,HuangAJW,HughesPJ,LewisDM,RadfarL,VistaES,EdgarCE,RohrerMD,StoneDU,VyseTJ,HarleyJB,GaffneyPM,JamesJA,TurnerS,AlevizosI,AnayaJM,RhodusNL,SegalBM,MontgomeryCG,ScofieldRH,KovatsS,MarietteX,RönnblomL,WitteT,RischmuellerM,Wahren-HerleniusM,OmdalR,JonssonR,NgWF;forUKPrimarySjögren’sSyndromeRegistry,NordmarkG,LessardCJ,SivilsKL.,PLoSGenet.2017Jun
Page 33 of 54
22;13(6):e1006820.doi:10.1371/journal.pgen.1006820.[Epubaheadofprint>385.ChanK,ClarkeAE,Ramsey-GoldmanR,FoulkesW,TessierCloutierB,UrowitzMB,GladmanD,NivedO,
Romero-DiazJ,PetriM,GinzlerE,FortinPR,BaeSC,Wallace DJ, Yelin EH, Bernatsky S, Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment, Lupus. 2017 Jan 1:961203317713146. doi: 10.1177/0961203317713146.[EpubaheadofprintPMID:28595511
386. Arthritis Rheumatol.2017Jul10.doi:10.1002/art.40207.[Epubaheadofprint] Sharma R1,2,3, HarrisVM1,4,2, Cavett J1,2, KurienBT1,2,3, LiuK5,6, KoelschKA1,2,3, Fayaaz A3, ChaudhariKS3, Radfar L7,
Lewis D7, Stone DU8, KaufmanCE2, Li S9, Segal B10, Wallace DJ11, Weisman MH11, VenuturupalliS11, KellyJA1, Pons-Estel B12, Jonsson R13,14, Lu X9, GottenbergJE15, Anaya JM16, Cunninghame-GrahamDS17, Huang AJW18, Brennan MT19, Hughes P18, Alevizos I20, Miceli-Richard C21, KeystoneEC22, BykerkVP23, HirschfieldG24, XieG25, NordmarkG26, Bucher SM27, Eriksson P28, Omdal R29, Rhodus NL30, Rischmueller M31,32, Rohrer M18, Wahren-Herlenius M33, Witte T34, Alarcon-RiquelmeM35, Mariette X21, Lessard CJ1, Harley JB5,6,36, Ng WF37, Rasmussen A1, SivilsKL1,4, ScofieldRH1,4,2,3.,RareXchromosomeabnormalitiesinsystemiclupuserythematosusandSjogren’ssyndrome,
387.CarlD.Langefeld1,2,HannahC.Ainsworth1,2,*,DeborahS.CunninghameGraham3,*,JenniferA.Kelly4,*,MaryE.Comeau1,2,MirandaC.Marion1,2,TimothyD.Howard1,5,PaulaS.Ramos6,7,JenniferA.Croker8,DavidL.Morris3,JohannaK.Sandling9,JonasCarlssonAlmlo¨f9,EduardoM.Acevedo-Va´squez10,GracielaS.Alarco´n8,AlejandraM.Babini11,VicenteBaca12,AndersA.Bengtsson13,GuillermoA.Berbotto14,MarcBijl15,ElizabethE.Brown8,HermineI.Brunner16,MarioH.Cardiel17,LuisCatoggio18,RicardCervera19,JorgeM.Cucho-Venegas10,SolbrittRantapa¨a¨Dahlqvist20,SandraD’Alfonso21,BertaMartinsDaSilva22In˜igodelaRu´aFigueroa23,AndreaDoria24,JeffreyC.Edberg8,EmokeEndreffy+25,JorgeA.Esquivel-Valerio26,PaulR.Fortin27,BarryI.Freedman1,28,JohanFrostegård29,MercedesA.Garcı´a30,IgnacioGarcı´adelaTorre31,GaryS.Gilkeson7,DafnaD.Gladman32,IvaGunnarsson33,JoelM.Guthridge4,JenniferL.Huggins16,JudithA.James4,34,CeesG.M.Kallenberg35,DianeL.Kamen7,DavidR.Karp36,KennethM.Kaufman37,LeahC.Kottyan37,La´szlo´Kova´cs38,HelleLaustrup39,BernardR.Lauwerys40,Quan-ZhenLi36,MarcoA.Maradiaga-Cecen˜a41,JavierMartı´n42,JosephM.McCune43,DavidR.McWilliams1,2,JoanT.Merrill4,PedroMiranda44,Jose´F.Moctezuma45,SwapanK.Nath4,TimothyB.Niewold46,LorenaOrozco47,NorbertoOrtego-Centeno48,MichellePetri49,ChristianA.Pineau50,BernardoA.Pons-Estel51,JanetPope52,PrithviRaj36,RosalindRamsey-Goldman53,JohnD.Reveille54,LaurieP.Russell1,2,Jose´M.Sabio55,CarlosA.Aguilar-Salinas56,HugoR.Scherbarth57,RaffaellaScorza58,MichaelF.Seldin59,ChristopherSjo¨wall60,ElisabetSvenungsson33,SusanD.Thompson37,SergioM.A.Toloza61,LennartTruedsson62,TeresaTusie´-Luna63,CarlosVasconcelos64,LuisM.Vila´65,DanielJ.Wallace66,MichaelH.Weisman66,JoanE.Wither32,TusharBhangale67,JorgeR.Oksenberg68,JohnD.Rioux69,PeterK.Gregersen70,Ann-ChristineSyva¨nen9,LarsRo¨nnblom71,LindseyA.Criswell72,ChaimO.Jacob73,KathyL.Sivils4,BettyP.Tsao7,LauraE.Schanberg74,TimothyW.Behrens67,EarlD.Silverman75,MartaE.Alarco´n-Riquelme4,76,77,RobertP.Kimberly8,JohnB.Harley37,EdwardK.Wakeland36,RobertR.Graham67,PatrickM.Gaffney4&TimothyJ.Vyse3,Transancestralmappingandgeneticloadinsystemiclupuserythematosus,NatureCommunications,2017
388.JollyM,TolozaS,GokerB,ClarkeAE,NavarraSV,WallaceD,WeismanM,MokCC,Disease-specificqualityoflifeinpatientswithlupusnephritis,Lupus.2017Jan1:961203317717082.doi:10.1177/0961203317717082.[Epubaheadofprint]
389.MerrillJT,WallaceDJ,WaxS,KaoA,FraserPA,ChangP,IsenbergD,Efficacyandsafetyofataciceptinpatientswithsystemiclupuserythematosus:Resultsofa24week,randomized,placebo-controlled,PhaseIIbstudy,ArthritisRheumatol.2017Oct26.doi:10.1002/art.40360.[Epubaheadofprint]
390.BarberMRW,HanlyJG,SuL,UrowitzMB,PierreYS,Romero-DiazJ,GordonC,BaeSC,BernatskyS,WallaceDJ,IsenbergDA,RahmanA,GinzlerEM,PetriM,BruceIN,FortinPR,GladmanDD,Sanchez-GuerreroJ,Ramsey-GoldmanR,KhamashtaMA,AranowC,MackayM,AlarcónGS,ManziS,NivedO,JönsenA,ZomaAA,vanVollenhovenRF,Ramos-CasalsM,Ruiz-IrastorzaG,SamLimS,KalunianKC,InancM,KamenDL,PeschkenCA,JacobsenS,AskanaseA,TheriaultC,FarewellV,ClarkeAE,EconomicevaluationoflupusnephritisintheSystemicLupusInternationalCollaboratingClinicsinceptioncohortusingamultistatemodelapproach,ArthritisCareRes(Hoboken).2017Nov28.doi:10.1002/acr.23480.
391.FerreiraI,CrocaS,RaimondoMG,MatharuM,MillerS,GilesI,IsenbergD,IoannouY,HanlyJG,UrowitzMB,Anderson N, Aranow C, Askanase A, Bae SC, Bernatsky S, Bruce IN, Buyon J, Clarke AE, Dooley MA, Fortin P, GinzlerE,GladmanD,GordonC,InancM,JacobsenS,KalunianK,KamenD,KhamashtaM,LimS,ManziS,MerrillJ,NivedO,PeschkenC,PetriM,Ramsey-GoldmanR,Ruiz-IrastorzaG,Sanchez-GuerreroJ,SteinsonK,SturfeltGK,vanVollenhovenR,WallaceDJ,ZomaA,RahmanA,Nitratednucleosomelevelsandneuropsychiatriceventsinsystemiclupuserythematosus:amulti-centerretrospectivecase-controlstudy,ArthritisResTher.2017Dec22;19(1):287. doi: 10.1186/s13075-017-1495-6.
392.D.Isenberg,J.Sturgess,E.Allen,C.Aranow,A.Askanase,B.Sang-Cheol,S.Bernatsky,I.Bruce,J.Buyon,R.Cervera,A.Clarke,MaryAnneDooley,P.Fortin,E.Ginzler,D.Gladman,J.Hanly,M.Inanc,S.Jacobsen,D.Kamen,M.Khamashta,S.Lim,S.Manzi,O.Nived,C.Peschken,M.Petri,K.Kalunian,A.Rahman,R.Ramsey-Goldman,J.Romero-Diaz,G.Ruiz-Irastorza,J.Sanchez-Guerrero,K.Steinsson,G.Sturfelt,M.Urowitz,R.vanVollenhoven,D.J.Wallace,A.Zoma,J.MerrillandC.GordonStudyofflareassessmentinsystemiclupuserythematosusbasedon
Page 34 of 54
paper patients, pp 98-103, Arthritic Care and Research 70: 98-103, 2008 8 DEC 2017 | DOI: 10.1002/acr.23252393.HanlyJG,LiQ,SuL,UrowitzMB,GordonC,BaeSC,Romero-DiazJ,Sanchez-GuerreroJ,BernatskyS,Clarke
AE,WallaceDJ,IsenbergDA,RahmanA,MerrillJT,FortinP,GladmanDD,BruceIN,PetriM,GinzlerEM,DooleyMA,SteinssonK,Ramsey-GoldmanR,ZomaAA,ManziS,NivedO,JonsenA,KhamashtaMA,AlarcónGS,ChathamW,vanVollenhovenRF,AranowC,MackayM,Ruiz-IrastorzaG,Ramos-CasalsM,LimSS,InancM,KalunianKC,JacobsenS,PeschkenCA,KamenDL,AskanaseA,TheriaultC,FarewellV,Cerebrovasculareventsinsystemiclupus.ArthritisCareRes(Hoboken).2018Jan5.doi:10.1002/acr.23509.[Epubaheadofprint]
PMID:29316357394.DanielJWallaceResponseto:‘Neuropsychiatriclupusornot?Cerebralhypoperfusionbyperfusion-weightedMRI
innormal-appearingwhitematterinprimaryneuropsychiatriclupuserythematosus’byPapadakietalAnnRheumDisPublished17 January 2018, doi:10.1136/annrheumdis-2018-212937
395.PrestoJK,OkonLG,FengR,WallaceDJ,FurieR,FiorentinoD,WerthVP,Computerizedplanimetrytoassessclinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus, Br J Dermatol. 2018Jan16.doi:10.1111/bjd.16337.[Epubaheadofprint)PMID29336019
396.SiobhánSmith,MelodyWu,ThiliniFernando,JaneSeo,JoanNíGabhann,OlgaPiskareva,EoghanMcCarthy,Donough Howard,PaulO’Connell,RichardConway,PhilGallagher,EamonnMolloy,RaymondStallings,GrainneKearns,DanielWallace,MichaelWeisman,andCarolineAJefferies.(2017)MicroRNA-302dtargetsIRF9toregulatethe IFN-induced gene expression in SLE. Journal of Autoimmunity, 2017 May;79:105-111.
397.WallaceDJ.,Epratuzumab:reveilleorrequiem?TeachablemomentsforlupusandSjogren’sclinicaltrials,ArthritisRheumatol.2018Jan30.doi:10.1002/art.40427.[Epubaheadofprint]
398.FurieRA,WallaceDJ,AranowC,FettiplaceJ,WilsonB,MistryP,RothDA,GordonD,Long-termsafetyandefficacyofbelimumabinpatientswithsystemiclupuserythematosus:acontinuationofthePhase3UnitedStatesBLISS-76 trial,
ArthritisRheumatol.2018Feb6.doi:10.1002/art.40439.399.KheirJM,GuthridgeCJ,JohnstonJR,AdamsLJ,RasmussenA,GrossTF,MunroeME,BournRL,SivilsKL,
GuthridgeJM,WeismanMH,WallaceDJ,AnayaJM,RojasVillarragaA,JarvisJN,HarleyJB,JamesJA.Uniqueclinicalcharacteristics,autoantibodiesandmedicationuseinNativeAmericanpatientswithsystemiclupuserythematosus.
LupusSciMed.2018Feb27;5(1):e000247.doi:10.1136/lupus-2017-000247.eCollection2018.400.StClairEW,BaerAN,WeiC,NoaisehG,ParkeA,CocaA,UtsetTO,GenoveseMC,WallaceDJ,McNamaraJ,
BoyleK,Keyes-ElsteinL,BrowningJL,FranchimontN,SmithK,GuthridgeJM,SanzI,JamesJA;AutoimmunityCentersofExcellence,Theclinicalefficacyandsafetyofbaminercept,alympotoxin-Breceptorfusionprotein,inprimarySjogren’sSyndrome:Reultsfromarandomized,double-blind,placebo-controlledPhaseIItrial,ArthritisRheumatol.2018Mar31.doi:10.1002/art.40513.[Epubaheadofprint]
401.JollyM,SequeiraW,BlockJA,TolozaS,BertoliA,BlazevicI,VilaLM,MoldovanI,TorralbaKD,MazzoniD,CicognaniE,HasniS,GokerB,HaznedarogluS,Bourre-TessierJ,NavarraSV,MokCC,WeismanM,ClarkeAE,WallaceD,AlarconG,Genderdifferencesinqualityoflifeinpatientswithsystemiclupuserythematosus,ArthritisCareRes(Hoboken).2018Apr25.doi:10.1002/acr.23588.[Epubaheadofprint]
402.BhattacharyaJPappasK,TozR,AranowC,MckayM,GregersonPK,DoumboO,TraoreAK,LesserML,McMahonM,UtsetT,SilvermanE,LevyD,McCuneWJ,JollyM,WallaceD,WeismanM,Romero-Diaz,DiamondB,Serologicfeaturesofcohortswithvariablegeneticriskofsystemiclupus,erythematosus,MolecularMedicinehttpa://doi.org/10.1186/s10020-018-0019-4
403.YoungKA,MunroeME,HarleyJB,GuthridgeJM,KamenDL,GilkensenGS,WeismanMH,KarpDR,WallaceDJ, James JA, Norris JM, Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematousus, Lupus 2018 Jan 1:961203318778368. doi: 10.1177/0961203318778368.
404.PrestoJK1,2,OkonLG1,2,FengR3,WallaceDJ4,FurieR5,FiorentinoD6,WerthVP,Computerizedplanimetrytoassess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus, Br J Dermatol.2018Jun;178(6):1308-1314.doi:10.1111/bjd.16337.Epub2018Apr17
405. Patel Z, Lu X, Miller D, Forney CR, Lee J, Lynch A, Schroeder C, Parks L, Magnusen AF, Chen X, Pujato M, Maddox A,ZollerEE,NamjouB,BrunnerHI,HenricksonM,HugginsJL,WilliamsAH,ZieglerJT,ComeauME,MarionMC,GlennSB,AdlerA,ShenN,NathSK,StevensAM,FreedmanBI,Pons-EstelBA,TsaoBP,JacobCO,KamenDL,BrownEE,GilkesonGS,AlarcónGS,MartinJ,ReveilleJD,AnayaJM,JamesJA,SivilsKL,CriswellLA,ViláLM,PetriM,ScofieldRH,KimberlyRP,EdbergJC,Ramsey-GoldmanR,BangSY,LeeHS,BaeSC,BoackleSA,CunninghameGrahamD,VyseTJ,MerrillJT,NiewoldTB,AinsworthHC,SilvermanED,WeismanMH,WallaceDJ,RajP,GuthridgeJM,GaffneyPM,KellyJA,Alarcón-RiquelmeME,LangefeldCD,WakelandEK,KaufmanKM,WeirauchMT,HarleyJB,KottyanLC.HumMolGenet.2018Apr18.doi:10.1093/hmg/ddy140.[Epubaheadofprint]A plausiblycausalfunctionallupus-associatedriskvariantintheSTAT1-STAT4locus.
Abstracts:1. Wallace,D.,“RNAtumorvirusesandaging,”Clin. Res., 22:198A, 1974.2. Wallace,D.,Fan,P.,Gatti,R,Goldfinger,D.,Klinenberg,J.,andBluestone,R,“Effectsoflymphoplasmapheresison
Page 35 of 54
immunologicstatus,”Arthritis Rheum 22:670, 1979.3. Wallace,D.,Goldfinger,D.,Gatti,R,Fan,P.,Klinenberg,J.,andBluestone,R,“Longtermplasmapheresisand
Iymphoplasmapheresisinthemanagementofrheumatoidarthritis,” Arthritis Rheum,22:670, 1979.4. Wallace,D.,Goldfinger,D.,Brachman,M.,Bluestone,R,andKlinenberg,J.,“Therapeuticpheresisinthe
managementofrheumatoidarthritis,”Clin. Res., 28:77A, 1980.5. Wallace,D.,Podell,T.,Forouzesh,S.,Cox,M.,Weiner,J.,andDubois,E.,“Systemiclupuserythematosus:A
retrospectivestudyof443patientsfollowedinprivatepracticewithemphasisonsurvival,”Clin. Res., 28:77A, 1980.6. Wallace,D.,Goldfinger,D.,Bluestone,R,andKlinenberg,J.R,“Therapeuticpheresisinthemanagementof
rheumatoidarthritis,”ArthritisRheum23:759,1980.7. Podell,T.,Wallace,D.,Forouzesh,S.,Cox,M.,Weiner,J.,Klinenberg,J.,andDubois,E.,“SLE:Aretrospective
studyof443patientsfollowedinaprivatepracticewithemphasisonsurvival,”ArthritisRheum,23:732,1980.8. Brachman,M.B.,Wallace,D.,Tanasescu,D.,Ramanna,L.,andWaxman,A.,“Rheumatoidarthritis:Canquantitative
jointscanningbeusedtoevaluatetheresponsetotherapy?”Clin. Nuclear Med., 5:S38-29, 1980.9. Wallace,D.,Goldfinger,D.,Thompson-Breton,R,Martin,V.,Lowe,C.,andKlinenberg,J.,“Adoubleblind
controlledstudyofIymphoplasmapheresisinrheumatoidarthritis,”ArthritisRheum, 24:S125, 1981.10.Wallace.D.,Podell,T.,andDubois,E.,“Nitrogenmustardinlupusnephritis,”Arthritis,24:70S,1981.11.Podell,T.,Wallace,D.,Forouzesh,S.,Cox,M.,Weiner,J.,andDubois,E.,“Experiencewith230lupusnephritis
patients:1950-1980,”ArthritisRheum,24:121S,1981.12.Brachman,M.B.,Wallace,D.J.,Garcia,E.,Klinenberg,J.,Brown,D.E.,Tanasescu,D.E.,Ramanna,L.,andWaxman,
A-D.,“Quantitativejointscanninginrheumatoidarthritis,”Clin. Nuclear Med. 6: 455, 1981.13.Wallace,D.,Goldfinger,D.,Brachman,M.,andKlinenberg,J.,“Adouble-blindcontrolledstudyof
lymphoplasmapheresisinrheumatoidarthritis,”ArthritisRheum,25:3S,1982.14.Wallace,D.,Goldfinger,D.,andKlinenberg,J.,“Therapeuticplasmapheresisinsystemiclupuswithnephrotic
syndrome,”ArthritisRheum,25:S81,1982.15.Wallace,D.,Goldfinger,D.,Klinenberg,J.,Barnett,E.,andCurd,J.,“Immunologicregulationinselective
plasmapheresisinrheumatoidarthritis,”ArthritisRheum,26:S44,1983.16. Wallace,D.,“Plasmapheresisvslymphoplasmapheresis:Immunologicdifference,”JClin. Apheresis, 2:141, 1984.17.WallaceD.,Goldfinger,D.,andKlinenberg,J.R,“Plasmapheresisinlupusnephritis:Acontrolledstudy,
Preliminaryresults,”ArthritisRheum,28:S46,1985.18.WallaceD.J.,Brachman,M.,Feldman,G.,Reichman,R,andKlinenberg,J.R,“Quantitativecomputeizedjoint
scanninginrheumatoidarthritis:Anaccurate,reproduciblemethodofquantitatingsynovitis,”Arthritis Rheum, 29: S81. 1986.
19.Wallace,D.J.,Goldfinger,D.,andKlinenberg,J.R,“Plasmapheresisinlupusnephritis:Acontrolledstudy—preliminaryresults,”Plasma Therapy, 7:418, 1986.
20.Wallace,D.J.,Peter,J.B.,Wiedmann,C.R,Knight,P.J.,andKlinenberg,J.R,“Antibodiestonon-cardiolipinantibodiesinSLE:Clinicalassociations,”Arthritis Rheum, 30:S26, 1987 (Suppl 1).
21.Wallace,D.J.,Goldfinger,D.,Goodman,D.,Fichman,M.,andKlinenberg,J.R,“AcontrolledstudyontheuseofplasmapheresisinsteroidimmunosuppressiveresistantSLEpatientswithnephroticsvndrome,”Arthritis Rheum, 30:S26, 1987 (Suppl 1).
22.Wallace,D.J.,Wiedmann,C.,Peter,J.,KnightP.,andKlinenberg,J.R,“AnticardiolipinisotypesinSLE,”Arthritis Rheum, 30:S29, 1987 (Suppl 1).
23.Wigfall,D.R,Wallace,D.J.,Sakai,RS.,andJordan,S.C.,“Invitrointerleukin-2receptorgenerationbyPBLisolatedfromSLEpatients,”Pediat. Res., 21:A486, 1987.
24.Wallace,D.J.,Wiedmann,C.E.,Peter,J.B.,Knight,P.K.,andKlinenberg,J.R,“AntiphospholipidantibodyisotypesinSLE,”Arthritis Rheum, 30:S5S, 1987.
25.Wallace,D.J.,Goldfinger,D.,Goodman,D.,andFichman,M.,“Predictivevalueofoutcomevariablesinimmunosuppressiveresistantlupusnephritis,”Arthritis Rheum 30:S70, 1987.
26.Wigfall,D.R,Wallace,D.J.,Sakai,RS.,andJordan,S.C.,“Invitrointerleukin-2receptorexpressionbyPBLisolatedfromSLEpatients,”Kidney Int. 33: 331, 1988.
27.Peter,J.B.,Lee,C.T.,Wallace,D.J.,“Studiesofimmuneregulationinprimaryfibromyalgiasyndrome,”Arthritis Rheum, 31 :R18, 1988.
28.Wigfall,D.R,Wallace,D.J.,Sakai,RJ.,Jordan,S.C.,“Interleukin-2receptorexpressioninperipheralbloodlymphocytesinSLEpatients,relationshiptoclinicalactivity,”Arthritis Rheum, 32:R22, 1988.
29.WallaceD.J.,Goldfinger,D.,Dubois,E.L.,Klinenberg,J.R,“Refractorylupusnephritis:Acontrolledstudyontheuseofplasmapheresisin59patients,”Artificial Organs 12:286, 1988.
30. Wigfall, D.R, Wallace, D.J., Sakai, RS., Jordan S.C., “B-cell interleukin-2 (IL-2) receptor expression in systemic lupus erythematosus(SLE),”Arthritis Rheum 31:S106, 1988.
31.Wallace,D.J.,Margolin,K.,“Acute-onsetfibromyalgiaasacomplicationofinterleukin-2therapy,”Arthritis Rheum 31: S24, 1988.
32.Peter,J.B.,Wallace,D.J.,“Abnormalimmuneregulationinfibromyalgia,”Arthritis Rheum 31: S24, 1988.
Page 36 of 54
33.Wallace,D.J.,Bowman,R,Wormley,S.B.,Peter,J.B.,“Arethereimmunoregulatoryabnormalitiesintheprimaryfibromyalgia(fibrositis)syndrome?”Arthritis Rheum 32:S69, 1989.
34.Chong,P.J.,Matzner,W.L.,Wallace,D.J.,Klinenberg,J.R,Jordan,S.C.,“Proteinkinase-CpathwayreglationofimmunoglobulinsynthesisinperipheralbloodmononuclearcellsofpatientswithSLE,”Arthritis Rheum 32: S92, 1989.
35.Pistiner,M.,Wallace,D.J.,Klinenberg,J.R,“Asurveyof536patientswithlupuserythematosus,”Arthritis Rheum 33:R5, 1990.
36.Wallace,D.J.,Metzger,AL.,“Antihyperlipidemicactionsofhydroxychloroquine(Plaqueril),”Arthritis Rheum 33:R7, 1990.
37.Wallace,D.J.,“Genitourinarymanifestationsoffibromyalgia:anincreasedassociationwiththefemaleurethralsyndrome,”Arthritis Rheum 33:R8, 1990.
38.Linker-IsraeliM,DeansRJ,WallaceDJ,JordanS,QuismorioFP,KlinenbergJR,Ozeri-ChenT,“Up-regulationofspontaneousIgGbyendogenouscytokinesinsystemiclupuserythematosus,”FASEB J4:A2104, 1990.
39.WallaceDJ,PistinerM,KlinenbergJR,“464patientswithidiopathicSLE:Clinicalandlaboratoryfindings,”Arthritis Rheum 33:S130, 1990.
40.WallaceDJ,PistinerM,KlinenbergJR,“464patientswithidiopathicSLE:Naturalcourse,treatmentandcausesofdeath,”Arthritis Rheum 33: S130,1990.
41.WallaceDJ,MetzgerAL,StecherV,KernP,“Cholesterolloweringeffectofhydroxychloroquineinrheumaticdiseasepatients.Reversalofdeleteriouseffectsofsteroidsonlipids,”Arthritis Rheum 33: S165, 1990.
42.Linker-IsraeliM,WallaceDJ,Ozeri-ChenT,KlinenbergJR,“SolubleCD4andCD8inSLEsera:Possiblenewmarkersfordiseaseactivityandenphritis,”Arthritis Rheum 34:R15, 1991.
43.Linker-IsraeliM,WallaceDJ,PrehnJ,Oseri-ChenT,KlinenbergJR,“ElevatedlevelsofendogenousIL6insystemiclupuserythematosus(SLE):Aputativeroleinpathogenesis,”Arthritis Rheum 34:R15, 1991.
44.Linker-IsraeliM,WallaceDJ,JordanSC,KlinenbergJR,“DemonstrationofIL-1,IL-6andIFNgarnmainSLEkidneybiopsies,”Arthritis Rheum 34:R20, 1991.
45.SilvermanSL,WallaceDJ,“Calcitoninhelpsasubsetofpatientswithfibromyalgia,”Arthritis Rheum34:R21, 1991.46.Wallace,DJ,PistinerM,NessimS,MetzgerAL,KlinenbergJR,“Chroniccutaneous(Discoid)lupus(DLE):
Clinicalandlaboratoryparametersin67patientsfollowedinaprivatepractice(1980-1989),”Arthritis Rheum 34:S130, 1991.
47.Linker-IsraeliM,WallaceDJ,PrehnJ,Ozeri-ChanT,KlinenbergJR,“ElevatedlevelsofendogenousIL-6insystemiclupuserythematosus(SLE):Aputativeroleinpathogenesis,”Arthritis Rheum 34:S141, 1991.
48.LahitaRG,RivkinE,WallaceDJ,CavanaghL,“LowLDLcholesterolandapolipoproteinA1levelsinpatientswithSLEandIgGcardiolipinantibodies:Apossibleetiologicfactorinatherosclerosis,”Arthritis Rheum 34:S42, 1991.
49.HyunS,Linker-IsraeliM,Ozeri-ChenT,WallaceDJ,KlinenbergJR,“Dosolubleaccessorymoleculesplayaroleinautoimmunity?”FASEB J 6: 1980, 1992.
50.WallaceDJ,“Anewroleforhydroxychloroquineinthe1990s?,”Lupus 1:98 (S1), 1992.51.NeumannK,WallaceD,AzenC,GoodmanD,FichmanM,KlinenbergJ,“Influenceoftreatmentandbiopsy
variablesonoutcomeof150lupusnephritispatientsseeninaprivatepracticebetween1950and1980,”Arthritis Rheum 35:S357, 1992.
52.Linker-IsraeliM,HyunS,Ozeri-ChenT,WallaceDJ,KlinenbergJR,“SolubleCD8moleculesinsystemiclupuserythematosus,”Arthritis Rheum 35:S138, 1992.
53.Linker-IsraeliM,PrehnJ,WallaceDJ,LiL,ToyodaH,KlinenbergJR,“NovelpolymorphismsoftheIL-6geneinsystemiclupuserythematosus,”Arthritis Rheum 35:S175, 1992.
54.WallaceDJ,MetzgerAL,“Antimalarialsdecreasetheriskofthromboemboliceventsinanticardiolipinpositivelupuspatients,”Arthritis Rheum 35:S110, 1992.
55.WallaceDJ,Linker-IsraeliM,StecherV,KlinenbergJR,“Theeffectofhydoxycholorquine(HC)onsolubleaccessorymoleculesandcytokinesinsystemiclupuserythematosus(SLE),”Arthritis Rheum 36:R6,1993 (supp).
56.NeumannK,WallaceDJ,KlinenbergJR,“Influenceofclinicalvariables,biopsyandtreatmentontheoutcomeof150patientswithlupusnephritisseenatasinglecenterinthe1980s,”Arthritis Rheum 36:S229, 1993.
57.ShenG,LiL,WallaceDJ,LinH-C,“CombinedmeasurementsofserumhyaluronicacidandIgMRFlevelsincreasethesensitivityforthediagnosisofrheumatoidarthritiswithoutsacrificins~thespecificity,”Arthritis Rheum 36:S125, 1993.
58.LivenL,ShenG,WallaceDJ,“Arapidandspecificenzymeimmunoassaytomeasureserumhyaluronicacidconcentration,”Arthritis Rheum 36:S126, 1993.
59.WallaceDJ,LinH-C,PeterJB,“The‘doessheordoesn’thavelupus’consultation:Improvingdiagnosticacumen,”Arthritis Rheum 36:S185, 1993.
60.AllosachieI,LinH-C,ShoenfeldY,WallaceDJ,“Evaluationofneuronalantibodyreactivityinneuropsychiatricsystemiclupusbyflowcytometry,”Arthritis Rheum 36:S185, 1993.
61.WallaceDJ,Linker-IsraeliM,HyunS,StecherV,KlinenbergJR,“Theeffectofhydroxychloroquine(HC)therapyonserumlevelsofimmunoregulatorymoleculesinpatientswithsystemiclupuserythematosus,”Arthritis Rheum
Page 37 of 54
36:S231, 1993.62.Linker-IsraeliM,PrehnJ,WallaceDJ,LiL,KlinenbergJR,“StudyofanIL-6geneXBAIrestrictionfragment
associatedwithsystemiclupuserythematosus,”Arthritis Rheum 36:S 111, 1993.63.Linker-IsraeliM,PrehnJ,LiL,WallaceDJ,KlinenbergJR,“IL-6genepolymorphismsinSLE(systemiclupus
erythematosus),”JImmunol 150 A40, 1993.64.Linker-IsraeliM,PrehnJ,WallaceDJ,KlinenbergJR,“Cytokinegenesoflupuspatients:Dotheydifferfrom
normal?,”Arthritis Rheum 37:S168, 1994.65.StecherVJ,WallaceDJ,MetzgerAL,“Antihyperlipidemicactionsofhydroxychloroquine(Plaquenil),”Rev Bras
Rheumatol 34:S88 (suppl), 1994.66.ShenGQ,LinH-C,WallaceDJ,ShoenfeldY,LaiN,PeterJB,“Detectionof(H2A-H2B)-DNAhistone-complex
antibodiesinautoimmune-diseasesanddrug-inducedlupus,”JAm S Nephrol 5:769, 1994.67.Linker-IsraeliM,HyunS,Ozeri-ChenT,WallaceD,KlinenbergJ,“ElevatedinvivoandinvitrosecretionofCD8-a
moleculesinpatientswithsystemiclupuserythematosus,”Lupus 4:48, 1995 (suppl 2).68.Linker-IsraeliM,PrehnJ,ToyodaH,WallaceD,“Theinterleukin-6gene;Studiesinpatientswithsystemiclupus
erythematosus(SLE),”Lupus 4:7, 1995 (suppl 2).69.Linker-IsraeliM,WallaceD,ElstnerE,KoefilerP,KlinenbergJ,“VitaminD3inhibitsimmunoglobulinproduction
byperipheralbloodmononuclearcells(PBMC)ofsystemiclupuserythematosus(SLE)patients,”Lupus 4:63, 1995 (suppl 2).
70. WallaceDJ,PepkowitzS,GoldfingerD,“Pulsesynchronizationplasmapheresisforproliferativelupusnephritiswithnephroticsyndrome:Arandomizedtrialprogressreport,”JClin Apheresis 10:55, 1995.
71.SchwartzEF,WallaceDJ,KlinenbergJR,“Clinicalandlaboratoryfeaturesof20patientswithsclerodermaandsiliconebreastimplants,”Arthritis Rheum 38: RS, 1995 (suppl).
72.BasbugE,WallaceDJ,NessimS,KlinenbergJR,“Clinicalandlaboratoryfeaturesof24patientswithsystemiclupuserythematosusandsiliconebreastimplants,”Arthritis Rheum 38:R8, 1995 (suppl).
73.BasbugE,SchwartzE,WallaceDJ,NessimS,KlinenbergJR,“Clinicalandlaboratoryfeaturesof30patientswithsystemiclupuserythematosusandsiliconebreastimplants,”Arthritis Rheum 1995;38:S265.
74.WallaceDJ,CozenLJ,“AvascularnecrosisinSLE:Lackofassociationwithantiphospholipidantibodiesandotherclinicalcorrelates,”Arthritis Rheum 1996; 39:R4.
75.Linker-IsraeliM,WallaceDJ,PrehnJ,MichaelD,YangH,KlinenbergJR,“SkewedalleledistributionoftheIL-6geneassociatedminisatelliteinpatientswithSLE,”JExperimental Med 1996; 44:A276.
76.Linker-IsraeliM,WallaceDJ,PrehnJ,MichaelD,YangH,NandR,KlinenbergJR,“AberrantdistributionoftheIL-6geneminisatelliteallelesinSLEpatients:Populationandmultiplexfamilystudies,”Arthritis Rheum 1996; 39:S128.
77.TsaoBP,CantorRM,KalunianKC,ChenC-J,SinghR,WallaceDJ,KitridouRC,ChenSI,ShenN,SongYW,IsenbergDA, Yu C-I, Hahn BH, Rotter JL, “Evidence for linkage of a candidate chromosome 1region to systemic lupus erythematosus(SLE),”Arthritis Rheum 1996; 39:S217.
78.Linker-IsraeliM,EblingF,WallaceDJ,NandR,SinghRR,LinP,KlinenbergJR,HahnBH,“TcellsofSLEpatientsrecognizeVHdeterminantsofantidsDNAautoantibodies,”Arthritis Rheum 1996; 39:S267.
79.HalleguaD,WallaceDJ,MetzgerAL,KlinenbergJR,“Cyclosporineformembranouslupusnephritis”,Arthritis Rheum 1997; 40 S57.
80.WallaceD,GoldfingerD,PepkowitzS,“Aprospective,controlledtrialofpulsesynchronizationcyclophosphamide(CTX)/apheresisforproliferativelupusnephritis”,Arthritis Rheum 1997; 40: S58.
81.TsaoBP,CantorRM,BadshaH.GrossmanJM,KalunianKC,HartungK,ArnettFC,WallaceDJ,HahnBH,RotterJI,“AsusceptibilitygeneforSLEmapstoa5cMregionofchromosomelq”,Arthritis Rlteum 1997; 40 S315.
82.MoserKL,YuH.AsundeN.KoelschG.SalmonJE,WallaceD,GinzlerE,WolfRE,BrunerG.NeasBR,HarleyJB,“Evidenceforracialdifferencesingeneticlinkagetomultiplelocispanningchromosomelqinhumansystemiclupus”,Arthritis Rheum 1997; 40: S315.
83.WallaceDJPostS,“AnepidemiologicsurveyofMoorpark,California”, Lupus 1998; 7: 23, Supp 1.84.WallaceDJ,GoldfingerD,PepkowitzS,FichmanM,MetzgerAL,”Arandomizedcontrolledtrialofpulse/
synchronizationcyclophosphamide/apheresisforproliferativenephritis”, Lupus 1998; 7: 79, supp 1.85.MoserKL,NeasBR,BrunerG,SalmonJ,HarleyJB,WallaceD,PetriM,McKownK,CarsonC,AlbertD,“Scanning
thegenomeforhumanSLEgenes:Designandcandidateregions”,Lupus 7: 13, 1998, Supp 186.HondaM,NandR,MandyamR,MengeshaE,WallaceDJ,MetzgerA,Bharler,KlinenbergJR,MorrisR,Linker-Israeli
M,“IL-6,IL-10andIL-4expressionandcrosstalkinpatientswithsystemiclupuserythmeatosus”, Arthritis Rheum 1998; 41: S39.
87.ShaiR,QuismorioFPJr,LiL,KwonOJ,MorrisonJ,WallaceDJ,NeuweltCM,GaudermanWJ,JacobCO,“Multigeniccontrolofdiseaseinmultiplexfamilieswithsystemiclupuserythematosus”, Arthritis Rheum 1998; 41:S80.
88.PachinianN,WallaceDJ,KlinenbergJR,“Mycophenolatemofetilforsystemiclupuserythematosus”, Arthritis Rheum 1998; 41: S110.
89.NeumannK,GoldeG,WallaceDJ,MetzgerAL,“Osteoporosis--lessthanexpectedinscleroderma?”, Arthritis
Page 38 of 54
Rheum 1998; 41:S216.90.SalonenE-M,WallaceDJ,MetzgerAL,Avaniss-AghajaniE,“Anti-telomereantibodiesarehighlyspecificfor
systemiclupuserythematosus(SLE)”, Arthritis Rheum 1998; 41: S247.91.HalleguaD,BonertV,MathurR,SilvermanS,WallaceDJ,KlinenbergJR,“Prevalenceoffibromyalgia(FM)ingrowth
hormonedeficient(GH)adults”,Arthritis Rheum 1998; 41:S256.92.Linker-IsraeliM,WallaceDJ,MichaelD,PrehnJ,NandP,TaylorKD,Paul-LabradorM,HondaM,Fishel-
GhodsianN,FraserPA,KlinenbergJR,“NovelallelesoftheIL-6geneminisatelliteareassociatedwithsystemiclupuserythematosus(SLE)andwithdifferentialIL-6expression”, Arthritis Rheum 1998; 41:S282.
93.WeinrebA,GrossmanJM,TheophilovN,ZhaoY,WallaceDJ,HahnBH,TsaoBP,“Family-basedandcase-controlassociation studies of the interleukin-1 receptor antagonist (IL-1RA) ILRN*2 allele in North-American caucasian and han-Chinesepopulationswithsystemiclupuserythematosus(SLE)andglomerulonephritis”, Arthritis Rheum 1998; $1:S285.
94.GrossmanJM,TeophilovN,KalunianKC,WallaceDJ,ArnettFC,HartungK,GoldsteinR,LinHY,HahnBH,TsaoBP,“Comparisonofclinicalmanifestationsoflupuspatientsinsimplexandmultiplexfamilies”,Arthritis Rheum 1998; 41:S329.
95.HalleguaD,WallaceDJ,MetzgerAL,KlinenbergJR,“Associationofgoatmilkexposurewithautoantibodies”,Arthrits Rheum 1998; 41:S331.
96.MoserKL,NeasBR,SalmonJE,YuH,McGuireC,AsundiN,GrunerGR,FoxJ,KellyJ,HenshallS,BacinoD,DietzM,HogueR,KoelschG,NightingaleL,AbdouN,AlbertD,CarsonC,GinzlerE,McKowenK,PetriM,Ramsey-GoldmanR,TreadwallE,WallaceD,WilsonJ,WolfR,SahverT,JamesJA,HarleyJB,“Genomescanofhumansystemiclupuserythematosus(SLE)identifiesmultiplelociinfluencedbyracialorigin”,Arthritis Rheum 1998; 41:S283.
97.TsaoBP,CantorRM,GrossmanJM,TheophilovN,WallaceDJ,ArnettFC,HartungK,GoldsteinR,KalunianKC,Hahn BH, Rotter JL, “ADPRTallelesfromthechromosome1q41-q42linkedregionareassociatedwithSLE”, Arthritis Rheum 1998; 41: S80.
98.Linker-IsraeliM,WallaceDJ,MichaelD,NandR,HondaM,KlinenbergJR,IL-6minisatelliteallelesareassociatedwith SLE and with up-regulated IL-6 expression, FASEB J 1998; 12: 3521.
99.HondaM,WallaceDJ,MetzgerA,MorrisR,BehariarB,KlinenbergJR,Linker-IsraeliM,ContrastingeffectsofIL-10andIL-4onIL-6contentofSLEPBMCsubsets,FASEB J 1998: 12:3524.
100.PimentelM,HalleguaD,WallaceD,BonorrisG,ChowE,TabibzadehS,LinHC,Eradicationofsmallintestinalbacterialovergrowthdecreasessymptomsinfibromyalgia,Arthritis Rheum 1999: 42:S343.
101.Linker-IsraeliM,WallaceDJ,MengeshaE,TaylorK,Fishel-GhodissianN,KlinenbergJR,SLE-associatedallelesoftheIL-63’flankingregionmodulateIL-6expression,Arthritis Rheum 1999; 42: S309.
102.AlbanoS,HalleguaD,WallaceDJ,KlinenbergJR,LinHC,Smallintestinalbacterialovergrowthinsystemiclupuserythematosus (SLE), Arthritis Rheum 1999; 42: S305.
103.GrossmanJM,HahnBH,KalunianKC,WallaceDJ,ArnettFC,RubinRL,TsaoBP,IgGanti-chromatinantibodiesareassociated with lupus nephritis, Arthritis Rheum 1999; 42: S215.
104.WeinrebA,GrossmanJM,CantorRM,TheophilN,WallaceDJ,HahnBH,TsaoBP,Associationoftheinterleukin-1receptor antagonist IL-1RN*1 allele with systemic lupus erythematosus (SLE) clinical phenotypes. Am J Hum Genet 1999; 65: 2277.
105.Linker-IsareliM,WallaceDJ,MengeshaE,TaylorKE,FischelgN,MuellerC,SLE-associatedallelesoftheIL-63’flankingregioncontributetoIL-6generegulation.FASEB J, 2000; 14: 1206.
106.PimentelM,ChowEJ,BonorrisG,HalleguaD,WallaceD,LinHC,Eradicationofsmall-intestinalbacterialovergrowthdecreasesthegastrointestinalsymptomsinfibromyalgia,Gastroenterology 2000; 118: 2143.
107. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman SL, Silver D, Weisman MH, Cytokines play an etiopathogenetic roleinfibromyalgia:Apilotstudy,Arthritis Rheum 2000; 43: S212.
108.LanderS,WallaceS,WeismanMH,IscelecoxibsafeinSLEwithorwithoutsulfaallergy?Apilotstudy,Arthritis Rheum 2000; 43: S242.
109.TsaoBP,GrossmanJM,ArnettFC,ChakS,WallaceDJ,GinzlerDM,GoldsteinR,KalunianKC,HahnBH,CantorRM,InvestigationofSLE-linkedregionsidentifiedbygenomescans:Supportfor1q24,16q13and20p12,Arthritis Rheum 2000; 43: S278.
110.Linker-IsraeliM,HondaM,WallaceDJ,AlbanoS,MengeshaE,NicholsS,KlinenbergJR,MetzgerA,MorrisR,LossoftelomericDNAandfewerproliferativecycles,contrastedbycontinuousinvitrocyclingofnon-senescent,CD28-CD8+Tcellsinpatientswithsystemiclupuserythematosus,Arthritis Rheum 2000; 43: S273.
111.RemerCF,WeismanMH,WallaceDJ,Benefitsofleflunomide(LEF)insystemiclupuserythematosus,Lupus2001;10: S10.
112.WallaceDJ,Telomereantibodiesandtelomerebiologyinautoimmunity,TheRyumachi2001;41:209.113.WallaceDJ,Docytokinesplayapathogeneticroleinfibromyalgia?Ahypothesisandpilotstudy,Journalof
Musculoskeletal Pain 2001; 9: 80 (supp5).114.GrossmanJM,KimSK,WallaceDJ,ChenCJ,LauCS,GinzlerDM,GoldsteinR,ShenN,KalunianKC,ArnettFC,
Page 39 of 54
Hahn BH, Interaction of loci at 1Q23 and IBD.1maycontributetolupussusceptibility,ArthritisRheum2001;44:S248.
115.TsaoBP,GrossmanJM,RiemekastenG,KasliJ,WallaceDJ,ChenCJ,LauCS,GinzlerEM,GoldsteinRM,ArnettFC,KalunianKC,HahnBH,FamilialtyofclinicalfeaturesofSLEinaffectedsibpairs,ArthritisRheum2001;44:S248.
116.StrandV,AranowC,CardielM,FurieR,SherrerY,TumlinJ,WallaceDJ,CrawfordB,ImprovementinhealthrelatedqualityoflifeinSLEpatientsenrolledinarandomizedclinicaltrialcomparingLJP394treatmentwithplacebo,Arthritis Rheum 2002; 46: S119.
117.AntoniCE,KavanaughA,KirkhamB,BurmeistrG,MangerB,TituncuZ,SchneiderU,EbnerW,WassenbergS,FurstD,MolitorJ,WeismanM,WallaceD,KeystoneE,KaldenJR,SmolenJ,TheInfliximabmultinationalpsoriaticarthritiscontrolledtrial(IMPACT):SubstantialefficacyofsynovitisandpsoriaticlesionswithorwithoutconcomitantDMARD therapy, Ann Rheum Dis 2003; 62: 90.
118.WuH,CantorRM,GrossmanJM,RumbinAA,ShenA,LauCS,WallaceDJ,ArnettFC,BadshaHM,ChngHH,HahnBH,TsaoBP,Markersina1-Mbintervalwithin1q23.2areassociatedwithsystemiclupussusceptibility,ArthritisRheum 2003; 47: S256..
119.AntoniC,KavanaughA,KirkhamB,BurmeisterG,MangerB,SchneiderU,TutuncuZ,EbnerW,WassenbergS,FurstD,MolitorJ,KeystoneE,GladmanD,WeismanM,WallaceD,KaldenJ,SmolenJ,Theoneyearresultsoftheinfliximabmultinationalpsoriaticarthritiscontrolledtrial(IMPACT),Arthritis2003;47:S265-266.
120.LannikMD,Salter-CidL,MillerAC,FurieRA,HorizonA,WeismanMH,WallaceDJ,MerrillJT,CockerillK,Domainspecificityofautoantibodiestobeta2-glycoprotein1inpatientswithantiphospholipidsyndromeenrolledinaphase½ trial with LJP, Arthritis Rheum 2003; 47: S356.
121.HorizonA,WeismanMH,WallaceDJ,MerillJT,LinnikMD,CockerillK,FurieRA,Resultsofarandomized,placebo,controlled,double-blindphase½clinicaltrial(RCT)toassessthesafetyandtolerabilityofLJP1082inpatientswithantiphospholipid syndrome, Arthritis Rheum 2003; 47: 364-365.
122.HorizonAA,YuX,HwangKK,FitzgeraldJ,WallaceDJ,MetzgerAL,WeismanMH,TheapplicationoftheCL154Cpeptide-mimetictostudydisease—relevantantiphospholipidantibodiesinpatientswithAPSandSLE,ArthritisRheum 2003; 47: 3638-3639.
123.LinnikMD,JohT,StrandV,CardielMH,TumlinJA,FurieRA,WallaceDJ,HuraC,SLEpatientswithsustainedreductionsinanti-DNAantibodieshaveareducedriskofrenalflareandmajorSLEflare,ArthritisRheum2003;47:S582.
124.CardielMH,TumlinJA,FurieRA,WallaceDJ,HuraC,StrandV,FosterV,HuJ,HelibrunnKR,LinnikMD,ClinicalefficacyresultsfromaRCTofLJP394inSLEpatientswithhistoryofrenaldisease,ArthritisRheum2003;47:S582-S583.
125.WallaceDJ,CardielMH,TumlinJA,FurieRA,HuraC,StrandV,WangS-L,YushamanovaI,HeilbrunnKR,Safetyresultsfromarandomized,controlledtrial(RCT)ofLJP394insystemiclupuserythematosus(SLE)patientswithahistory of renal disease, Arthritis Rheum 2003; 47: S583.
126.GinzlerEM,AranowC,BuyonJ,DooleyMA,MerillJT,PetriM,AllepG,CileksonG,WallaceD,WeismanM,Amulticenterstudyofmycophenolatemofetil(MMF)vsintravenouscyclosphosphamide(IVC)asinductiontherapyforsevere lupus nephritis (LN): Preliminary results, Arthritis Rheum 2003; 47: S647.
127.WuH,CantorRM,ShenN,ArnettFC,GrossmanJM,LauCS,BadshaHM,RumbinAA,WallaceDJ,ChingHH,Linkageandassociationofsystemic-lupus-erythematosus(SLE)on1q23,2,AmJHuGen2003;73:1950.
128.WallaceDJ,CardielMH,TumlinJA,FurieJ,HuraC,StrandV,WangS,YushmanovaI,HeilbrunnKR,Safet;yresultsfromaRCTofLJP394inSLEpatientswithahistoryofrenaldisease,AmJSocNephrol2003.
129.BombardieriS,CardielMA,TumlinJA,FurieRA,WallaceDJ,HuraC,SchneiderM,HieppeF,StrandV,JohT,FosterT,YushmanovaI,KeilbrunnKR,SummaryofsafetyresultsfromstudiesofLJP394inSLEpatients,AnnalsRheumDis2004 63: 216 supp1.
130.WallaceDJ,WeaverA,SteinB,CampbellD,HustonJ,GoldmanJ,XiaHA,LouieJ,Etanerceptofinfliximabincombinationwithmethotrexate(MTX)inthetreatmentofrheumatoidarthritis—resultsfromtheRadiusregistry,Annals Rheum Dis 2004 63: 251, supp1.
131.AntoniCE,KavanaughA,Kirkham,BurmeisterG,MangerB,SchneiderU,TutuncuZ,EbnerW,WassenbergS,FurstD,MolitorJ,KeystoneE,GladmanD,WeismanM,WallaceD,WeierR,KaldenJR,SmolenJ,Theinfliximabmultinationalpsoriaticarthritiscontrolledtrial(Impact1):TheconcomitantuseofDMARDSdoesnotinfluencetheefficacyandsafetyofinfliximaboveraoneyearperiod,AnnalsRheumDis2004;63:411,supp1.
132.ChiouC,WeismanM,SherbourneC,ReyesR,DylanM,OfmanJ,WallaceDJ,MiszutaniW,Suarex-AlmazorME,Meauring preference weights for health states with rheumatoid arthritis, Annals Rheum Dis 2004; 63: 534, supp 1.
133.McMahonM,GrossmanJ,FitzgraldJ,EblingF,Dahlin-LeeE,ThongB,KalunianK,WallaceDJ,BadshaH,NavabM,FogelmanAM,HahnBH,AtherosclerosisinSLEmayrelatetoabnormalprotectivecapacityofHDL,ArthritisRheum 2004; 5: S192.
134.BreyRL,FoxPT,NarayanaS,MartinezMJ,NaqibuddinM,HollidaySL,WallaceDJ,WeismanMH,BrainimagingfindingsinanSLEinceptioncohort:BrainCONNECTIONS,ArthritisRheum2004;50:S194.
135.PaulusHE,WeaverA,WallaceDJ,WhitmoreJB,LeffJA,TheCORRONApatientregistryforpatientswith
Page 40 of 54
rheumatic diseases, Arthritis Rheum 2004; 50: S376.136.NaqibuddinM,WallaceDJ,WeismanMH,HollidaySL,WingNF,BreyRL,PetriM,Cognitivefunctioninginrecently
diagnosed systemic lupus erythematosus, Arthritis Rheum 2004; 50: S195.137.KeilbrunnKR,CardielMH,TumlinJA,FurieRA,WallaceDJ,HuraC,StrandV,JohT,TheeffectofLJP394and
concomitantimmunosuppressiveagentsonlevelsofantidsDNAantibodiesinSLEpatients,ArthritisRheum2004;50: S406.
138.WuH,CantorRM,GrossmanJA,ParkE,RumbnAA,WallaceDJ,HahnBH,TsaoB,Toll-likereceptor9genepolymorphisms protective for SLE, Arthritis Rheum 2004; 50: S459.
139.LeeYH,WuH,CantorRM,GrossmanJM,RumbinAA,ParkE,ShenN,ChenCJ,HadshaHM,ThongBYH,ChongHH,WallaceDJ,HahnBH,TsaoBP,EvidenceforSLEsusceptibilitygene(s)at1q32,ArthritisRheum2004;50:607-608.
140.AntoniCa,KavanaughA,BirkhamB,TutuncuZ,BurmeisterGR,SchneiderU,FurstDE,MolitorJ,KeystoneE,GladmanD,MangerB,WassenbergS,WeierR,WallaceD,WeismanMH,KaldenJR,SmolenJ,Twoyeardata:Infliximabmaintainsclinicalresponseinpsoriaticarthritispatients:ananalysisoftheyear2datafromtheinfliximabmultinationalpsoriaticarthritiscontrolledtrial(IMPACT),AnnalsRheumDis2005;64:82.
141.FurstD,YocumD,WeismanM,TroumO,BrayV,WallaceD,GaylisN,RitterJ,YeildingN,GilmerK,InfliximabprovidesadditionalclinicalandradiographicalbenefitsinRApatientswhohaveaninadequateresponsetoetanercept, Annals Rheum Dis 2005; 64: 427.
142.BinderSR,HombergerHA,ModerKG,WenerMH,WeismanMH,WallaceDJ,Multi-SiteevaluationoftheBioPoex™ANAScreenKit,ClinicalChemistry2005;
143.AntoniCE,KavanaughA,KirkhamB,TutuncuZN,BurmeisterG,SchneiderU,FurstDE,MoliterJ,KeystoneEC,GladmanD,MangerM,WassenbergS,WeierR,WallaceD,WeismanM,KaldenJR,SmolenJS,2yeardata:Infliximabmaintainsclinicalresponseinpsoriaticarthritispatients—datafromtheinfliximabmultinationalpsoriaticarthritiscontrolledtrial(IMPACT),ArthritisRheum2005;52:S209
144.HanlyJG,UrowitzMB,Sanchez-GuerreroS,BaeSC,ClarkeA,GordonC,IsenbergD,AlarconG,WallaceDJ,PetriM,DooleyMA,GladmanD,FortinP,MerrillJT,SteinssonI,BruceI,AranowC,ZomaA,VanVollenhovenR,SturfeltG,NivedO,Ramsey-GoldmanR,KhamashtaM,Neuropsychiatriceventsatdiagnosisofsystemiclupuserythematosus, Arthritis Rheum 2005; 52: S379
145.NaqibuddinM,WallaceDJ,WeismanMH,BreyRL,SampedroM,CarsonKA,HollidaySL,PetriM,Depressionis associated with poorer cognitive function in newly diagnosed systemic lupus erythematosus patients, Arthritis Rheum 2005; 52: S379-S380
146.NaqibuddinM,WallaceDJ,WeismanMH,BreyRL,SampedroM,CarsonKA,HollidaySL,PetriM,Changeincognitive function in newly diagnosed systemic lupus erythematosus patients, Arthritis Rheum 2005: 52: S380
147.UrowitzMB,Sanchez-GuerreroJ,GladmanDD,FortinPR,ClarkeA,BaeSC,GordonC,IsenbergD,HanlyJ,MerrillJ,GinzlerE,AlarconG,WallaceDJ,PetriM,SteinssonK,DooleyMA,ManziS,Bruce,MaddisonP,SturfeltG,NivedO,ZomaA,AranowC,Ramsey-GoldmanR,vanVollenhovenR,KhamashtaM,StollT,SystemicLupusInternationalCollaboratingClinics(SLICC)inceptioncohortregistrytostudyriskfactorsforatherosclerosis(SLICCRAS):Firstfollow up report, Arthritis Rheum 2005; 52: S608.
148.NaqibuddinM,SampedroM,WallaceDJ,WeismanMH,BreyRL,HollidaySL,CarsonKA,Anti-NR2andantidsDNAinnewlydiagnosedsystemiclupuserythematosus:Analysisofcognitivefunction,brainMRIandPET,ArthritisRheum 2005; 52: S621-S622.
149.McMahonM,GrossmanJ,FitzgeraldJ,Dahlin-LeeE,EblingF,ThongB,BadshaH,WallaceDJ,KalunianK,HahnBH,Pro-inflammatoryHDLasabiomarkerforatherosclerosisinSLEandRA,ArthritisRheum2005;52:S697-698.
150.WeismanM,FurstD,ParkG,KremerJ,SmithK,Smith-RiggsM,MeyerG,BarhamR,CaldwellJ,WallaceD,HettingerK,DervieuxT,Riskgenotypesinfolate-dependentenzymesprofilerheumatoidarthritispatientswithsideeffects to methotrexate therapy, Arthritis Rheum 2005; 52: S722-723.
151.HanlyJG,UrowitzMB,Sanchez-GuerreroJ,BaeSC,ClarkeA,GordonC,IsenbergD,AlarconG,WallaceDJ,PetriMA,DooleyMA,GladmanD,FortinP,MerrillJT,ManziS,SteinssonK,BruceI,AranowC,ZomaA,VanVollenhovenR,SturfeltG,NivedO,Ramsey-GoldmanR,KhamashtaM,Attributionofneuropsychiatriceventsatdiagnosisofsystemic lupus erythematosus, Arthritis Rheum 2005; 52: S727.
152.GordonC,WallaceDJ,KalunianKC,ShinadaS,ForbessL,BraunsteinGD,WeismanMH,Testosteronepatchesinthe management of patients with mild/moderate systemic lupus erythematosus, Arthritis Rheum 2005; 52: S741.
153.FerbasJ,WallaceDJ,WeismanMH,BelouskiSS,KesslakJP,VincentM,MaJ,ZackD,HendricksL,ChungJ,AsystemicanalysisofcirculatingBcellpopulationsinhealthyandSLEsubjects,AnnalsRheumDis2006;65:584,s.11
154.RojasJ,VisvanathanS,WeismanM,TroumO,BrayV,WallaceD,GaylisN,RitterJ,YocumD,HegedusR,GilmerKE,FurstDE,Open,randomizedstudyofrheumatoidarthritispatientsswitchedfrometanercepttoinfliximabcomparedwiththosewhoremainedonetanercept:Changesinseruminflammatory,bone,andcartilagemarkerscorrelatedwithefficacy,AnnalsRheumDis2006;65:464,s.11
155.PetriM,WallaceDJ,StohlW,McKayJ,SternS,FurieR,McCainA,GinzlerE,ChathamW,HallL,MigoneT,PinedaL,FreimuthW,ChevrierM,SLEpatientswithactiveproductionofantinuclearautoantibodies(ANA)havedistinct
Page 41 of 54
patternsoflupusactivityandperipheralBcellbiomarkerscomparedtoANAnegativepatients,AnnalsRheumDis2006; 65: 356, s.11
156.WallaceDJ,LisseJ,StohlW,McKayJ,BolingE,MerrillJT,FurieR,PetriM,GinzlerE,ChathamW,FernandezV,ZhongJ,ChevrierM,FreimuthW,Belimumab(BMAB),afullyhumanmonoclonalantibodytoB-lymphocytestimulator(BlyS),showsbioactivityandreducessystemiclupuserythematosusdiseaseactivity,AnnalsRheumDis2006; 65: 62-63, s.11
157.BurgeDJ,ShuC,MartinRW,LittlejohnTW,WallaceDJ,TabornJ,PalmerWR,KivitzA,TRU-015,asmallmodularimmunopharmaceutical(SMIP-TM)drugcandidatedirectedagainstCD20,demonstratesclinicalimprovementinsubjectswithrheumatoidarthritis,ArthritisRheum2006;53:S230
158.OstergaardM,WiellC,SierakowskiS,WallaceD,HuMax-CD20,anovelfullyhumanmonoclonalIgG1antibodyinthe treatment of rheumatoid arthritis, Arthritis Rheum 2006; 53: S832
159.UrowitzMB,GladmanDD,IbanezD,FortinPR,Sanchez-GuererroJ,BaeS,ClarkeA,CordonC,HanlyJ,IsenbergD,WallaceD,GinzlerE,MerrillJ,AlarconG,SteinssonK,PetriM,DooleyM,BruceI,ManziS,Ramsey-GoldmanR,NivedO,SturfeltG,MaddisonP,KhamashtaM,FontJ,ZomaA,AranowC,vanVollenhovenR,KalunianK,StollT,Systemiclupusinternationalcollaboratingclinics(SLICC)inceptioncohortregistrytostudyriskfactorsforatherosclerosis:Reportonthefirst582patients,ArthritisRheum2006;53:S281
160.UrowitzM,GladmanD,FortinP,IbanezD,Sanchez-GuerreroJ,BaeSC,ClarkeA,GordonC,HanlyJ,IsenbergD,WallaceD,GinzlerE,MerrillJ,AlarconG,SteinssonK,PetriM,DooleyMA,BruceI,ManziS,Ramsey-GoldmanR,NivedO,SturfeltG,MaddisonP,KhamashtaM,FontJ,ZomaA,AranowC,vanVollenhovenR,KalunianK,StollT,Systemiclupusinternationalcollaboratingclinicsinceptioncohortregistrytostudyriskfactorsforatherosclerosis:Metabolicsyndrome,prevalenceandassociatedfeatures,ArthritisRheum2006;53:S282
161.PetriM,KasitanonN,MagderLS,BaeSC,HanlyJG,IsenbergD,NivedO,SturfeltG,vanVolenhovenR,WallaceDJ,AlarconG,AduJ,Avila-Casado,BernatskyS,BruceI,ClarkeA,ContrerasG,FineDM,GladmanD,GordonC,KalunianK,MadaioMP,RovinBH,Sanchez-GuererroJ,SteinssonK,Systemiclupusinternationalcollaboratingclinics (SLICC) renal activity/response exercise (RARE): Comparison of agreement in renal response, Arthritis Rheum 2006; 53: S444
162.PetriM,KasitanonN,MagderLS,BaeSC,HanlyJG,IsenbergD,NivedO,SturfeltG,vanVolenhovenR,WallaceDJ,AlarconG,AduJ,Avila-Casado,BernatskyS,BruceI,ClarkeA,ContrerasG,FineDM,GladmanD,GordonC,KalunianK,MadaioMP,RovinBH,Sanchez-GuererroJ,SteinssonK,Systemiclupusinternationalcollaboratingclinics (SLICC) renal activity/response exercise (RARE): Developing a renal activity index and a renal response index, Arthritis Rheum 2006; 53: S444
163.PetriM,HewittA,WallaceDJ,Celecoxibdoesnotincreasehypercoagulabilityinserumnordecreaseurinary2,3-dinor-6-keto-PGF1alphainSLE,ArthritisRheum2006;53:S446
164..UrowitzM,GladmanD,FortinP,IbanezD,Sanchez-GuerreroJ,BaeSC,ClarkeA,GordonC,HanlyJ,IsenbergD,WallaceD,GinzlerE,MerrillJ,AlarconG,SteinssonK,PetriM,DooleyMA,BruceI,ManziS,Ramsey-GoldmanR,NivedO,SturfeltG,MaddisonP,KhamashtaM,FontJ,ZomaA,AranowC,vanVollenhovenR,KalunianK,StollT,Systemiclupusinternationalcollaboratingclinics(SLICC)inceptioncohortregistrytostudyriskfactorsforatherosclerosis: accumulation of atherosclerotic risk factors over 3 years, Arthritis Rheum 2006; 53: S521
165.BreyRL,NaqubuddinM,Holliday,SL,PadillaPA,FoxPT,NarayanaS,FranklinC,SamerdroM,WallaceDJ,WeismanMH,PetriM,Matrixmetalloproteinase-9level,brainimagingfindingsandcognitivedysfunctioninanSLEinceptioncohort:BrainCONNECTIONS,ArthritisRheum2006;53:S552
166.DriverCB,ForbessCJ,PourrabbaniS,WallaceDJ,WaxmanAD,LiouD,MinoshimaS,WeismanMH,Clinicalvalidation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus, Arthritis Rheum 2006; 53: S620
167.HanlyJG,UrowitzMB,Sanchez-GuerreroJ,BaeS-C,GordonC,WallaceDJ,IsenbergD,AlarconG,ClarkeA,BernatskyS,MerrillJT,PetriM,DooleyMA,GladmanD,FortinPR,SteinssonK,BruceI,ManziS,KhamashtaM,ZomaA,AranowC,GinzlerE,VanVolenhovenR,FontJ,Sturfelt,NivedO,Ramsey-GoldmanR,KalunianK,DouglasJ,ThompsonK,FarewellV,Clinicalsignificanceofneuropsychiatriceventsatthetimeofdiagnosisofsystemic lupus erythematosus, Arthritis Rheum 2006; 53: S274
168.HanvivadhanakulP,JohnsonB,WuH,GrossmanJM,CantorRM,HebertLA,RovinBH,BirminghamDJ,YungYuc,WallaceDJ,GoodshipTHJ,HahnBH,FengX,TsaoBP,Associationbetween2functionalsinglepolymorphisms(SNPs) in complement factor H (CFH) and SLE, Arthritis Rheum 2006; 53: S297
169.WuH,BoackieS,HanvivadhanakulP,UlgiatiD,GrossmanJ,LeeY,ShenN,AbrahamL,MercerT,ParkE,HerbertL,RovinB,BirminghamD,ChangC,ChenC,McCurdyD,BadshaH,ThongB,ChingH,ArnettF,WallaceD,YuCY,HahnBH,CantorR,TsaoB,Associationofacommonhaplotypeofcomplementreceptor2(CR2)withincreasedriskof SLE, Arthritis Rheum 2006; 53: S291
170.IshimoriML,MetzgerAL,WallaceDJ,MorrisRI,SamaJ,WeismanMH,Screeningforautoantibodies:thesignificanceofANAtiteranditsrelationshiptootherantibodies,ArthritisRheum2006;53:S441-442
171.NazibuddinM,CarsonKA,SampedroMM,WallaceDJ,WeismanMH,BreyRL,HollidaySL,NarayanaS,FoxPT,FranklinC,PadillaPA,PetriM,Brainimaging(MRIandFDG-PET)andcognitivefunctioninnewlydiagnosedSLE,
Page 42 of 54
Arthritis Rheum 2006; 53: S623172.StohlW,WallaceDJ,MerrillJT,ChathamW,GruhnW,AranowC,BurnetteM,PogueB,McCuneW,Petrone
D,ZhongJ,MigoneTS,Freimuth,ChevrierM,ChangesincirculatingB-cellcounts,autoantibodylevelsandimmunoglobulinsthatassociatewiththerapeuticresponsivenessinSLEtoBLySproteinantagonismbybelimumab,Arthritis Rheum 2006; 53: S780
173.WallaceDJ,LisseJ,StohlW,McKayJ,BolingE,MerrillJT,FurieR,PetriM,GinzlerE,ChathamW,FernandezV,ZhongJ,ChevrierM,FreimuthW,Belimumab(BmAb)reducesSLEdiseaseactivityanddemonstratesdurablebioactivityat76weeks,ArthritisRheum2006;53:S790
174.ShoenwetterM,AguilarD,DuboisRW,HectorR,RussakSM,RessRM,WallaceDJ,EisenbergD,WeismanMH,ContentdevelopmentforanewSLEqualityoflifequestionnaire:Useofopenandclosed-endedpatientinputstoidentify important themes in daily functioning among SLE patients, Arthritis Rheum 2006:; 54: 404804049.
175.ShoenwetterM,AguilarD,DuboisRW,HectorR,RussakSM,RessRM,WallaceDJ,EisenbergD,RobinsonDJr,CalimlimBM,WeismanMH,ContentdevelopmentforanewSLEqualityoflifequestionnaire:Useofopenandclosed-endedpatientinputstoidentifyimportantthemesperceivedtobemostimportantamongSLEpatients,Arthritis Rheum 2006:; 54: 4100-4101 .
176.Dall’EraM,ChakravartyE,GenoveseM,WallaceD,KavanaughA,KalunianK,DharP,Pena-RossiC,WofsyD,Trialof atacicept in patients with systemic lupus erythematosus, Arthritis Rheum 2006; 54: 4042-4043.
177. Wallace DJ, Preventive strategies without using lupus medicine and newer concepts for older lupus medications, Lupus 2007; 16: 39 (supp)
178.FurieR,WallaceD,LisseJ,StohlW,MerrillJ,PetriM,GinzlerE,AranowC,WeinsteinA,StrandV,FernandezV,ZhongJ,FreimuthW,Novelcombinedresponseendpointshowsthatbelimumab(fullyhumanmonoclonalanatibodytoBlymphocytestimulator<BLyS>improvesorstabilizesSLEdiseaseactivityinaPhaseIItrial,Lupus2007; 16: 43-44 (supp)
179.WuH,GrossmanJM,CantorRM,HerbertLA,RovinBH,BirminghamDJ,WallaceDJ,YuCY,HahnBH,TsaoBP,EvidenceforSLEsusceptibilitygene(s)at1q23-24,Lupus2007;16:63(supp)
IshimoriM,SchoenwetterM,AguilarD,DuboisRW,HectorR,NicassionP,RussakSM,RessRM,180.WallaceDJ,EisenbergD,RobinsonDJr,GetsyJA,WeismanMH,Differencesbetweenpatientandclinicianperceptionsofphysical and psychosocial issues in systemic lupus erythematosus, Lupus 2007; 16: 107 (supp)
180.HanlyJG,UrowitzMB,Sanchez-GuererroJ,BaeSC,GordonC,WallaceDJ,IsenbergD,AlarconG,ClarkeA,BernatskyS,MerrillJT,PetriM,DooleyMA,GladmanD,FortinP,SteinssonE,BruceI,ManziS,KhamashtaM,ZomaA,AranowC,GinzlerE,VanVollenhovenR,FontJ,SturfeltG,NivedO,Ramsay-GoldmanR,KalunianK,DouglasJ,ThompsonK,FarewellV,Clinicalsignificanceofneuropsychiatric(NP)eventsatthetimeofdiagnosisofsystemic lupus erythematosus (SLE), Lupus 2007; 16: 116-117 (supp)
181.WuH,YuY,HanvivadhanakulP,JohnsonBB,QianXX,FengX,GrossmanJM,CantorRM,HebertLA,RovinBH,BirminghamDJ,ChenCJ,BadshaHM,BernardYH,ChingHH,WallaceDJ,HahnBH,GoodshipTHJ,ShenN,TsaoBP,AssociationbetweentheY402HpolymorphismofcomplementfactorHandlupusnephritisisidentifiedandconfirmedinChinesefamilies,Lupus2007;16:153(supp)
182. Wallace D, Levin R, Matheson R, Merrill R, White B, Early safety results of MEDI-545, an anti-interferon-alpha-monoclonalantibody,inpatientswithsystemiclupuserythematousintheMI-CP126trial,Lupus100716:233(supp)
183.GinzlerE,FurieR,WallaceD,StrandV,LisseJ,StohlW,MerrillJ,PetriM,AranowC,WeinsteinA,FernandezV,ZhongJ,FreimuthW,Novelcombinedresponseendpointshowsthatbelimumab(fullyhumanmonoclonalantibodytoB-lymphocytestimulator(BLYS)improvesorstabilizesSLEactivityinaphaseIItrial,AnnRheumDis2007;62.0P0018
184.NestrorovI,PenaRossiC,ManafoA,PapasouiltiotosO,RoggeM,Dall’EraM,WofsyD,ChakravartyE,GenoveseM,WeismanM,KavanaughA,KalunianK,DharP,NasanovE,StanislavM,YakusevichV,ErshovaO,LomarevaN,WallaceD,Pharmacokineticsandbiololgicalactivityofataciceptafterintravenousandsubcutaneousadministrationto SLE patients, Ann Rheum Dis 2007; 0P0021
185.WallaceD,GottoJ,Bipolarillnesswithcomplaintsofchronicmusculoskeletalpainisaformofpseudofibromyalgia.J Musculoskeletal Pain 2007; 15: Supp: 59.
186.BurgeD,MartinR,WallaceD,LittlejohnT,BookbinderS,BanninkJ,ShuC,SafetyandpharmacodynamicsofrepeatadministrationofTRU-015,aCD20-directedSMIPtherapeutic,insubjectswithrheumatoidarthritis,ArthritisRheum2007; 56: S168-169.
187.UrowitzM,GladmanDD,IbanezD,FortinPR,Sanchez-GuerreroJ,BaeS-C,GordonCP,ClarkeAE,HanlyJG,WallaceDJ,IsenbergDA,MerrillJT,GinzlerEM,AlarconGS,SteinssonK,PetriMA,KhamashtaMA,BruceI,DooleyMA,ManziS,Ramsey-GoldmanR,SturfeltGK,NivedO,ZomaAA,MaddisonPJ,FontJ,vanVollenhovenR,AranowC,KalunianKC,StollT,WofsyD,BuyonJP,Diseaseoutcomesinthefirst4yearsofSLE:ResultsfromtheSLICC inception cohort, Arthritis Rheum 2007; 56: S454-455
188.UrowitzM,GladmanDD,IbanezD,FortinPR,Sanchez-GuerreroJ,BaeS-C,GordonCP,ClarkeAE,HanlyJG,WallaceDJ,IsenbergDA,MerrillJT,GinzlerEM,AlarconGS,SteinssonK,PetriMA,KhamashtaMA,BruceI,DooleyMA,ManziS,Ramsey-GoldmanR,SturfeltGK,NivedO,ZomaAA,MaddisonPJ,FontJ,vanVollenhoven
Page 43 of 54
R,AranowC,KalunianKC,StollT,WofsyD,BuyonJP,Accumulationofatheroscleroticriskfactorsover3yearsbyethnicity in an International Inception Cohort, Arthritis Rheum 2007; 56:S455.
189.MerrillJR,WallaceDJ,StohlW,FurieR,GinzlerE,SternS,LisseJ,LeeE,McCainA,PinedaL,RonnigerJ,FreimuthW,Safetyprofileofbelimumab(fullyhumanmonoclonalantibodytoBlyS)inpatientswithsystemiclupuserythematosus(SLE)treatedduringaplacebo-controlledtrialandinalong-termcontinuationstudy,ArthritisRheum2007; 56: S210
190.MundwilerML,BrownDL,SilvermanJM,FurstDE,KhannaD,LeiblingM,LouieJS,WallaceDJ,WeismanMH,What is the utility of the MRI in predicting radiographic erosions in the rheumatoid foot, Arthritis Rheum 2007; 56:S276-277
191.PetriM,WallaceDJ,WeismanM,GladmanD,FortinP,UrowitzM,WerthV,CostnerM,GordonC,AlarconGS,Ramsey-GoldmanR,MaddisonP,ClarkeA,ManziS,BaeS-C,MerrillJT,GinzlerE,HanlyJ,NivedO,SturfeltG,Sanchez-GuerreroJ,BruceI,AranowC,IsenbergD,ZomaA,TheassociationbetweenreferencelaboratoryvaluesandtheclassificationofSLE,ArthritisRheum2007;56:S218.
192.McMahonMA,GrossmanJ,SkaggsB,LiM,FitzgeraldJ,CharlesC,RagavendraR,WallaceD,WeismanM,ChenW,HahnBH,AcceleratedatherosclerosisinwomenwithSLEandpro-inflammatoryHDLmayinpartbeexplainedbyreducedApo3activity,ArthritisRheum2007;56:S216-217.
193.IshimoriML,SchoenwetterM,AguilarD,DuboisRW,HectorR,NiccasioP,RussakS,RessRM,WallaceDJ,EisenbergD,RobinsonDJr,GetsyJA,Patientsandclinicalperceptionsofimportancedifferonphysicalandpsychosocial issues in systemic lupus erythematosus (SLE), Arthritis Rheum 2007; 56: S457.
194. Posalski J, Ishimori ML, Wallace DJ, Weisman MH, Mycophenolate mofetil in SLE: Results from treatment of 75 patients in a community practice, Arthritis Rheum 2007; 56: 4290-4291.
195.WallaceDJ,PetriM,OlsenN,KyriouK,DennisG,YaoY,JallalB,CoyleA,ZengL,WhiteB,MEDI-545,ananti-interferonalphamonoclonalantibody,showsevidenceofclinicalactivityinsystemiclupuserythematosus,ArthritisRheum 2007; 56: S526.
196.PetriM,FurieR,GinzlerE,WallaceDJ,StohlW,StrandV,WeinsteinA,McKayJ,ZhongJ,FernandezV,FreimuthW,Novelcombinedresponseendpointandsystemiclupuserythematosus(SLE)flareindex(SFI)demonstratebelimumab(FullyhumanmonoclonalantibodytoBLyS)improvesorstabilizesSLEdiseaseactivityandreducesflarerate over 2.5 years, Arthritis Rheum 2007; 56: S527.
197.HanlyJG,UrowitzMB,SiannisF,FarewellV,GordonC,BaeSC,IsenbergD,DooleyMA,ClarkeAE,BernatskyS,GladmanD,FortinPR,ManziS,SteinssonK,BruceI,GinzlerE,AranowC,WallaceDJ,Ramsey-GoldmanR,VanVollenhovenR,SturfeltF,NivedO,Sanchez-GuererroJ,AlarconGS,PetriM,KhamashtaM,ZomaA,FontJ,KalulnianK,QiDQ,MerrillJT,Autoantibodiesandneuropsychiatriceventsatdiagnosisofsystemiclupuserythematosus, Arthritis Rheum 2007; 56: S749.
198.PetriM,NarayanaS,NaqibuddinM,SampedroM,BreyRL,HollidaySL,KochunovP,FranklinC,WallaceDJ,WeismanMH,FoxPT,WhitematterinflammationrevealedbyFDG-PETasamarkerofSLEdiseaseactivity,ArthritisRheum 2007; 56: S797.
199.NaqibuddinM,SampedroM,CarsonKA,WallaceDJ,WeismanMH,BreyRL,HollidaySL,PetriM,Cognitivefunction changes in newly diagnosed systemic lupus erythematosus, Arthritis Rheum 2007; 56: S823.
200.UrowitzM,GladmanDD,IbanezD,FortinPR,Sanchez-GuerreroJ,BaeS-C,GordonCP,ClarkeAE,HanlyJG,WallaceDJ,IsenbergDA,MerrillJT,GinzlerEM,AlarconGS,SteinssonK,PetriMA,KhamashtaMA,BruceI,DooleyMA,ManziS,Ramsey-GoldmanR,SturfeltGK,NivedO,ZomaAA,MaddisonPJ,FontJ,vanVollenhovenR,AranowC,KalunianKC,StollT,WofsyD,BuyonJP,ArterioscleroticvasculareventsinamultinationalinceptioncohortofSLE:Descriptionandattribution,ArthritisRheum2007;55:S454-455.
201.BurgeD,MartinR,WallaceDJ,BookbinderS,KirschT,BassD,LittlejohnT,RepeatedtherapywithTRU-015iswelltolerated and results in consistent pharmacodynamic effects in rheumatoid arthritis patients, Annals Rheum Dis 2008; 67 supp 2; 128.
202.MerrillJ,LantisK,WallaceDJ,ShanahanJ,UtsetT,NeuweltC,WallaceD,GordonC,OatesJ,IsenbergD,ZhangD,BrunettaP,Designandbaselinecharacteristicsofpatientsinarandomizeddouble-blind,placebo-controlledPhaseII/IIIstudy(Explorer)toevaluatetheefficacyandsafetyofrituximabinpatientswithmoderatetoseverelyactive systemic lupus erythematosus (SLE), Annals Rheum Dis 2008; 67 supp 2: 347
203.PetriM,BarryA,KelleyL,StrandV,WallaceDJ,HoussiauF,HobbsK,TakPP,WegenerW,Randomizedcontrolledtrialsofepratuzumab(AntiCD22MABtargetingBcells)revealclinicallymeaningfulreductionsincorticosteroid(CS)usewithfavorablesafetyprofileinmoderateandsevereflaringSLEpatients,AnnalsRheumDis2008;67supp2;53
204.GinzlerE,WallaceDJ,FreimuthW,HoughD,DooleyM,MartinD,ZhongJ,WolfeS,McCuneJ,MerrillJ,FurieR,McKayJ,ChathamW,Belimumab(fullyhumanmonoclonalantibodytoBlyS)reducedsteroiddoseinsystemiclupuserythematosus (SLE) patients during 3 years of therapy, Annals Rheum Dis 2008; 67 supp 2; 217
205.MerrillJ,WallaceD,McCainA,LisseJ,LeeE,McKayJ,GinzlerE,PinedaL,WellborneF,FreimuthW,RonnigerJ,MishraN,Long-termsafetyprofileofbelimumab(fullyhumanmonoclonalantibodytoBlyS)inpatientwithsystemiclupus erythematosus (SLE), Annals Rheum Dis 2008; 217
Page 44 of 54
206.PetriM,FurieR,GinzlerEM,WallaceDJ,WeismanMH,StohlW,McKayJ,StrandV,ClarkeA,BurnetterMC,WellborneF,DooleyM,McCuneJ,LatnisK,ZhongJ,PendaL,Freimuth,Belumumab(fullyhumanmonoclonalantibodytoBlyS)improvedorstabilizedsystemiclupuserythematosus(SLE)diseaseactivityover2.5yearsoftherapy, Lupus 2008; 17: 453.
207.GinzlerEM,ChathamW,StohlW,WallaceDJ,MerrillJT,PetriM,FurieR,AranowC,McCuneJ,McCainA,WeinsteinA,DiskinK,ZhongJ,PinedaJ,FreimuthW,Correlationofbiomarkerchangeswithclinicalimprovementover2.5yearsofbelimumab(fullyhumanmonoclonalantibodytoBlyS)therapyinsystemiclupuserythematosuspatients, Lupus 2008; 17: 457.
208.WallaceDJ,MerrillJT,StohlW,FurieR,GinzlerEM,PetriM,WolfeSM,McKayJ,DooleyM,PinedaL,RonnigerJ,FreimuthW,Longtermsafetyprofileofbelimumab(fullyhumanmonoclonalantibodytoBlyS)inpatientswithsystemic lupus erythematosus (SLE), Lupus 2008; 17: 483.
209.WallaceD,HobbsK,HoussiauF,StrandV,TakP,WegenerW,KelleyL,BarryA,Randomizedcontrolledtrialsofepratuzumab(antiCD22MABtargetingBcells)revealclinicallymeaningfulreductionsincorticosteroid(CS)usewithfavorablesafetyprofileinmoderateandsevereflaringSLEpatients,AnnRheumDis2008;67supp2;212.
210.BurgeD,MartinRW,BookbinderS,LittlejohnT,WallaceD,KirschT,BassD,ShuC,TRU-015adminsiteredevery24 weeks for 2 years is well tolerated and maintains consistent pharmacodynamic effects in rheumatoid arthritis patients, Arthritis Rheum 2008; 58: S 374
211.UrowitzMB,GladmanDD,IbanezD,Sanchez-GuererroJ,BaeSC,GordonC,FortinPR,Clarke,HanlyJG,WallaceD,etal,Accumulationofatheroscleroticriskfactorsandlupusdiseaseriskfactorsinthefirst5yearsofSLE:Resultsfrom the SLICC inception cohort, Arthritis Rheum 2008; 430
212.UrowitzMB,GladmanDD,Ibanezd,Sanchez-GuererroJ,BaeSC,GordonC,FortinPR,ClarkeA,HanlyJG,WallaceD,etal,Predictorsofatheroscleroticvascularevents(AVE)inamultnationalinceptioncohortofSLE:atimeto event analysis, Arthritis Rheum 2008; 58: S 431
213.HanlyJG,UrowitzMB,SuL,Sanchez-GuererroJ,BaeSC,GordonC,WallaceDJ,Short-termoutcomeofneuropsychiatric events in SLE patients upon enrollment into an international inception cohort study, Arthritis Rheum 2008; 58: S 460
214.McMahonM,GrossmanJM,SahakianL,SkaggsBJ,FitzGeraldDJ,Charles-SchoemanC,RagavendraN,WallaceDJ, Weisman M, Witzum J, Hahn BH, PiHDL is a stronger predictor for atherosclerosis than other high-risk inflammatorylipids,andisassociatedwitha17-foldriskofsubclinicalatherosclerosisinSLE,ArthritisRheum2008;58: S 571
215.UrowitzMB,GladmanDD,IbanezD,Sanchez-GuererroJ,BaeSC,GordonC,FortinPR,ClarkeA,HanlyJG,Wallace D, et al, Arhterosclerotic vascular events in a multinational inception cohort of SLE: description and attributionoveran8yearperiod,ArthritisRheum2008;58:S664
216.AuK,SahakianL,SkaggsB,GrossmanJ,FitzgeraldJ,WallaceD,HahnB,Lipidbiomarkersmaybeassociatedwithosteoporosis in systemic lupus erythematosus, Arthritis Rheum 2008; 58: S 665
217.McKayJ,MerrillJT,WallaceDJ,FurieR,StohlW,LatinisK,WellborneF,WolfeSmAngellyT,ChenA,PinedaL,HoughD,Long-termsafetyprofileofbelimumab(FullyhumanmonoclonalantibodytoBlyS)inpatientswithsystemic lupus erythematosus (SLE), Arthritis Rheum 2008; 58: S 1064
218.StohlW,MerrillJT,LooneyRJ,BuyonJ,WallaceDJ,WeismanM,GinzlerEM,etal,PhaseIasingle-andphaseIbmultiple-dosestudiesofAMG623(ananti-BAFFpeptibody)insystemiclupuserythematosus,(SLE),ArthritisRheum2008; 58: S 1065
219.UtowitzM,GladmanDD,IbanezD,BaeSC,GordonC,FortinPR,ClarkeA,HanlyJG,WallaceD,etal,ChangesinQualityofLifeinthefirst5yearsofdiseseinamulticentrecohortofpatientswithsystemiclupuserythematosus(SLE), Arthritis Rheum 2008; 58: S 1072
220.PetriM,HobbsK,GordonC,StrandV,WallaceDJ,KellyL,WegenerW,BarryA,Clinicalmeaningfulimprovementswithepratuzumab(Anti-CD22mABtargetingBcells)inpatientswithmoderate/severeSLEflares:Resultsfrom2randomized controlled trials, Arthritis Rheum 2008; 58: S 1084
221.WallaceDJ,HobbsK,HoussiauF,StrandV,TakPP,WegnerWA,KellyL,BarryA,Epratuzumab(anti-CD22mABtargetingB-cells)providesclnicallymeaningfulreductionsincorticosteroid(CS)usewithafavorablesafetyprofileinpatientswithmoderate/severeflaringSLE:Resultsfromrandomizedcontrolledtrials(RCTs),ArthritisRheum2008;58: S 1087
222.ChathamW,FurieR,PetriM,GinzlerEM,WallaceDJ,StohlW,StrandV,WeinsteinA,ZhongJ,HoughD,FreimuthW,Belimumab(FullyhumanmonoclonalantibodytoBlyS)improvedorstabilizedsystemiclupuserythematosus(SLE) disease activity over 3 years of therapy, Arthritis Rheum 2008; 58: S 1088
223.PetriM,NaqibuddinM,WallaceDJ,WeismanMH,HollidaySL,SampedroMM,CarsonK,PadillaP,BreyRL,CognitivefunctionovertimeinSLE:TheBrainCONNECTIONSinceptioncohort,ArthritisRheum2008;58:S1094
224.PetriM,SturfeldtG,NivedO,WallaceDJ,WeismanM,GladmanD,etal,Therelationshipofanti-C1qtotheACRClassificationCriteriaforSLE,ArthritisRheum2008;58:S1256
225.JollyM,PickardAS,FoggL,WilkeCT,LinHW,MikolaitisRA,SequeiraW,UtsetTO,GordonC,IsenbergDA,HsiehHJ,ZhangD,BrunettaPG,Efficacyandsafetyofrituximabinpatientswithmoderatelytoseverelyactivesystemic
Page 45 of 54
lupuserythematosus(SLE):Resultsfromtherandomized,double-blindphaseII/IIIstudyEXPLORER,ArthritisRheum2008; 58:
226.MerrillJT,Burgos-VargasR,WesthovensR,ChalmersA,D’CruzD,WallaceD,BaeSC,SigalL,BeckerJ-C,KellyS,RaghupathiK,PengY,KinaszczukM,NashP,TheefficacyandsafetyofabataceptinSLE:Resultsofa12month-exploratory study, Arthritis Rheum 2008; 58:
227.MerrillJT,FurieR,WallaceDJ,McKayJ,GinzlerEM,WellborneF,AranowC,BurnetteM,MishraN,PinedaL,ZhongJ,HoughD,FreimuthW,4yearexperienceofbelimumab,afullyhumanmonoclonalantibody,inthetreatmentofsystemiclupuserythematosus,AnnRheumDis2009;68:THU245
228.MerrillJT,Burgos-VargasR,WesthovensR,ChalmersA,D’CruzD,WallaceDJ,BaeSC,SigalLH,BeckerJC,KellyS,RaghupathiK,LiT,PengY,KinaszukM,NashP,ActivityofabataceptinSLE:Resultsofa12monthphasIIexploratory study, Ann Rheum Dis 2009; 68: OP0009.
229.MerrillJ,ShanahanJ,NeuweltC,LatinisK.,HsiehHJ,IsenerD,BrunettaP,GordonC,WallaceD,ZhangD,OatesJ,UtsetT,Rituximabinextra-renalSLEpatientsshowednosignificantdifferencecomparedtoplaceboat52weeksintherandomized,double-blindphasePhaseII/IIIExplorer,AnnRheumDis2009;68:THU0230.
230.MerrillJT,WallaceDJ,LatinisKM,UtsetTO,FurieR,NeuweltCM,LooneyRJ,HsiehH,WagnerB,BrunettaP,Treatmentofsystemiclupuserythematosus(SLE)withrituximab:78-weeksafetydaafromthePhaseII/IIIEXPLORERTrial,ArthritisRheum2009;60:S103-104
231.McMahonM,SahakianLJ,GrossmanJM,SkaggsBJ,FitzGeraldJD,Charles-SchoemanC,RagavendraN,GornAH,KarpouzisGA,VolkmanER,WeismanM,WallaceD,HahnBH,PiHDLisassociatedwitha19-foldincreasedriskofprogressionofsubclinicalatherosclerosisinSLE,ArthritisRheum2009;50:S108-109
232.PetriM,FurieR,MerrillJ,WallaceDJ,GinzlerEM,StohlW,ChathamW,McCuneJ,WeinsteinA,PinedaL,ZhongZJ,KleinJ,HoughD,FreimuthW,Four-yearexperienceofbelimumab,aBlySspecificinhibitor,insystemiclupuserythematosus (SLE), Arthritis Rheum 2009; S515-516
233.VinetE,ClarkeAE,GordonC,UrowitzMB,PineauCA,IsenbergDA,RahmanA,WallaceDJ,AlarconGS,BruceIN,PetriMA,DooleyMA,AranowC,vanVollenhovenRF,DecreasedlivebirthsinwomenwithSLE,ArthRheum2009;60: S584
234.VolkmannER,GrossmanJM,SahakianLJ,SkaggsBJ,FitzGeraaldJD,RagavendraN,Charles-SchoemanC,ChenW,GornAH,KarpouzisGA,WeismanMA,WallaceDJ,HahnBH,McMahonMA,Lowphysicalactivityisassociatedwithproinflammaorydhigh-densitylipoproteinandincreasedsubclinicalatherosclerosisinwomewithsystemiclupus erythematosus, Arthritis Rheum 2009; S 590
235.CerveraJ,IshimoriML,CoorayD,JollyM,KatsarosE,MoldovanI,ShinadaS,TorralbaKD,WallaceDJ,BlockJA,Weisman MH, Nicassio P, Predictors of SF36 scores in a new lupus cohort in Southern California, Arthritis Rheum 2009; 60: S 721
236.GordonC,MerrillJT,WallaceDJ,HsiehH,BrunettaP,BILAGversusSELENA-SLEDAIscoringinsystemiclupuserythematosus (SLE) patients in EXPLORER, Arthritis Rheum 2009; S774
237.JollyM,IshimoriM,MoldovanI,KatsarosEP,TorralbaKD,CoorayD,ShinadaS,BlockJA,WallaceDJ,WeismanMH, Nicassio P, What does patient-reported Systemic Lupus Activity Questionnaire (SLAQ) measure? Arthritis Rheum 2009; S775
238.GoykhmanP,ThompsonLEF,YangY,ShawLJ,BermanDS,GillE,IshimoriML,MartinR,WallaceDJ,SchapiraJM,ShufeltCL,WeismanMH,BaireyMerzCN,Theutilityofadenosinestress-restcardiacmagneticresonanceimagingin evaluating cardiac function and perfusion in women with systemic lupus erythematosus, J Am College Cardiology 2010; 55: A127E1190 (supp 1).
239.FurieRA,MerrillJ,WallaceD,GinzlerE,StohlW,ChathamW,McCuneJ,WeinsteinA,PetriM,PinedaL,ZhongZJ,KleinJ,FreimuthW,Four-yearexperiencewithbelimumab,aBLySspecificinhibitor,inpatientswithsystemiclupus erythematosus (SLE) LBS02/99 study, J Clin Rheumatol 2010; 16: S58-S59.
240.FurieRA,GladmanD,d’CruzD,ZamaniO,WallaceD,vonVollenhovenR,TegzovaD,MerrillJT,SchwartingA,ClarkeAE,DoriaAE,Sanchez-GuererroJ,ChathamWW,ManziS,GinzlerE,McKayJ,StohlW,ZhongZJ,HoughD,CooperSM,FreimuthW,PetriM,Belimumab,aBLySspecificinhibitor,reduceddiseaseactivityandsevereflareswith seropositive SLE: BLISS-76 study, Lupus 2010 19S: 13.
241.WallaceDJ,KalunianK,PetriM,StrandV,KilgallenB,BarryA,GordonA,Epratuzumabdemonstratesclinicallymeaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from the EMBLEM,aphaseIIbstudy,Lupus2010:19S,14.
242,GordonC,WallaceDJ,PetriM,HoussiauF,PikeM,KilgallenB,BarryA,KalunianK,BILAGmeasuredimprovementinmoderatelyandsevereyaffectedbodysystemsinpatientswithsystemiclupuserythematosus(SLE):resultsfromEMBLEM,aphaseIIbstudy,Lupus2010:19S,14.
243.McBrideJ,WallaceDJ,MorimotoAY,ZhenlingY,AbbasA,RomeoM,JiangJ,DrappaJ,SafetyandpharmacodyamicresponsewithadministrationofsingleandrepeatdosesofrontiluzmabinaphaseI,placebo,controlled,double-blind,doseescalaionstudyinSLE,Lupus2010;19S:15.
244.JollyM,PickardAS,McElhoneK,TheSL,MikoliatisRA,RodbyR,SequeiraW,UtsetTO,NicassioP,IshimoriM,
Page 46 of 54
WallaceDJ,WeismanMH,BlockJA,DiseasespecificpatientreportedoutcomebenchmarksforUSlupuspatients:Lupus PRO and Lupus QoL-US, Lupus 2010; 19S: 134.
245.JollyM,PickardAS,Mikolatisr,WilkeCF,RodbyR,FoggR,SequieraW,UtsetTO,CashTF,MoldovanImKatasorosE,NicassioP,IshmoriM,WallaceDJ,BlockJA,TheLupusPRO:adiseasespecificpatientreportedoutcomemeasure for systemic lupus erythematosus in the USA, Lupus 2010; 19S: 134.
246.HanlyJG,UrowitzMB,JacksonD,BaeSC,GordonC,WallaceD,ClarkeA,BernatskyS,BasudevanA,IsenbergD,RahmanA,Sanchez-GuererroJ,Romero-DiazJ,AlarconGS,MerrillJT,FortinP,GladmanD,BruceI,SteinssonK,KhamashtaM,PetriM,SturfeltG,NivedO,Ramsey-GoldmanRmDooleyMA,AranowC,vanVollenhovenR,Ramos-CasalsM,ZomaA,KalunianK,FarewellV,ChangeinSF-36summaryandsub-scalescoresinSLEpatientswho have clinical improvemen and deterioration in neuropsychiatric (NP) events; Lupus 2010; 19S: 139.
247.PetriM,WallaceD,FurieR,MerrillJT,GinzlerE,StohlW,ChathamWW,McCuneJ,WeinsteinA,KleinJ,ZJZhong,FreimuthW,Five-yearexperiencewithbelimumab,aBlyS-specificinhibitor,inpatientswithsystemiclupuserythematosus (SLE), Lupus 2010; 19S: 153.
248.UrowitzMB,GladmanDD,IbanezD,GordonC,BaeSC,ClarkeA,BernatskyS,HanlyJ,IsenbergD,RahmanA,Sanchez-GuererroJ,FortinPR,WallaceD,VasudevanA,MerrillJ,AlarconGS,BruceIN,SturfeltF,NivedO,SteinssonK,KhamashtaMA,PetriM,ManziS,DooleyMA,Ramsey-GoldmanR,AranowC,vanVollenhovenR,Ramos-CasalsM,StollT,KalunianK,ZomaA,MaddisonP,ACRcriteriaatinceptionandaccumulationover5yearsin SLE, Lupus 2010; 19S: 142-3.
249.UrowitzMB,GladmanDD,IbanezD,GordonC,BaeSC,ClarkeA,BernatskyS,HanlyJ,IsenbergD,RahmanA,Sanchez-GuererroJ,FortinPR,WallaceD,VasudevanA,MerrillJ,AlarconGS,BruceIN,SturfeltF,NivedO,SteinssonK,KhamashtaMA,PetriM,ManziS,DooleyMA,Ramsey-GoldmanR,AranowC,vanVollenhovenR,Ramos-CasalsM,StollT,KalunianK,ZomaA,MaddisonP,Clinical-serologicdiscordanceinamulticentre,international cohort of patients with SLE, Lupus 2010; 19S: 143.
250.UrowitzMB,GladmanDD,IbanezD,GordonC,BaeSC,ClarkeA,BernatskyS,HanlyJ,IsenbergD,RahmanA,Sanchez-GuererroJ,FortinPR,WallaceD,VasudevanA,MerrillJ,AlarconGS,BruceIN,SturfeltF,NivedO,SteinssonK,KhamashtaMA,PetriM,ManziS,DooleyMA,Ramsey-GoldmanR,AranowC,vanVollenhovenR,Ramos-CasalsM,StollT,KalunianK,ZomaA,MaddisonP,DamageduetoglucocorticoidsinanSLEinceptioncohort, Lupus 2010; 19S: 144.
251.UrowitzMB,GladmanDD,IbanezD,GordonC,BaeSC,ClarkeA,BernatskyS,HanlyJ,IsenbergD,RahmanA,Sanchez-GuererroJ,FortinPR,WallaceD,VasudevanA,MerrillJ,AlarconGS,BruceIN,SturfeltF,NivedO,SteinssonK,KhamashtaMA,PetriM,ManziS,DooleyMA,Ramsey-GoldmanR,AranowC,vanVollenhovenR,Ramos-CasalsM,StollT,KalunianK,ZomaA,MaddisonP,BruceI,Prevalenceandpersistenceofmetabolicsyndrome in a multicentre international inception cohort of patients with SLE, Lupus 2010; 19S, 144.
252.ChathamW,WeinsteinA,PetriM,MerrillJT,FurieR,WallaceDJ,GinzlerEM,StohlW,McCuneJ,PinedaL,ZhongZJ,KleinJ,HoughD,FreimuthW,Fiveyearsoftreatmentwithbelimumab,aBlyS-specificinhibitor,inpatientswithsystemiclupuserythematosus(SLE):Long-termsafetyandefficacyanalyses,AnnalsRheumDis(Supp3)2010;69:147-148.
253.VanVollenhovenRF,ZamaniO,WallaceD,TegzovaD,MerrillJT,ChathamWW,SchwartingA,HiepeF,DoriaA,Sanchez-GuererroJ,JekaS,DyczekA,FurieR,PetriM,d’CruzD,FojtikZ,PinedaL,ZhongZJ,HoughD,FreimuthW,CerveraR,Belimumab,aBlyS-specificinhibitorreducesdiseaseactivityandsevereflaresinseropositiveSLEpatients: BLISS-76 study, Annals Rheum Dis 2010; 69 (Supp 3), 74-75.
254.KalunianK,WallaceD,PetriM,HoussiauF,PikeM,KilgallenB,BarryA,GordonC,BILAG-measuredimprovementinmoderatelyandseverelyaffectedbodysystemswithsystemiclupuserythematosus(SLE)byepratuzumab:Resultsfrom EMBLEM, a Phase IIB study, Annals Rheum Dis 2010: 69 (Supp 3), 553.
255.WallaceD,KalunianK,PetriM,StrandV,KilgallenB,BarryA,GordonC,Epratuzumabdemonstratesclinicallymeaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM,aPhaseIIbstudy,AnnalsRheumDis2010;69(Supp3):558
256.TingMHX,DonnRP,LuntM,UrowitzMB,GladmanDD,IbanezD,GordonC,BaeSC,ClarkeA,BernaskyS,HanlyJ,IsenbergD,RahmanA,Sanchez-GuererroJ,Romero-DiaJ,FortinPR,WallaceD,GinzlerE,VasudevanA,MerrillJ,AlarconGS,FesslerB,SturfeltG,NivedO,SteinssonK,KhamashtaM,PetriM,ManziS,DooleyM,Ramsey-GoldmanR,AranowC,VanVolenhovenR,RamosM,StollT,Kalunian,ZomaA,MaddisonP,BruceIN,AntimalarialsmayattenuatetheriskofmetabolicsyndromeinSLE:ResultsfromanInternationalInceptionCohortRegistry,Arthritis Rheum 2010, 62:S187
257.UrowitzMB,GladmanDD,IbanezD,GordonCP,BaeS-C,ClarkeAE,BernatskySR,Sanchez-Gererro,HanlyJG,IsenbergDA,RahmanA,FortinPR,WallaceDJ,GinzlerEM,MerrillJT,AlarconGS,FesslerBJ,BruceIN,SturfeltGK,NivedO,SteinssonK,KhamashtaMA,PetriMA,Ramsey-GoldmanR,ManziS,DooleyMA,VanVollenhovenRV,AranowCB,StollT,RamosM,KalunianKC,ZomaAA,Ruiz-IrastorzaG,MaddisonPJ,KamenDL,LimSS,PeschkenCA,AtheroscleroticvasculareventsinamultinationalinceptioncohortofSLE:Descriptionandattributionover an 8 year period, Arthritis Rheum 2010; 62:S188
Page 47 of 54
258.VanVolenhovenFR,GallacherA,NavarraS,GinzlerEM,DooleyMA,CerveraR,LiEK,LevyRA,GuzmanR,ZhongZJ,CooperS,PinedaL,HoughD,WallaceDJ,Belimumab,aBlyS-specificinhibitor,reducedcorticosteroiduseinpatients with active SLE: Results from the Phase 3 BLISS-52 and -76 studies, Arthritis Rheum 2010; 62:S189
259.KalunianKC,WallaceDJ,PetriMA,HoussiauFA,PikeMC,KilgallenB,KelleyL,GordonCA,BILAG-measuredimprovementinmoderatelyandseverelyaffectedbodysystemsinpatientswithsystemiclupuserythematosus(SLE)byepratuzumab:ResultsfromEMBLEM,aPhaseIIIstudy,ArthritisRheum2010;62:S190
260.VanVollenhovenR,JacobsenS,WallaceDJ,HanlyJG,PetriMA,IsenbergDA,ClarkeAE,SimardJF,PineauCA,Bernatsky SR, Biologics use in SLE in 7 centers---Data from the International Registry for Biologics in SLE (IBRIS), Arthritis Rheum 2010; 62:S191
261.ChathamWW,WallaceDJ,StohlW,LatinisK,ManziS,McCuneJ,TegzovaD,McKayJ,Avila-Armengol,UtsetTO,ZhongZJ,HoughD,FreimuthW,MigoneTS,Effectofbelimumab,aB-lymphocytestimulator-specificinhibitor,onfunctionalantibodiestopneumococcal,tetanusandinfluenzavaccines,ArthritisRheum2010;62:S192
262.McMahonMA,GrossmanJM,SahakianL,SkaggsB,FitzGeraldJD,Charles-SchoemanC,GornAH,WeismanMH,WallaceDJ,HahnBH,PiHDLandhighplasmaleptinlevelsarepredictorsoflongitudinalprogressionofsubclinicalatherosclerosis in SLE, Arthritis Rheum 2010; 62: S197-198.
263.UrowitzMB,GladmanDD,IbanezD,BruceINGordonCP,BaeS-C,ClarkeAE,BernatskySR,Sanchez-Guererro,HanlyJG,IsenbergDA,RahmanA,FortinPR,WallaceDJ,GinzlerEM,MerrillJT,AlarconGS,FesslerBJ,BruceIN,SturfeltGK,NivedO,SteinssonK,KhamashtaMA,PetriMA,Ramsey-GoldmanR,ManziS,DooleyMA,VanVollenhovenRV,AranowCB,StollT,RamosM,KalunianKC,ZomaAA,Ruiz-IrastorzaG,MaddisonPJ,KamenDL,LimSS,PeschkenCA,Prevalenceandpersistenceofmetabolicsyndromeinamulticentreinternationalinceptioncohort of patients with SLE, Arthritis Rheum 2010, S200.
264.WallaceDJ,NavarraS,GallacherA,GuzmanR,ThomasM,FurieRA,ZamaniO,LevyRA,vanVollenhovenR,CooperS,ZhongZJ,FreimuthW,PinedaL,CerveraR,Safetyprofileofbelimumab,aBlyS-specificinhibitorinpatients with active systemic lupus erythematosus (SLE): Pooled data from phase 2 and 3 studies, Arthritis Rheum 2010; 62: S491.
265.WallaceDJ,KalunianKC,PetriMA,StrandV,KilgallenB,KelleyL,GordonCP,Epratuzumabdemonstratesclinicallymeaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM,aPhaseIIbstudy,ArthritisRheum2010;62:S605.
266.FurieRA,ZamaniO,WallaceDJ,TegzovaD,PetriM,MerrillJT,ChathamWW,StohlW,SchwartingA,CooperS,ZhongZJ,FreimuthW,HoughDR,vanVollenhovenR,Belimumab,aBlyS-specificinhibitor,reduceddiseaseactivityandsevereflaresinseropositiveSLEpatients:BLISS-76studyresultsthroughweek76,ArthritisRheum2010;62:S606.
267.MerrillJT,WallaceDJ,FurieRA,PetriMA,StohlW,ChathamWW,McCuneJ,WeinsteinA,McKayJ,ZhongZJ,PinedaL,KleinJ,FreimuthW,GinzlerEM,Five-yearexperiencewithbelimumab,aBlyS-specificinhibitor,inpatients with SLE, Arthritis Rheum 2010; 62: S608.
268.UrowitzMB,GladmanDD,IbanezD,BruceINGordonCP,BaeS-C,ClarkeAE,BernatskySR,Sanchez-Guererro,HanlyJG,IsenbergDA,RahmanA,FortinPR,WallaceDJ,GinzlerEM,MerrillJT,AlarconGS,FesslerBJ,BruceIN,SturfeltGK,NivedO,SteinssonK,KhamashtaMA,PetriMA,Ramsey-GoldmanR,ManziS,DooleyMA,VanVollenhovenRV,AranowCB,StollT,RamosM,KalunianKC,ZomaAA,Ruiz-IrastorzaG,MaddisonPJ,KamenDL,Lim SS, Peschken CA, Arthritis Rheum 2010; 62: S941
269.HanlyJG,UrowitzMB,SuL,GladmanDD,BaeS-C,GordonC,ClarkeAE,BernatskySR,Sanchez-Guererro,HanlyJG,IsenbergDA,RahmanA,FortinPR,WallaceDJ,GinzlerEM,AlarconGS,FesslerBJ,BruceIN,SturfeltGK,NivedO,SteinssonK,KhamashtaMA,PetriMA,Ramsey-GoldmanR,ManziS,DooleyMA,VanVollenhovenRV,AranowCB,StollT,RamosM,KalunianKC,ZomaAA,Ruiz-IrastorzaG,MaddisonPJ,KamenDL,LimSS,PeschkenCA,Farewell,ThompsonK,TheriaultC,MerrillJ,Autoantibodiesasbiomarkersforthepredictionofneuropsychiatric events in systemic lupus erythematosus, Arthritis Rheum 2010; 62: S943.
270.UrowitzMB,GladmanDD,IbanezD,GordonCP,BaeS-C,ClarkeAE,BernatskySR,Sanchez-Gererro,HanlyJG,IsenbergDA,RahmanA,FortinPR,WallaceDJ,GinzlerEM,MerrillJT,AlarconGS,FesslerBJ,BruceIN,SturfeltGK,NivedO,SteinssonK,KhamashtaMA,PetriMA,Ramsey-GoldmanR,ManziS,DooleyMA,VanVollenhovenRV,AranowCB,StollT,RamosM,KalunianKC,ZomaAA,Ruiz-IrastorzaG,MaddisonPJ,KamenDL,LimSS,PeschkenCA,SLEandatheroscleroticriskfactorsbyethnicityandgeographicdistributionatinceptioninaninternationalcohort of SLE, Arthritis Rheum 2010; 62: S784-785.
271.vanVollenhovenRF,ZamaniO,WallaceD,TegzovaD,PetriM,MerrillJR,ChathamW,StohlW,SchwartingA,CooperS,ZhongZJ,FreimuthW,HoughD,FurieR,BelimumabreduceddiseaseactivityinpatientswithSLE:BLISS-76, Lupus 2011; 20: 349,.
272.GordonC,PetriM,KalunianK,StrandV,HoussiauF,PikeM,KilgallenB,KelleyL,WallaceDJ,Epratuzumabdemonstrates clinically meaningful improvements in patients with moderate-to-severe systemic lupus erythematosus:ResultsfromEmblem,Lupus2011;20:301.
273.FurieR,MerrillJT,WallaceDJ,StohlW,ChathamW,McCuneW,WeinsteinA,McKayJ,GinzlerEM,ZhongZJ,PinedaL,KleinJ,FreimuthW,PetriM,Five-yearexperiencewithbelimumabinSLE,Lupus2011;20:425.
Page 48 of 54
274.vanvollenhovenR,GallacherA,NavarraS,GinzlerEM,DooleyMA,CerveraR,LiEK,LevyRA,GuzmanR,ZhongZJ,CooperS,PindeaL,HoughD,WallaceD,BelimumabreducedcorticosteroiduseinpatientswithSLE:Resultsfrom the phase 3 BLISS-52 and BLISS-76 studies, Lupus 2011; 20: 425.
275.WallaceDJ,ChathamW,StohlW,LatinisK,ManziS,McCuneWJ,TegzovaD,McKayJ,Avila-ArmengolHE,UtsetTO,ZhongZJ,HoughD,FreimuthW,MigoneTS,Effectofbelimumabonfunctionalantibodiesinpneumococcal,tetanus,andinfluenzavaccines,Lupus2011;20:425-426.
276.VanVollenhovenR,SchneiderM,WallaceD,GallacherA,RothD,JiB,KleodisC,FreimuthW,HoughD,Efficacyofbelimumabinpatientswithsystemiclupuserythematosus:FocusonpatientswithlowcomplementandpositiveantidsDNAantibodies—ResultsfromBliss52/Bliss76,AnnRheumDis2011;70(S3):124.
277.PetriM,WallaceD,SpindlerA,ChindaloreV,WangL,GrethW,Sifalimumab,afullyhumananti-inferferon-alphamonoclonalantibody,insubjectswithsystemiclupuserythematosus(SLE):ResultsofaPhaseIBramdonized,placebo-controlled,dose-escalationintravenousstudy,AnnRheumDis2011;70(S3);125.
278.PetriM,FurieR,MerrillJ,WallaceD,StohlW,ChathamW,WeinsteinA,McKayJ,GinzlerE,ZhongZ,PinedaL,KleinJ,FreimuthW,Six-yearexperiencewithbelimumabinpatientswithSLE;AnnRheumDis2011;70(S3):314
279.UrowitzM,IsenbergD,WallaceDJ,Prelude—EdratidePhase-IIstudyoutcome—frompredefinedanalysestomorerecent assessment approaches, Ann Rheum Dis 2011; 70 (S3); 315.
280.WallaceD,NavarraS,HoussiauF,GallacherA,GuzmanR,ThomasM,FurieR,ZamaniO,LevyR,vanvollenhovenR,CooperS,Zhongz,FreimuthW,HoughD,CerveraR,Safetyprofileofbelimumabinpatientswithactivesystemiclupus erythematosus: Pooled Phase 2/3 data, Ann Rheum Dis 2011; 70 (S3); 318
281.VanVollenhovemR,JacobsenS,WallaceD,HanlyJ,PetriM,IsenbergD,ClarkeA,PineauC,BernatskyS,SimardJ,SimonM,BaeS-C,Ramos-CasalsM,Diaz-LagresC,Ruiz-IrastorzaG,Martinez-BerriotxoaA,Garcia-HernandezF,Gonzalez-LeonR,Castillo-Palma,deRamonE,SaezL,LuisCallejasC,RasconJ,InancM,Artim-EsenB,Ramsay-GoldmanR,PeschkenC,BiologicsuseinSLEin18centers—DatafromtheInternationalRegistryforBiologics,Annals Rheum Dis 2011; 70 (S3):322.
282.JollyM,KosinskiM,GarrisCP,JhinganPM,MikolatisRA,DennisG,WallaceDJ,ClarkeA,ParkeA,DooleyMA,StrandV,AlarconGS,Validationofthelupusimpacttracker:AtoolforpatientstoassessandmonitortheimpactofSLE; Annals Rheum Dis 2011; 70 (S3): 322.
283.JollyM,KosinskiM,GarrisCP,JhinganPM,MikolatisRA,DennisG,WallaceDJ,ClarkeA,ParkeA,DooleyMA,StrandV,AlarconGS,Developmentofthelupusimpacttracker:Atoolforpatientsandphysicianstoassessandmonitor the impact of SLE; Annals Rheum Dis 2011; 70 (S3): 501.
284.SBernatsky,Ramsey-GoldmanR,FoulkesW,GordonC,ZomaA,ManziS,GinzlerE,UrowitzM,GladmanD,FortinP,PetriM,YelinE,WallaceDJ,EdworthyS,BarrS,JacobsenS,BaeS,PeschkenC,KalunianK,IstenbergD,RahmanA,AranowC,DooleyM,SteinssonK,NIvedO,SturfeltG,AlarconGS,KamenD,KanlyJ,EnsworthS,PopeJ,Senecal J, Zummer M, Clarke AE, Breast, ovarian and endometrial malignancies in systemic lupus, Annals Rheum Dis 2011; 70 (S3): 506.
285.OrbaiAM,FangH,MerrillJR,AlarsonGS,GordonC,FortinPR,BruceIN,IsenbergDA,WallaceDJ,NivedO,SturfeltGK,Ramsay-GoldmanR,BaeS-C,J-G,Sanchez-GuererroJ,ClarkeAE,AranowC,ManziSmUrowitzMB,GladmanDG,KalunianKC,CostnerMI,MagderLS,Antibeta-2glycoproteinIIgAinsystemiclupuserythematosus,Arthritis Rheum 2011; 63: S2
286.OrbaiAM,,FangH,MerrillJR,AlarsonGS,GordonC,FortinPR,BruceIN,IsenbergDA,WallaceDJ,NivedO,SturfeltGK,Ramsay-GoldmanR,BaeS-C,J-G,Sanchez-GuererroJ,ClarkeAE,AranowC,ManziSmUrowitzMB,GladmanDG,KalunianKC,CostnerMI,MagderLS,PrevalenceofdirectCoombstestinsystemiclupuserythematosus: Clinical and Immunologic associations, Arthritis Rheum 2011; S541
287.MunroeME,GuthridgeJM,KamenDL,NorrisJM,MoserKL,NiewoldTB,GilkesonGS,KarpDR,WeismanMH,IshimoriML,WallaceDJ,HarleyJB,JamesJA,Alteredsolublemediatorsofinflammationatbaselineinindividualswhosubsequentlytransitiontosystemiclupuserythematosus:EarlystudiedsfromtheLupusAutoimmunityinRelatives (LAUREL) study, Arthritis Rheum 2011; 63: S650
288.CarrFN,NicassioPM,CoorayD,MoldovanI,KatsorosEP,TorralbaKD,ShinadaS,JollyM,IshimoriML,WilsonAL,WallaceDJ,WeismanMH,Theroleofpainanddepressioninself-reportedfatigue,ArthritisRheum2011;63:S938
289.JollyM,BlockJA,MikolatisRA,WallaceD,Duran-BarraganS,BertoliS,TolozaS,BlazevicI,VilaLM,CoorayD,KatsarosEP,TorralbaK,WeismanMH,AlarconGS,SpanishLupusPRO;Crossculturalvalidationstudyforlupus,Arthritis Rheum 2011; 63: S725
290.WallaceDJ,Safetyprofileofbelimumab,aB-lymphocytestimulator-specificinhibitor,inPhase2and3clinicaltrialsof patients with active systemic lupus erythematosus, Arthritis Rheum 2011; 63:S220
291.McMahonM,LorencoE,GrossmanJM,SahakianL,FitzGeraldJ,RagvendraN,Charles-SchoemanC,GornAH,WeismanMH,WallaceD,HahnBH,SkaggsB,Plasmatumornecrosisfactor-likeinducerofapoptosis(sTWEAK)levelsareassociatedwithcarotidplaqueprogressioninwomenwithSLE,ArthritisRheum2011;63:S310
292.vanVollenhovenR,JacobsenS,WallaceD,HanlyJG,PetriM,IsenbergDA,ClarkeAE,PineauCA,BernatskyS.SimardJF,BaeS-C,Ramos-CasalsM,Diaz-LigaresC,Ruiz-IrastorzaG,Martinez-BerriotxoaA,Garcia-HernandezFJ,Gonzalez-LeonR,Castillo-PalmaMJ,SaezL,CallejasJL,RasconJ,deRamonE,Ayala-GuttierezM,CampsM,Mild
Page 49 of 54
M,InancM,Artim-EsenB,Ramsay-GoldmanR,PeschkenCa,SuartritoD,EmmiL,KovacsL,DoriaD,SkekanecZ,FerraccioliG,GremeseE,SatoEI,Biologicsusein23centers—DatafromtheInternationalRegistryforBiologicsinSLE (IRBIS), Arthritis Rheum 2011; 63: S235
293.HanlyJG,UrowitzMB,SuL,GordonC,BaeS-C,Sanchez-GuererroJ,Romero-DizJ,WallaceD,ClarkeAE,BernatskyS,GinzlerEM,MerrillJR,IsenbergDA,RahmanA,GladmanDD,PetriM,FortinPR,BruceIN,SteinissonK,DooleyMA,KhamashtaMA,AlarconGS,FesslerNJ,Ramsey-GoldmanR,ManziS,ZomaAA,SturfeltGK,AranowC,RamosM,vanVollenhovenRF,KalunianKC,Ruiz-IrastorzaG,LimSS,KamenDL,PeschkenCA,InancM,Predictors of seizures in systemic lupus erythematosus, Arthritis Rheum 2011; 63: 226
294.HanlyJG,UrowitzMB,SuL,GordonC,BaeS-C,Sanchez-GuererroJ,Romero-DizJ,WallaceD,ClarkeAE,BernatskyS,GinzlerEM,MerrillJR,IsenbergDA,RahmanA,GladmanDD,PetriM,FortinPR,BruceIN,SteinissonK,DooleyMA,KhamashtaMA,AlarconGS,FesslerNJ,Ramsey-GoldmanR,ManziS,ZomaAA,SturfeltGK,AranowC,RamosM,vanVollenhovenRF,KalunianKC,Ruiz-IrastorzaG,LimSS,KamenDL,PeschkenCA,InancM,A prospective study of seizures in systemic lupus erythematosus, Arthritis Rheum 2011; 63L S226-S227
295.MerrillJT,FurieRA,WallaceDJ,StohlW,ChathamWW,WeinsteinA,McKayJ,GInzlerDM,ZhongZJ,PinedaL,KleinJ,FreimuthW,PetriM,Sustaineddiseaseimprovementandsafetyprofileoverthe1500patient-yearexperience(6years)withbelimumabinpatientswithsystemiclupuserythematosus,ArthritisRheum2011;63:S222-S223
296.WallaceD,StrandV,FurieR,PetriM,KalunianK,PikeM,KelleyL,GordonC,Evaluationoftreatmentsuccessinsystemiclupuserythematosusclinicaltrials:DevelopmentoftheBILAGbasedcompositelupusassessmentendpoint, Arthritis Rheum 2011; 63: S885-886
297.PetriM,OrbaiA-M,AlarconGS,GordonC,MerrillJT,FortinPR,BruceIN,IsenbergDA,WallaceDJ,NivedO,SturfeltGK,Ramsey-GoldmanR,BaeSang-Choi,JanlyJG,Sanchez-Gurerrero,ClarkeAE,AranowC,ManziS,UrowitzMB,MagderL,DerivationandvalidationoftheSLICCclassificationforsystemiclupuserythematosus,Arthritis Rheum 2011; 63: S669
298.OrbaiAM,SturfeltGK,NivedO,FangH,AlarconGS,GordonC,MerrillJT,FortinPR,BruceIN,IsenbergDA,WallaceDJ,Ramsey-GoldmanR,BaeS-C,HanlyJG,Sanchez-GuerreroJ,ClarkeAE,AranowC,ManziS,UrowitzMB,PetriM,Anti–C1qantibodyinsystemiclupuserythematosus,ArthritisRheum2011;S538
299.DoriaA,Sanchez-GuerreroJ,TegzovaD,GinzlerEM,ZhongZJ,DennisG,WallaceDJ,EarlyclinicalimprovementinSLEpatientstreatedwithbelimumab,AnnalsRheumDis2012;71(S3),535.
300.ZimmerR,WallaceDJ,MullerS,Randomized,double-blind,placebo-controlledstudiesofP140peptideinmannitol(Lupozor) and trehalose (Forigerimod) in patients with SLE, Arthritis Rheum 2012; 64: S1110
301.HobbsK,WallaceDJ,StrandV,KalunianK,KilgallenB,BongardtS,WegenerWA,GoldenbergDM,Safetyandefficacyofepratuzumabinopen-labelextensionstudy(SL006),ArthritisRheum2012;64:S276-277
302.StrandV,HobbsK,WallaceDJ,KalunianK,KilgallenB,NikalE,WegenerWA,GoldenbergDM,Epratuzumab-treatedsystemiclupuserythematosuspatientsreportimprovementsinhealth-relatedqualityoflife:Finalresultsfromanopen-labelextensionstudy(SL006),ArthritisRheum2012;64:S953-954
303.MerrillJT,FurieRA,WallaceDJ,StohlW,ChathamWW,WeinsteinA,McKayJD,GinzlerEM,ZhongW,FreimuthWW,PetriMA,Sustaineddiseaseimprovementandsafetyprofileover1745patient-year(7years)withbelimumabin systemic lupus erythematosus patients, Arthritis Rheum 2012; 64: S1110-S1111
304.ShumKM,AskanaseA,BuyonJP,BelmontHM,FranksAG,FurieR,KamenDL,ManziS,PetriM,Ramsey-GoldmanR,TsengCE,vanVollenhovenRF,WallaceD,Favorableresponsetobelimumabat3months,ArthritisRheum2012;64: S610
305.McMahonM,GrossmanJM,SkaggsB,LourencoE,LeeC,SahakianL,FitzGeraldJ,Charles-SchoemanC,GornAH,KarpouzasG,WeismanMH,WallaceDJ,ChenW,HahnBH,InflammatorybiomarkersofatherosclerosisandoxidativestressareassociatedwithdiseaseflareinSLE,ArthritisRheum2012;64:S272-273
306.ChurchillM,Flores-SuarezLF,WallaceD,PhillipsK,MartinRW,CardielM,KaneJ,BautistaE,SalingerDH,StevensE,RussellCB,MartinD,APhaseIbmultiple,ascendingdosestudyevaluatingsafety,pharmacokinetics,andearlyclinicalresponsetobrolalumab,ahumanantiinterleukin-17receptorantibodyinrheumatoidarthritis,ArthritisRheum 2012; 64: S555
307.BernatskyS,AE.Clarke,KCostenbader,MB.Urowitz,D.Gladman,PR.Fortin,MPetri,SManzi,D.A.Isenberg,ARahman,DWallace,CGordon,CPeschke,MADooley,E.M.Ginzler,CAranow,SM.Edworthy,ONived,SJacobsen,GRuiz-Irastorza,EYelin,SG.Barr,IBlanco,CH.Feldman,R.Ramsey-GoldmanLymphomariskinsystemic lupus: Effects of disease activity versus treatment, Arthritis Rheum 2012; 64: S1087
308,MunroeME,JM.Norris,JM.Guthridge,DL.Kamen,KMoserSivils,TB.Niewold,GS.Gilkeson5, M H. Weisman, ML.Ishimori,DJ.Wallace,DR.Karp,JB.Harley,JA.James,Altleredsolublemediatorsinindividualswithincomplete lupus in the Lupus Autoimmunity in Relatives (LAUREL) study, Arhtirits Rheum 2012; 64: S290
309.MJolly,MKosinski,STolozaJBlock,RMikolaitis,SDurán-Barragan,AM.Bertoli,IBlazevic,LM.Vila,DCooray,EP.Katsaros,K.Torralba,IMoldovan,AKay,BGoker,SHaznedaroglu,ME.Tezcan,JBourré-Tessier,SBernatsky,AE.Clarke,MH.Weisman,SV.Navarra,DJ.Wallace16GracielaS.Alarcon,;Equivalenceofvariouslanguageversionsoflupusspecificpatientreportedoutcomesmeasure(LupusPRO),ArthritisRheum2012;64:S607-608
Page 50 of 54
310.ClarkeAE,BernatskyS,CostenbaderKH,UrowitzMB,GladmanDD,FortinPR,PetriM,ManziS,IsenbergDA,RahmanA,WallaceD,GordonC,PeschkenC,DooleyMA,GinzlerEM,AranowC,EdowrthySM,NivedO,JacobsenS,Ruiz-Irastorza,YelinE,BarrSG,Criswell,SturfeltG,DreyerL,BlancoI,GottesmanL,FeldmanCH,Ramsey-GoldmanR,Lymphomariskinsystemiclupus:effectsoftreatmentversusdiseaseactivity,ArthritisResearch&Therapy2012:14:S3,A16.
311.IshimoriM,GalNJ,RogatkoA,BermanDS,WilsonA,WallaceDJ,MerzNB,WeismanMH,Prevalenceofanginainpatientswithsystemiclupuserythematosus,ArthritisResearch&Therapy,2012;14:(S3);A62.
312.MLu,Ramsey-GoldmanR,BernatskyS,PetriM,ManziS,UrowitzMB,GladmanD,FortinPR,GinzlerE,YelinE,BaeS-C,WallaceDJ,JacobsenS,DooleyMA,PeschkenCA,AlarconGS,NivedO,GottesmanL,CriswellL,SturfeltG,Dreyer L, Lee JL, Clarke AE, Nonlymphoma hematological malignancies in systemic lupus erythematosus, Arthritis Research&Therapy2012;14:S3,A64.
313.ReddyA,BuyonJP,FranksAG,FurieR,KamenDL,ManziS,PetriM,Ramsey-GoldmanR,TsengCE,vanVollenhovenFR,WallaceDJ,AskanaseA,Favorableclinicalresponsetobelimumabatthreemonths,AnnRheumDis2013;72:THU0271.
314.vanVolenhovenR,MildM,JacobsenS,WallaceDJ,HanlyJG,PetriMA,BernatskySR,BaeSC,Ramos-CasalsM,Garcia-HernandezF,Ayala-GuiterrezMDM,Ramsey-GoldmanR,DoriaA,MoscaM,Twoyearfollowuponbiologicsusein13centers:DatafromtheIntenrationalRegistryforBiologicsinSLE(IRBIS),AnnRheumDis2013;72:THU0283.
315.StrandV,LeszczynskiP,KeisermanM,KilgallenB,BongardtS,WallaceDJ,GordonC,Immunologicresponsetolong-termepratuzumabtreatmentinSL0008,anopen-labellong-termextensionstudyinpatientswithmoderate-to-severesystemiclupuserythematosus,AnnalsRheumDis2013;72:THU0286.
316.GordonC,ClowseM,HoussiauF,PetriM,KilgallenB,KalunianK,StrandV,BongardtS,WallaceDJ,Epratuzumabmaintains improvements in disease activity for over two years in patients with moderate-to-severe systemic lupus erytheamtosus:Resultsfromanopen-label,long-termextensionsstudy(SL0008),AnnalsRheumDis2013;72:THU0272.
317.WallaceDJ,Ordi-RosJ,NeuweltM,KalunianK,KilgallenB,BongardtS,PetriM,PikeM,JekaS,GordonC,StrandV,Epratuzumab:Susteainedsafetyprofileandeffectoncorticosteroiduseonlong-termtreatmentinpateitnswithmoderate-to-severesystemiclupuserythematosus:Resultsfromanopen-label,long-termextensionsstudy(SL0008),AnnalsRheumDis2013;72:THU0277.
318.GoldenbergDM,RossiEA,MichelR,WallaceDJ,ChangCH,EpratuzumabmediatesBCR-antigentrogocytosisaspotential mechanism of action in systemic lupus erythematosus (SLE), Annals Rheum Dis 2013; 72: OP0118.
319.WallaceDJ,GillisBS,GavinI,KarpenkoO,Acytokine/chemokinemultiplexassaythatissensitiveandspecificforfibromyalgiacomparedtocontrols,systemiclupuserythematosusandrheumatoidarthritis,ArthritisRheum2013;65:abst842
320.JollyM,AouhabZ,TolozaS,BertoliA,BlazevikI,VilaL,ModovanI,TorralbaKM,KayaA,GokerB,TezcanM,HaznedarogluS,Bourre-TessierJ,ClarkeAE,WallaceDJ,WeismanMH,AlarconGS,Diseasespecificqualityoflifedomainsareimpairedinpatientswithlupusnephritis,ArthritisRheum2013;65:abst610.
321.ClowseME,HoussiauF,PetriM,KilgallenB,StrandV,BongardtS,GordonC,WallaceDJ,KalunianK,Epratuzumabmaintains improvements in disease activity for over 2 years in patients with moderate-to-severe systemic lupus: Resultsfromanopen-labellong-termextensionstudy,ArthritisRheum2013;65:abst1738
322.KalunianK,ClowseME,HoussiauF,PetriM,KigallenB,GordonC,StrandV,BongardtS,WallaceDJ,StustainedBritishIslesAssessmentGroup-measuredimprovementinmoderate-to-severlyaffectedbodysymptomsbyepratuzumab:Resultsfromanopen-labelextensionstudy,ArthritisRheum2013;65:abst1739.
323.AskanaseA,ReddyA,BuyonJ,FranksA,FurieR,KamenDL,ManziS,PetriM,Ramsey-GoldmanR,TsengC-E,vanVollenhovenRF,WallaceDJ,Favorableclinicalresponsetobelimumabatthreemonths,ArthritisRheum2013;65:abst1574.
324.HanK,NagarS,PatelJ,OhA,WalalceDJ,MoltaCT,Continuousvariablesoftreatmentinterventionsinpatientsdiagnosed with systemic lupus erythematosus among commercially and Medicaid insured populations in the US, ArthritisRheum2013;65:abst1587.
325.WallaceDJ,Ordi-RosJ,NeuweltCM,KalunianK,PetriM,SlawomirJ,vanVollenhovenR,KigallenB,BongardtS,GordonC,StrandV,Overviewofthesafetyofepratuzumabinsystemiclupuserythematosus,ArthritisRheum2013;65:abst1606.
326.MunroeME,YoungKA,NorrisJM,GuthridgeJM,KamenDL,HiewoldTB,GilkesonGS,WeismanMH,IshimoriML,WallaceDJ,KarpDR,HarleyJB,JamesJA,Gender,race,andsolublemediatrosdistinguishbloodrelativeswhodevelopincompletelupusorclassifiedSLEintheLupusAutoimmunityinRelatives(LAUREL)study,ArthritisRheum2013: 65: 1767.
327.HanlyJG,UrowitzMB,O’KeefeA,GordonC,BaeSC,Sanchez-GuerreroJ,Romero-DiazJ,ClarkeAE,BernatskyS,WallaceDJ,etal,“LupusHeadache”:Resultsfromaprospective,internationalcohortstudy,ArthritisRheum2013:65: 1592.
328.vanVollenhovenRF,PetriM,WallaceDJ,RothD,MoltaCT,HammerH,TangT,ThompsonA,Corticosteroiduse
Page 51 of 54
across52weeksofbelimumabtherapyinpatientswithsystemiclupuserythematosus:CombinedanalysisfromtheBLISStrials,ArthritisRheum2013;65:abst1585.
329.vanVollenhovenRF,MildM,JacobsenS,BernatskyS,WallaceDJ,BaeSC,Ramos-CasalsM,Garcia-HernandezFJ,Ramsey-GoldmanR,DoriaA,MoscaM,PetriMA,Ayala-GutierrezM,HanlyJG,Twoyearfollow-uponbiologicsusein13centers:Datafromtheinternationalregistryforbiologicsinsystemiclupuserythematosus,ArthritisRheum2013;65:abst1607.
330.ClowseMDB,HoussiauF,PetriM,KilgallenB,KalunianK,StrandV,BongardtS,GordonC,WallaceDJ,Epratuzumabmaintainsimprovementsindiseseactivityforover2yearsinpatientswithmoderate-to-severesystemic lupus erythematosus, Lupus 2014; 23: 485-486.
331.WallaceDJ,Odio-RosJ,NeuweltM,KalunianK,KilgallenB,BongardtS,PetriM,JekaS,GordonC,StrandV,Epratuzumab:Sustainedlong-termsafetyprofileandeffectoncorticosteroiduseinpatientswithmoderate-to-severe systemic lupus erythematosus, Lupus 2014; 23: 486.
332.PetriM,GordonC,KalunianK,PikeM,HoussiauF,StrandV,LeszcynskiP,KeisermanM,WagnerWA,WallaceDJ,BongardtS,KilgallenB,GoldenbergDM,Immunologicresponsetoepratuzumabinpatientswithwithsystemiclupus erythematosus, Lupus 2014: 23: 487.
333.FurieRA,PetriM,GordonC,StrandV,GalatenuC,BondardtS,KoetseW,WallaceDJ,CorrelationoflaboratoryandclinicalparameterswithBritishLupusAssessmentGroupResponseinanopen-labelextensionstudyofepratuzumabinsystemiclupuserythematosus,AnnRheumDis2014:73:THU023.Supp2
334.AskanaseA,LiX,ReddyA,BuyonJ,FurieRA,RiachardDL,ManziS,PetriM,Ramsey-GoldmanR,vanVollenhovenRF,WallaceDJ,Clinicalresponsetobelimumabinacademicclinicalpractices,AnnRheumDis2015;73:FRI0372.Supp 2
335.BernatskyS,Ramsey-GoldmanR,BoivinJ-F,JosephL,PetriMA,ZomaA,ManziS,UrowityMB,GladmanDD,FortinPR,GinzlerEM,YeliE,BaeS-C,WallaceDJ,EdwowrthySM,JacobsenS,GordonC,DooleyMA,PeschkenCA,HanlyJG,AlarconGS,NivedO,Ruiz-IrasdtozzaG,IsenbergD,RahmanA,witteT,AranowC,KamenDK,SteinssonK,AskanaseA,BarrSG,CriswellCA,SturfeltG,PatelNM,SenecalJ-L,ZummerM,PopeJE,EnsworthS,El-GabalwyJ-L,McCarthyT,St-PierreY,ClarkeAR=E,Cancerriskfactorsinsystemiclupuserythematosus:multivariateregressionanalysisin16,409patients,ArthritisRes&Therapy2014;16:(S1)A35
336.ForbessL,WallaceD,IshimoriM,WeismanM,Outcomemeasuresinsystemiclupuserythematosus:constructingameaningfulresponseindexfromexistingtrialdata,ArthritisRes&Therapy2014;16:(S1)A43.
337.ReddyA,LiX-Q,BuyonJP,FranksAG,FurieRA,KamenDL,ManziS,PetriM,Ramsey-GoldmanR,TsengC-E,vanVollenhovenR,WallaceDJ,AskanaseAD,Clinicalresponsetobelimumabinacademicclinicalpractices,ArthritisResearch&Therapy2014;16:A49
338.JollyM,SequiraW,TolozaS,BertoliAM,VilaLM,BlazevicI,MoldovanI,TorralbaKD,GokerB,Bourre-Tessier,NavarraSV,WallaceDJ,WeismanMH,ClarkeAE,MokCC,BlockJA,Simplediseaseassessmentforpeoplewithlupus erythematosus, Arthritis Rheum 2014; 66: S312-313.
339.JollyM,SequiraW,HansiS,AliZ,TolozaS,BertoliAM,BlazevicI,VilaLM,MoldovanI,TorralbaKD,GokerB,Bourre-TessierJ,NavarraS,WallaceD,WeismanMH,ClarkeAE,MokCC,Hydroxychloroquineuseisassociatedindependentlywithimprovedqualityoflifeinsystemiclupuserythematosus,ArthritisRheum2014;66:S297-298
340. Modi M, Ishimori ML, Wallace DJ, Weisman M, Lupus chest pain in the emergency department: a common diagnostic dilemma, Arthritis Rheum 2014; 66: S 307-308.
341.MyungG,ForbessLJ,IshimoriML,WallaceDJ,WeismanMH,Prevalenceofcardiacarrhythmiasinsystemiclupuserythematosus, Arthritis Rheum 2014; 66: S 476.
342.MokCC,TolazaS,GokerB,ClarkeAE,NavarraS,WallaceDJ,WeismanMH,JollyM,Diseasespecificqualityoflifein patients with lupus nephritis, Arthritis Rheum 2014; 66: S736.
343.MunroeME,YoungKA,FesslerJ,FifeD,KamenDL,GuthridgeJ,NiewoldTB,WeismanMH,IshimoriML,WallaceDJ,KarpDR,HarleyJB,GilkesonGS,NorrisJM,JamesJ,Elevatedlevelsofsolubleinflammatorymediatorsandlupus-specificconnectivetissuediseasequestionnairescoresdiscernunaffectedfirstdegreerelativesoflupuspatient from unaffected individuals not related to lupus patients, Arthritis Rheum 2014; 66: S 1258.
344.FurieRA,PetriMA,GordonC,StrandV,GalatenuC,BongardtS,KoetseW,WallaceDJ,CorrelationoflaboratoryandclinicalparameterswithBritishIslesLupusAssessmentGroupresponseinanopen-labelextensionofepratuzumabinsystemiclupuserythematosus,ArthritisRheum2014;66:S1238.
345.HanlyJG,SuL,UrowitzM,Romero-DiazJ,GordonC,BaeS-C,BernatskyS,ClarkeAE,WallaceDJetal,Mooddisorders in systemic lupus erythematosus (SLE): Results from an international inception cohort study, Arthritis Rheum 2014; 66: S1158-1159.
346.HanlyJG,O’KeefeAO,SuL,UrowitzMB,Romero-DiazJ,GordonC,BaeS-C,BernatskySR,ClarkeAE,WallaceDJ,etal,Outcomeoflupusnephritisandimpactonhealthrelatedqualityoflife:Resultsfromaninternational,prospective, inception cohort study, Arthritis Rheum 2014; 66: S 428.
347.WallaceDJ,PopaS,SpindlerAJ,EimonA,Gonzalez-RiveraT,UtsetTO,PetriM,LipskyPE,MerrillJT,StrandV,WajdulaJ,ChristensenJ,LiC,DiehlA,VincentM,Beebe,SridharanS,ImprovementofdiseaseactivityandreductionofsevereflaresfollowingsubcutaneousadministrationofanIL-6monoclonalantibodyinsubjectswith
Page 52 of 54
active generalized systemic lupus erythematosus (SLE), Arthritis Rheum 2014; 66: 3531348.IsenbergD,MerrillJ,HoffmanR,LinnikM,Morgan-CoxM,VeenhuizenM,IlkuniN,DicksonC,SilkM,WallaceD,
DornerT,Efficacyandsafetyoftabalumabinpatientswithsystemiclupuserythematosus(SLE):resultsfrom2phase3,52week,multicenter,randomized,placebo-controlledtrials,AnnalsRheumDis2015;74:OP0184,s2p141
349.SmolenJ,PopaS,SzombatiI,WallaceD,PetriM,LipskyP,MerrillJ,StrandV,HealeyP,LiC,ChristensenJ,DiehlA,BeebeJ,VincentM,WajdulaI,SridharanS,SignificanclinicalimprovementandreductionofsevereflaresflaresfollowingadministrationofanIL-6monclonalantibodyinsystemiclupuserythematosus(SLE)subjectswithhighdisease activity, Annals Rheum Dis 2015: 74: 0P0185, S2, 141-142.
350. Wallace DJ, Biologicals: evidence, trials, state of the art, Clin Exp Rheumatol 2015; 33 (supp9c): S5.351.McMahonMA,GrossmanJ,LorencoE,SakakianL,FitzGeraldJ,WeismanM,WallaceD,HahnB,SkaggsB,
Plasma myeloperoxidase levels are inversely associated with future piHDL formation in women with SLE, Clin Exp Rheumatol 2015; 33 (supp9c): S47.
352.MunroeMD,YoungKA,NorrisJM,AberleT,RobertsVC,GuthridgeJM,KamenDL,GilkesonGS,WeismanMH,IshimoriML,WallaceDJ,KarpDR,SivlisKL,HarleyJB,JamesJA,Alteredsolublemediators,autoantibodiesandlupus-specificconnectivediseasequestionnairescoresdistinguishbloodrelativesfromincompletelupusfromunaffectedrelativesandrelativeswithclassifiedSLE,ArthritisRheumatol2015;67:S10abst13.
353.YoungKA,MunroeME,GuthridgeJM,KamenDL,NiewoldTB,GilkesonGS,WeismanMH,IshimoriML,WallaceDJ,KarpDR,HarleyJB,JamesJA,NorrisJM,InvestigatingtheroleofvitaminDinthetransitiontosystemiclupuserythematosusinindividualsatriskforthedisease,ArthritisRheumatol2015;67:S10,abst24
354.RasmussenA,RadfarL,GrundahlK,LewisDM,StoneDU,KaufmanCE,WallaceDJ,WeismanMH,VenuturupalliS,LessardCJ,KurienB,AnayaJM,RohrerMD,GopalakrishnanR,HoustonGD,ChodoshJ,HughesPJ,RhodusNL,IseJ,HefnerK,KellyJA,SivlisKL,ScofieldRH,PreviousdiagnosisofSjogren’ssyndromeasrheumatoidarthritisorsystemiclupuserythematosus,ArthritisRheumatol2015;67:S10,abst621
355.SturgessJ,AllenE,IsenbergDA,AranowC,AringerM,AskanaseA,BaeSC,BernatskyR,BruceIN,BuyonJP,CerveraR,ClarkeA,DooleyMA,FortinPR,GilesI,GinzlerEM,GladmanD,GordonC,GriffithsB,HanlyJG,inancM,JacobsenS,KamenDL,KhamashtaM,LanyonP,LimSS,ManziS,Ruiz-IrastorzaG,Sanchez-GuerreroJ,SchneiderM,SteinssonK,SturfeltGK,UrowitzM,vanVollenhovenF,VasconcelosC,WallaceDJ,ZomaA,MerrillGJ,MorandE,ChambersS,Costedoat-ChalumeauN,CrocaS,Apaperpatient-basedflarestudyinSLE,ArthritisRheumatol2015;67:S10,abst737
356.ChoiM,HanlyJG,UrowitzM,Romero-DiazJ,GordonC,BaeSC,BernatskyS,WallaceDJ,MerrillJT,IsenbergDA,RahmanA,GinzlerEM,FortinPR,GladmanD,Sancehez-GuerreroJ,PetriM,BruceIN,DooleyMA,Ramsey-GoldmanR,AranowC,AlarconGS,SteinssonK,NivedO,SturfeltGK,ManziS,KhamashtaM,vanVollenhovenRF,ZomaA,Ruiz-IrastorzaG,LimSS,StollT,InancM,KalunianKC,KamenDL,MaddisonP,PeschkenCA,JacobsenS,AskanaseA,BuyonJP,ChathamWW,Ramos-CasalsM,StPierreY,ClarkeAE,FritzlerMJ,Theprevalenceofanti-DFS70antbodiesinaninternationalinceptioncohortofsystemiclupuserythematosus,ArthritisRheumatol2015;67:S10,abst740.
357.StClairEW,BaerAN,NosaisehG,ParkeA,CocaA,UtsetT,GenoveseMC,WallaceDJ,McNamaraJ,BoyleK,Keyes-ElsteinL,FraichimontN,JamesJA,Theclinicalefficacyandsafetyofbaminercept,alymphotoxin-betareceptorfusionproteininprimarySjogren’ssyndrome,Resultsfromarandomized,double-bline,placebo-controlledPhaseIItrial,ArthritisRheumatol2015;67:S10,abst2013
358.WallaceD,SilvermanSL,BarkenD,ConklinJ,DervieuxT,Cellboundcomplementactivationproductsinmultianalyteassaywithalgorithmhaveutilityindistinguishingprimaryfibromyalgiafromsystemiclupuserythematosus,ArthritisRheumatol2015;67:S10,abst3087.
359.SandhuVK,IshimoriML,WeiJ,ThmopsonL,BermanD,SchapiraJ,BaireyMerz,WallaceDJ,Weisman,A5yearfollowupofmicrovasculardysfunctionandcoronaryarterydiseaseinSLE:Resultsfromacommunity-basedlupuscohort,ArthritisRheumol2015;67:S10,abst1810.
360.hawJ,IshimoriML,SandhuVK,SharifB,ThomsonL,LiD,SchapiraJ,WallaceD,BaireyMerzN,WeismanM,BermanD,MyocardialtissuecharacterizationwithnativemyocardialT1mappinginSLEpatientswithchestpain,ArthritisRheumatol2015;67:S10,abst1817.
361.McMahonMA,GrossmanJM,SahakianL,LaurencoE,FitzGeraldJ,Charles-SchoemanC,GornA,WeismanM,WallaceDJ,HahnBH,SkaggsB,PlasmamyeloperoxidaselevelsareinverselyassociatedwithcarotidplaqueinSLE,Arthritis Rheumatol 2015; 67:S 10, 2015.
362.WilhelmM,WangF,SchallN,FaludiM,KleinmannJF,NashiEP,MartinT,SibiliaJ,PasqualiJL,WallaceD,MullerS,AutophagypathwayasatargetoftherapeuticP140peptideusedinlupus,ArthritisRheumatol2015;67:S10,abst1934.
363.RasmussenA,LessardCJ,AdriantoI,WileyGB,StoneDU,KaufmanCE,RadfarL,LewisDM,YoungSK,WeismanMH,WallaceDJ,VenuturupalliS,SegalBM,IceJA,AnayaJM,RohrerMD,GopalakrishnanR,HoustonGD,ChodoshJ,HughesPJmRhodusNL,KellyJA,GrundahlK,HefnerK,ScofieldRH,SivlisKL,CharacterizationofearlyandprogressiveautoimmunityinSjogren’ssyndrome:TheincompleteSjogren’ssyndromemodel;ArthritisRheumatol2015;67:S10,Abst3200.
Page 53 of 54
364.HanlyJG,SuL,UrowitzM,Romero-DiazJ,GordonC,BaeSC,BernastskyS,ClarkeA,WallaceDJ,MerrillJT,IsenbergDA,RahmanA,GinzlerEM,PetriM,BruceIN,DooleyMA,FortinP,GladmanDD,Sanchez-GuerreroJ,SteinssonK,Ramsey-GoldmanR,KhamashtaM,AranowC,AlarconGS,FeslerBJ,ManziS,NivedO,SturfeltGK,ZomaA,vanVolenhovenRF,Ramos-CasalsM,Ruiz-IrastorzaG,LimSS,KalunianKC,InancM,KamenDL,PeschkenCA,JacobsenS,AskanaseA,TheriaultC,FarewellV,LongitudinalanalysisofchangeinlupusnephritisinaninternationalinceptioncohortusingamultistateMarkovmodelapproach,ArthritisRheum2015;67:S10,Abst3122
365.BarberM,HanlyJG,O’keefeA,SuL,UrowitzM,StPierreY,Romero-DiazJ,GordonC,BaeSC,BernastskyS,WallaceDJ,MerrillJT,IsenbergDA,RahmanA,GinzlerEM,PetriM,BruceIN,DooleyMA,FortinP,GladmanDD,Sanchez-GuerreroJ,SteinssonK,Ramsey-GoldmanR,KhamashtaM,AranowC,AlarconGS,FeslerBJ,ManziS,NivedO,SturfeltGK,ZomaA,vanVolenhovenRF,Ramos-CasalsM,Ruiz-IrastorzaG,LimSS,KalunianKC,InancM,KamenDL,PeschkenCA,JacobsenS,AskanaseA,TheriaultC,FarewellVClarkeAE,Economicevaluationoflupusnephritis in an international inception cohort: Comparing the hospitalization, medication, dialysis and procedure costsofthosewithandwithoutnephritis,ArthritisRheum2015;67:S10,Abst989
366.HanlyJG,LiQ,SuL,UrowitzM,Romero-DiazJ,GordonC,BaeSC,BernastskyS,ClarkeA,WallaceDJ,MerrillJT,IsenbergDA,RahmanA,GinzlerEM,PetriM,BruceIN,DooleyMA,FortinP,GladmanDD,Sanchez-GuerreroJ,SteinssonK,Ramsey-GoldmanR,KhamashtaM,AranowC,AlarconGS,FeslerBJ,ManziS,NivedO,SturfeltGK,ZomaA,vanVolenhovenRF,Ramos-CasalsM,Ruiz-IrastorzaG,LimSS,KalunianKC,InancM,KamenDL,PeschkenCA,JacobsenS,AskanaseA,TheriaultC,FarewellV,Aninitialpresentationofcerebrovasculardiseaseattributedtolupusismostfrequentearlyinthediseasecourse:Resultsfromaninternationalinceptioncohortstudy,ArthritisRheum2015;67:S10,Abst2902
367.ClowseMEB,WallaceDJ,FurieR,PetriM,PikeM,LeszczynskiP,NeuweltCM,HobbsK,KeisermanM,DucaL,KalunianK,BongardtS,StachC,BeaudotC,KilgallenB,GalatenuC,GordonC,Efficacyandsafetyofepratuzumabinpatientswithmoderate-to-severesystemiclupuserythematosus:ResultsfromtwoPhase3randomized,placebo-controlledtrials,ArthritisRheumatol2015l67:S10,abstract4L
368.WallaceDJ,WegenerWA,HorneH,GoldenbergDM,PhaseIBstudyofImmu-115(humanizedantiCD74antibody)targeting antigen presenting cells in patients with systemic lupus erythematosus, Lupus Sci Med 2016; 3:A37-38, Supp 1
369.UrowitzM,GladmanD,AndersonN,SuJ,Romero-DiazJ,BaeSC,FortinP,Sanchez-GuererroJ,ClarkeA,BernatskyS,GordonC,HanlyJ,WallaceD,etal,CardiovasculareventspriortoorearlyafterdiagnosisofsystemiclupuserythematosusintheSystemicLupusErythematosusCollaboratingClinicsCohort,LupusSciMed2016;3:A47-48, Supp 1
370.ChoiM,ClarkeA,HanlyJG,UrowitzM,Romero-DiazJ,GordonC,BaeSC,BernatskyS,WallaceDJ,etal,TheprevalenceanddeterminantsofantiDFS-70antibodiesinaninternationalinceptioncohortofpatientswithsystemic lupus erythematosus (SLE) patients, Lupus Sci Med 2016; 3: A55-A57, Supp 1
371.BernatskyS,UrowitzMB,HanlyJ,ClarkeAE,Gordon,Romero-DiazJ,AlarconGS,BaeSC,Petri,MerrillJ,WallaceDJ, et al, Cancer in systemic lupus erythematosus: Results from the SLICC inception cohort, Lupus Sci Med 2016; 3: A57-58.
372.BarberM,BruceIN,UrowitzM,HanlyJG,SuL,Romero-DiazJ,GordonC,BaeS-C,BernatskyS,WallaceDJ,etal,EconomicevaluationofdamageaccrualinaninternationalSLEInceptionCohort,ArthritisRheum2016;68:Abst3168.
373.SharmaR,HarrisVM,CavettJ,KurienBT,LiuK,KoelschKA,RadfarL,LewisDM,StoneDU,KaufmanCE,LiS,SegalBM,WallaceDJetal,VeryrareXchromosomeabnormalitiesinSLEandSjogren’smaylocalizeXgenedoseeffect,ArthritisRhem2016;68:Abst66.
374.HanyJG,LiQ,UrowitzM,Romero-DiazJ,GordonC,BaeS-C,BernatskyS,ClarkeAE,WallaceDJ,etal,Riskfactorsforcerebrovasculareventsinsystemiclupuserythematosus:ResultsfromanInternational,Inceptioncohortstudy,ArthritisRheum2016;68:Abst1773.
375.RasmussenA,StoneDU,FifeD,BrownM,EarleyK,RadfarL,KaufmanCE,LewisDM,RhodusNL,BegalBM,WallaceDJ,etal,Effectoftobaccosmokingontheclnical,histopathologicalandserologicalmanifestationsofSjogren’ssyndrome,ArthritisRheum2016;68:Abst2662.
376.WallaceDJ,Ramsey-GoldmanR,AskanasesAD,ManziS,AhearnJ,FurieR,WeinsteinA,PuttermanC,MassarottiE,CollinsC,KalunianK,ArriensC,SilvermanSL,ReddyS,ChitkaraP,IbarraC,BarkenD,AlexanderR,CohklinJ,DevrieuxT,ProspectivevalidationofpanelofautoantibodiesincombinationwithC4dboundcomplementactivationproductsforthedifferentialdiagnosisofsystemiclupuserythematosus,ArthritisRheum2016;68:Abst2797.
377.FurieR,AskanaseAD,KalunianK,MassarottiE,Ramsey-GoldmanR,WallaceDJ,etal,MulticentervalidationofplatetboundC4d,abiomarkerforsystemiclupuserythematosus,ArthritisRheum2016;68:Abst2798.
378.MunroeM,YoungKA,NorrisJM,AberleT,RobertsVC,GuthridgeJM,KamenDL,GilkesonGS,WeismanM,Ishimori M, Wallace DJ, et al, Unaffected lupus relatives are distinguished from SLE patients and unaffected individualsnotrelatedtoSLEpatientsbylupus-specificconnectivetissuediseasequestionnairescores,autoantibodiesanddistinctsolublemarkers,ArthritisRheum2016;68:Abst2871.
Page 54 of 54
379.BernatskyS,UrowitzM,HanlyJ,ClarkeAE,GordonC,Romero-DiazJ,AlarconGS,BaeS-C,PetriM,MerrillM,WallaceDJ,etal,ArthritisRheum2016;68:Abst2690.
380. Wallace DJ, Biologics for systemic lupus erythematosus, Journal of Rheumatic Disease, 2017; 24: 536, Supp1.381.MerrillJT,WallaceDJ,KaoA,VazquezMateoC,FraserPA,ChangP,IsenbergD,Efficacyandsafetyofatacicepet
inpatientswithhighdiseseactivityina24-week,randomized,placebo-controlled,PhaseIIBstudy(ADDRESSII),AnnRheumDis75:SAT0219,Supp,2017
382.WallaceDJ,IsenbergD,WaxS,KaoA,ChangP,FraserPA,MerrillJT,SafetyanddiseaseactivitychangesinanextensionofaPhaseIIbstudyofataciceptinpatientswithSLE(ADDRESSII),AnnRheumDis2017,75:SAT0236,sup.
383.WallaceDJ,GinzlerEM,MerrillJT,FurieRA,StohlW,ChathamW,WeinsteinA,McKayJ,McCuneWJ,PetriM,FettiplaceJ,RothD,JiB,HethA,Sustainedsafetyandefficacyover10yearswithbelimumab(BEL)plusstandardsystemic lupus erythemaotuss (SLE) therapy (SOC) in patients with SLE, Ann Rheum Dis 2017; 75: OP0232, Supp.
384.MerrillJT,WallaceDJ,Vazquez-MateoC,KaoKH,Fleuranceau-MorelP,ChangP,IsenbergDA,SafetyprofileinSLEpatientstreatedwithatacticeptinaPhaseIIbStudy(ADDRESSII)anditsextensionstudy,ArthritisRheumatol2017;69: suppl 10.
385.ArriensC,NarainS,SaxenaA,ColliinsCE,WallaceDJ,MassorottiE,ConklinJ,AlexanderR,KalunianKC,PuttermanC,Ramsey-GoldmanR,BuyonJP,AskanaseA,FurieR,ManziS,AhearnJ,WeinsteinA,DevrieuxT,Abnormalitiesincomplementsystemarerelatedtodiseaseseverityinsystemiclupuserythematosus,ArthritisRheumatol 2017; 60 suppl 10
386.YoungKA,MunroeME,GuthridgeJM,KamenDL,GilkesonGS,WeismanM,KarpD,HarleyJB,WallaceDJ,JamesJA, Norris JM, Less than seven hours of sleep per night is associated with transitioning to lupus, Arthritis Rheumatol 2017, suppl 10
387.SethlB,NikaA,SequueiraW,BlockJA,TolozaS,BertoliA,BlazevicI,VilaLM,MoldovanI,TorralbaK,MazzoniD,CicognaniE,HasniS,GokerB,HaznedarogluS,Bourre-Tesler,NavarraSV,MokCC,ClarkeA,WeismanM,WallaceDJ, Jolly M, Drivers of satisfaction with care in lupus, Arthritis Rheumatol 2017; suppl 10.
388.WallaceDJ,MassarottiE,Ramsey-GoldmanR,CollinsCE,AskanaseA,BuyonJP,FurieR,NarianS,SaxenaA,KalunianKC,ArriensC,PuttermanC,ConklinJ,AlexnderR,IbarraC,O’MalleyT,ChandraT,AhearnJ,ManziS,WeinsteinA,DevrieuxT,Cellboundcomplementactivationproductsdistinguishsystemiclupuserythematosusfromotherdiseasesamongpatientswithhighantinuclearantibodytitersandnormalcomplement,ArthritisRheumatol 2017; Suppl 10.
389.HanlyJG,LiQ,SuL,UrowitzM,Romero-DiazJ,GordonC,BaeS-C,BernatskyS,ClarkeAE,WallaceDJetal,Riskfactorsforcerebrovasculareventsinsystemiclupuserythematosus:Resultsfromaninternational,inceptioncohortstudy, Arthritis Rheumatol 2017, Suppl 10.
390.BernatskyS,UrowitzM,HanlyJG,ClarkeAE,FritzlerMJ,GordonC,Romero-DiazJ,AlarconGS,BaeS-C,PetriM,MerrillJT,WallaceDJ,etal,CancerinanSLEinceptioncohort:Smokingmayout-performtumormarkersasariskpredictor,, Arthritis Rheumatol 2017; suppl 10.
391.JamesJA,GuthridgeJM,ChenH,LuR,BournRL,BaerAN,NoasiehG,ParkeA,CocaA,UtsetT,GenoveseMC,AberleT,WallaceDJ,BopyleK,Keyes-EisteinL,FranchmontN,StClairE,PascualV,UtzPJ,SivlisKL,MolectularfeaturesdefineuniqueSjogren’ssyndromepatientsupsets,ArthritisRheumatol2017;Suppl10
392.YoungKA<MunroeME,GuthridgeJM,KJamenDL,GilkesonGS,WeismanM,KarpD,HarleyJB,WallaceDJ,JamesJA,NorrisJM,Identificationofkeyscreeningcharacteristicforsystemiclupuserythematosusnaturalhistory,Arthritis Rheumatol 2017, suppl 10
393.ClarkeAE,BruceIN,UrowitzM,HanlyJG,StPierreY,BaeS-C,BernatskyS,GladmanDD,Sanchez-GuererroJ,fortinP,Romero-diazJ,PetriM,Ramsey-GoldmanR,AranowC,JacobsenS,WallaceDJ,etal,Economicevaluationof damage accrual in the SLICC inception cohort, Arthritis Rheumatol 2017, suppl 10.
394.WallaceJD,FurieRA,TanakaY,KalunianKC,MoscaM,PetriMA,DornerT,CardielMH.BruceIN,GomezE,CarmackT,JanesJM,LinnikMD,SilkM,HoffmanR,BaricitinibinsystemiclupuserythematosuscDisease-2018-EULAR 1918m doi 10.1136.
395.MorandE,MerrillJT,IsenbergDA,KaoAH,Vazquez-MateoC,WaxS,ChangP,PudotaK,AranowC,WallaceD, Attainment of low disease activity with remission in systemic lupus erythematosus patients with high disease activity in the atacicept Phase IIB Address II Study and its long-term extension, DOIL 10.1136/annrheumdis-2018-eular.2618.
396.AringerA,CostenbaderKH,BrinksR,BoumpasD,DaikhD,JayneD,KamenD,MoscaM,Ramsey-GoldmanR,SmolenJS,WofsyD,DiamondB,Jacobsen,McCuneWJ,Ruiz-IrastorzaG,SchneiderM,UrowitzMB,BertsiasG,HoyerB,LeuchtenN,TaniC,TedeschiS,ToumaZ,AnicB,AssanF,ChanTM,ClarkeAE,CrowMK,CzirjakL,DoriaA,GraningerW,HasniS,IzmirlyP,JungM,KissB,MarietteX,PadjenI,Pegy-RegiosaJM,Romero-DiazJ,Roa-FigueroaI,SerorR,StummvollG,TanakaY,Tektonidou,VasconcelosC,VitalE,WallaceDJ,YavuzS,NadenRP,DornerT,JohnsonSR,Validationofnewsystemiclupuserythematosusclassificationcriteria,1.1136/annrheumdis-2018-eular.3679